flurbiprofen profile

Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain and inflammation. It is available as a generic drug and is sold under the brand names Ansaid, Ocufen, and Flo-Nap. Flurbiprofen is a propionic acid derivative. It is a racemate, a mixture of equal amounts of two enantiomers (optical isomers). The synthesis of flurbiprofen involves several steps, including the reaction of 2-fluoro-4-bromobenzoyl chloride with diethyl malonate followed by hydrolysis and decarboxylation to give the desired product. Flurbiprofen inhibits the production of prostaglandins, which are chemicals that cause pain and inflammation. It is used to treat a variety of conditions, including rheumatoid arthritis, osteoarthritis, gout, and menstrual cramps. Flurbiprofen is also used to treat pain associated with dental procedures and surgery. Flurbiprofen is generally well tolerated, but side effects can occur. The most common side effects are gastrointestinal upset, such as heartburn, nausea, and stomach pain. Flurbiprofen can also increase the risk of bleeding in the stomach or intestines. Flurbiprofen is an important drug for the treatment of pain and inflammation. It is effective in treating a variety of conditions and is generally well tolerated. Flurbiprofen is studied to improve its efficacy, reduce its side effects, and develop new formulations. Studies are being conducted to evaluate the potential benefits of flurbiprofen in the treatment of other conditions, such as cancer and Alzheimer's disease. '
```

Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	3394
CHEMBL ID	563
CHEBI ID	5130
SCHEMBL ID	2248
SCHEMBL ID	10029029
MeSH ID	M0008647

Synonym
[1,1'-biphenyl]-4-acetic acid, 2-fluoro-?-methyl-
bdbm50074922
2-fluoro-alpha-methyl-(1,1''-biphenyl)-4-acetic acid
2-(2-fluoro-[1,1''-biphenyl-4-yl])propanoic acid
HMS3393A05
HMS3268E10
AB00051999-17
BRD-A86044036-001-05-9
nsc685701
MLS000040873 ,
smr000042823
KBIO1_000804
DIVK1C_000804
NCI60_030812
(+-)-2-fluoro-alpha-methyl-4-biphenylacetic acid
anmetarin
2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid
flugalin
ocuflur
CHEBI:5130 ,
yakuban
mks-11
2-(2-fluorobiphenyl-4-yl)propanoic acid
2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
flurbiprofeno [inn-spanish]
u 27,182
fluriproben
(1,1'-biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-
flurbiprofene [inn-french]
flurbiprofenum [inn-latin]
einecs 225-827-6
4-biphenylacetic acid, 2-fluoro-alpha-methyl-
(1,1'-biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+-)-
fp 70
flubiprofen
u 27182
ccris 3708
bts 18322
(+-)-2-(2-fluoro-4-biphenylyl)propionic acid
c15h13fo2
SPECTRUM_001096
cas-5104-49-4
NCGC00016654-01
BSPBIO_000794
BSPBIO_002050
BPBIO1_000874
IDI1_000804
PRESTWICK3_000917
SPECTRUM5_000720
u-27182
zepolas
antadys
froben
bts-18322
stayban
cebutid
flurofen
adfeed
2-fluoro-alpha-methyl-4-biphenylacetic acid
3-fluoro-4-phenylhydratropic acid
FLP ,
BIM-0051387.0001
AB00051999
flurbiprofen
C07013
5104-49-4
flurbiprofen, cyclooxygenase inhibitor
MLS000758198
(+/-)-2-fluoro-alpha-methyl-4-biphenylacetic acid
DB00712
ansaid
rac-flurbiprofen
nsc-685701
D00330
ansaid (tn)
flurbiprofen (jp17/usp/inn)
PRESTWICK2_000917
NCGC00025287-03
NCGC00025287-04
MLS000028441
KBIOSS_001576
KBIO3_001270
KBIO2_006712
KBIOGR_001255
KBIO2_004144
KBIO2_001576
NINDS_000804
SPECTRUM4_000558
SPECTRUM3_000435
SPBIO_001209
PRESTWICK1_000917
SPBIO_002983
SPECTRUM2_001025
PRESTWICK0_000917
SPECTRUM1500308
MLS001201729
MLS001401361
HMS2051A05
HMS2090I06
HMS2091F21
bts 18,322
CHEMBL563 ,
u-27,182
nsc-757037
HMS502I06
FT-0660285
inchi=1/c15h13fo2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10h,1h3,(h,17,18)
sytbzmrglbwntm-uhfffaoysa-
F0371 ,
2-(2-fluorobiphenyl-4-yl)propionic acid
HMS1570H16
HMS1920O20
2-(3-fluoro-4-phenylphenyl)propanoic acid
STK802101
AKOS004119934
2-(2-fluoro[1,1'-biphenyl]-4-yl)propanoic acid
AO-295/42284050
NCGC00018157-04
NCGC00018157-08
NCGC00018157-05
NCGC00018157-03
HMS2097H16
HMS3259I12
dtxsid0037231 ,
tox21_302353
dtxcid8017231
NCGC00255457-01
BBL010980
nsc757037
pharmakon1600-01500308
tox21_110547
HMS2232I08
mpc7869
CCG-100759
CCG-40243
flurbiprofen [usan:usp:inn:ban:jan]
unii-5gro578klp
flurbiprofenum
flurbiprofeno
nsc 757037
(1)-2-fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid
einecs 257-262-6
flurbiprofene
5gro578klp ,
(1,1'-biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+/-)-
2-(3-fluoro-4-phenyl-phenyl)propanoic acid
FT-0603668
2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanoic acid
NCGC00018157-11
AKOS016340701
HMS3371I05
HMS3370N14
gtpl4194
flurbiprofen [mart.]
flurbiprofen [usp monograph]
(+/-)-2-fluoro-.alpha.-methyl-4-biphenylacetic acid
flurbiprofen [orange book]
flurbiprofen [usan]
flurbiprofen [vandf]
flurbiprofen [usp-rs]
flurbiprofen [mi]
flurbiprofen [inn]
flurbiprofen [ep monograph]
flurbiprofen [who-dd]
(+/-)-2-(2-fluoro-4-biphenylyl)propionic acid
flurbiprofen [jan]
(1,1'-biphenyl)-4-acetic acid, 2-fluoro-.alpha.-methyl-, (+/-)-
HY-10582
MLS006011431
NC00563
NC00009
SCHEMBL2248
KS-5035
2-(2-fluoro-4-biphenylyl)propionic acid
(r/s)-2-fluoro-alpha-methyl-4-biphenylacetic acid
2(2-fluoro-4-biphenylyl)propionic acid
2-(2-fluoro-4-biphenylyl)-propionic acid
alpha-methyl-2-fluoro-4-biphenylylacetic acid
2 -(2-fluoro-4-biphenylyl)propionic acid
2-(2-fluoro-biphenyl-4-yl)-propionic acid
2-(2-fluoro-biphenyl-4-yl)propionic acid
(rs)-2-(2-fluorobiphenyl-4-yl)propionic acid
flurbiprofen o
SCHEMBL10029029
51543-38-5
MLS006011931
Q-201129
flurbiprofen, antibiotic for culture media use only
2-fluoro-?-methyl-[1,1'-biphenyl]-4-acetic acid
2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-a cetic acid
HB3049
(.+/-.)-2-(2-fluoro-4-biphenylyl)propionic acid
2-fluoro-.alpha.-methyl(1,1'-biphenyl)-4-acetic acid
2-fluoro-.alpha.-methyl-4-biphenylacetic acid
[1,1'-biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-, (.+/-.)-
ocufen (salt/mix)
(.+/-.)-2-fluoro-.alpha.-methyl-4-biphenylacetic acid
4-biphenylacetic acid, 2-fluoro-.alpha.-methyl-
(.+/-.)-flurbiprofen
[1,1'-biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-
2-(2-fluoro[1,1'-biphenyl]-4-yl)propanoic acid #
HMS3649K11
AB00051999_18
OPERA_ID_777
mfcd00079303
dl-flurbiprofen
AC-8106
flurbiprofen, united states pharmacopeia (usp) reference standard
flurbiprofen, european pharmacopoeia (ep) reference standard
HMS3655G19
flurbiprofen, pharmaceutical secondary standard; certified reference material
flurbiprofen; (2rs)-2-(2-fluorobiphenyl-4-yl)propanoic acid
SR-01000003043-5
SR-01000003043-2
sr-01000003043
SR-01000003043-6
SBI-0051387.P003
HMS3714H16
2-fluoro--methyl-(1,1'-biphenyl)-4-acetic acid
flurbiprofen (nsaid)
FT-0771103
Q419890
flurbiprofen - cas 5104-49-4
FT-0668760
flurbiprofen (ansaid)
HMS3678N15
flurbiprofen,(s)
SR-01000003043-14
BCP09086
BCP13426
HMS3414N17
(r)-flurbiprofen;mpc7869
NCGC00018157-13
2-(2-fluoro-1,1'-biphenyl-4-yl)propanoic acid
(s)-(+)-2-fluoro-alpha-methyl-4-biphenylaceticacid
nsc755404
(+-)flurbiprofen
nsc-755404
[1,1'-biphenyl]-4-acetic acid, 2-fluoro-a-methyl-, (a+/-)-
EN300-7479231
Z2216885233
(2rs)-2-(2-fluorobiphenyl-4-yl)propanoic acid
2-fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid
flurbiprofen (usan:usp:inn:ban:jan)
flurbiprofen (usp-rs)
flurbiprofen (mart.)
flurbiprofen (ep monograph)
flurbiprofenum (inn-latin)
2-(2-fluoro-(1,1'-biphenyl-4-yl))propanoic acid
flurbiprofeno (inn-spanish)
m02aa19
antiphlamine pain relieving
m01ae09
r02ax01
s01bc04
flurbiprofen (usp monograph)
flurbiprofene (inn-french)

Excerpt	Reference	Relevance
"Flurbiprofen axetil (FA) is a prodrug of flurbiprofen (FP), and it is hydrolyzed to the active FP by carboxylesterase in plasma after intravenous injection. "	( Comparison of in vivo pharmacokinetic behaviors of R- and S-flurbiprofen after intravenous injection of flurbiprofen axetil. He, Y; Li, M; Qin, F; Qin, M; Tian, B; Zhi, D, 2023)	2.6
"Flurbiprofen (FB) is an effective nonsteroidal anti-inflammatory and BCS class II drug and its poor solubility plays a critical role in limiting its bioavailability. "	( The effect of critical process parameters of the high pressure homogenization technique on the critical quality attributes of flurbiprofen nanosuspensions. Celebi, N; Ilbasmis-Tamer, S; Oktay, AN, 2019)	2.16
"R-Flurbiprofen is a nonsteroidal antienflammatory drug and has potential anticancer activity."	( Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration. Caban-Toktas, S; Capan, Y; Dalkara, T; Esendagli, G; Karlı Oguz, K; Khan, M; Lule, S; Mut, M; Sahin, A; Soylemezoglu, F; Vural, I, 2020)	1.4
"Flurbiprofen, an NSAID, is a water insoluble drug that is also notorious for gastric irritation and inflammation. "	( Clove oil based co-surfactant free microemulsion of flurbiprofen: Improved solubility with ameliorated drug-induced gastritis. Asghar, S; Asif, M; Faran, SA; Gohar, UF; Hussain, T; Khalid, I; Khalid, SH; Khan, IU; Rehman, A; Tanzeem, MU; Ullah, MS, 2019)	2.21
"Flurbiprofen axetil (FA) is a commonly prescribed agent to relieve perioperative pain, but the relationship between FA and postoperative acute kidney injury (AKI) remains unclear. "	( Low dose of flurbiprofen axetil decrease the rate of acute kidney injury after operation: a retrospective clinical data analysis of 9915 cases. Liao, Q; Ou-Yang, W; Tang, YZ; Wang, D; Yang, SK; Zhang, H; Zhao, MX, 2020)	2.38
"Flurbiprofen (FB) is an analgesic and anti-inflammatory drug, but its low water solubility (BCS Class II) limits its dermal bioavailability. "	( Preparation and in vitro / in vivo evaluation of flurbiprofen nanosuspension-based gel for dermal application. Celebi, N; Han, S; Ilbasmis-Tamer, S; Oktay, AN; Uludag, O, 2020)	2.26
"Flurbiprofen is a non-steroidal anti-inflammatory drug. "	( Evaluation of bioequivalence of two flurbiprofen axetil injections: A randomized, open-label, double-cycle, and crossover study. Cai, Y; Dong, L; Wang, J; Wang, R, 2021)	2.34
"Flurbiprofen axetil is an injectable non-selective cyclooxygenase inhibitor that has a high affinity for inflammatory tissues to achieve targeted drug therapy and prolonged duration of action."	( Preoperative flurbiprofen axetil administration for acute postoperative pain: a meta-analysis of randomized controlled trials. Luo, J; Luo, T; Wang, K; Zheng, L, 2017)	1.55
"Flurbiprofen axetil is a non-selective cyclooxygenase inhibitor. "	( Analgesic effect of different dosage of Flurbiprofen axetil in laparoscopic cholecystectomy in comparison with other analgesic drugs. Luo, X; Lv, F; Peng, M, 2017)	2.17
"Flurbiprofen (F) is a nonsteroidal anti-inflammatory drug (NSAID) used therapeutically as the racemate of (R)-enantiomer and (S)-enantiomer. "	( Mutual inversion of flurbiprofen enantiomers in various rat and mouse strains. Angioni, C; de Bruin, N; Ferreirós, N; Geisslinger, G; Hofmann, M; Parnham, MJ; Schmidt, M, 2018)	2.25
"Flurbiprofen axetil is a targeted analgesic and non steroidal analgesic with lipid microspheres as drug carrier. "	( Flurbiprofen axetil: Analgesic effect and adverse reaction. Ji, L; Zhao, X, 2018)	3.37
"Flurbiprofen which is a non-steroidal anti-inflammatory drug (NSAID), has been safely used for the control of postoperative patient's morbidity after periodontal plastic surgeries requiring palatal graft harvesting, but there is little information on the efficacy of topical use. "	( Oral flurbiprofen spray for mucosal graft harvesting at the palatal area: A randomized placebo-controlled study. Akkale, H; Eraydin, N; Isler, SC; Ozdemir, B, 2018)	2.44
"Flurbiprofen is a kind of nonsteroidal anti-inflammatory drug, which has been widely used in clinic for treatment of rheumatoid arthritis and osteoarthritis. "	( Enantioseparation of flurbiprofen enantiomers using chiral ionic liquids by liquid-liquid extraction. Cui, X; Ding, Q; He, CH; Shan, RN; Wu, KJ, 2019)	2.28
"Flurbiprofen is a nonsteroidal anti-inflammatory agent preferentially used for local oromucosal treatment of painful and/or inflammatory conditions of the oropharynx such as gingivitis, stomatitis, periodontitis, pharyngitis and laryngitis. "	( Influence of the oral dissolution time on the absorption rate of locally administered solid formulations for oromucosal use: the flurbiprofen lozenges paradigm. De Gregori, S; Imberti, R; Lisi, L; Navarra, P, 2014)	2.05
"Flurbiprofen axetil (FPA) is an injection product and a prodrug of a non-steroidal anti-inflammatory drug (NSAID). "	( A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid. Ikeda, T; Kawai, K; Nishio, T; Ogata, K; Setoguchi, N; Takamura, N; Tanda, K; Tokunaga, J; Yamasaki, T, 2016)	2.17
"Flurbiprofen axetil (FA) is a potent non-steroidal anti-inflammatory drug (NSAID). "	( Intravenous flurbiprofen axetil accelerates restoration of bowel function after colorectal surgery. Chen, J; Chen, W; Lou, F; Tan, Z; Xu, Y, 2008)	2.17
"Flurbiprofen is a non-selective non-steroidal anti-inflammatory drug (NSAID), related to ibuprofen and naproxen, used to treat acute and chronic painful conditions. "	( Single dose oral flurbiprofen for acute postoperative pain in adults. Derry, S; McQuay, HJ; Moore, RA; Sultan, A, 2009)	2.14
"Flurbiprofen acts as a nonselective inhibitor for cyclooxygenases (COX-1 and COX-2), but its impact on hepatic ischemia/reperfusion (I/R) injury remains unclear. "	( Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3β signaling and mitochondrial permeability transition. Chen, H; Fu, H; Guo, M; Liu, F; Shi, X; Wang, C; Wang, Q; Xu, H, 2012)	3.26
"Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) that is commonly used to control moderate postoperative pain and is not associated with respiratory inhibition."	( Intravenous flurbiprofen for post-thymectomy pain relief in patients with myasthenia gravis. Chen, Z; Chou, CW; Liu, W; Luo, H; Su, C; Su, Y; Zou, J, 2012)	1.48
"Flurbiprofen is a non-steroidal anti-inflammatory compound with strong antifungal activity, which is not found in two well known and medically used antifungal organic acids like benzoic and salicylic acids."	( Flurbiprofen, a unique non-steroidal anti-inflammatory drug with antimicrobial activity against Trichophyton, Microsporum and Epidermophyton species. Adak, M; Bose, SK; Chowdhury, B, 2003)	3.2
"Flurbiprofen (FL) is a chiral 2-arylpropionate used clinically as the racemate (rac-FL). "	( In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. Aboul-Enein, HY; Radwan, MA, 2004)	2.02
"Nitroflurbiprofen is a nitrosylated flurbiprofen analog under development by NicOx for the potential treatment of urinary incontinence, Alzheimer's disease (AD) and the prevention and treatment of accelerated bone resorption associated with disorders such as osteoporosis, inflammatory joint disease and Paget's disease. "	( Nitroflurbiprofen (NicOx). Scatena, R, 2004)	1.35
"Flurbiprofen is a powerful nonsteroidal anti-inflammatory drug (NSAID)."	( Flurbiprofen and HCT1026 protect mice against acute pancreatitis-associated lung injury. Bhatia, M; Huang, J; Moochhala, SM; Moore, PK, 2005)	2.49
"Flurbiprofen is a nonsteroidal anti-inflammatory drug used as a racemic mixture. "	( Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Kamimura, H; Mano, Y; Usui, T, 2007)	2
"Flurbiprofen is a potent inhibitor of platelet aggregation as compared to aspirin (160 to 2200 more potent)."	( [Effect of flurbiprofen on platelet functions. Study of its interference with the synthesis of platelet thromboxane and production of prostacyclin by the rabbit aorta]. Bara, L; Caen, J; Lecrubier, C; Levy-Toledano, S; Maclouf, J; Samama, M, )	1.24
"As flurbiprofen is a more potent inhibitor of prostaglandin synthesis than indomethacin, these data cast doubt on the theory that nonsteroidal anti-inflammatory drugs antagonize the action of diuretics by prostaglandin synthetase inhibition."	( The effect of flurbiprofen on the responses to frusemide in healthy volunteers. Hind, ID; Kendall, MJ; Rees, JA; Symmons, DP, 1983)	1.14
"Flurbiprofen is a useful treatment for idiopathic detrusor instability and is well tolerated by most patients."	( Evaluation of flurbiprofen in detrusor instability. Cardozo, LD; Hole, D; Robinson, H; Stanton, SL, 1980)	1.34
"Flurbiprofen is a nonsteroidal anti-inflammatory (NSAI) agent currently undergoing clinical investigation. "	( Topical flurbiprofen or prednisolone. Effect on corneal wound healing in rabbits. Bergamini, MV; Gruenberg, P; Miller, D; Miller, R, 1981)	2.14
"Flurbiprofen is a propionic acid-derived non-steroidal anti-inflammatory drug (NSAID) used widely in the treatment of rheumatism and non-arthritic pain. "	( Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. Glass, RC; Leutenegger, E; Singlas, E; Taburet, AM; Thomas, F, 1995)	1.97
"Flurbiprofen is a chiral nonsteroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid class. "	( Clinical pharmacokinetics of flurbiprofen and its enantiomers. Davies, NM, 1995)	2.03
"Flurbiprofen is a chiral non-steroidal anti-inflammatory drug used in the treatment of pain or inflammation. "	( Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Gonzalez, FJ; Korzekwa, KR; Rosenbluth, BW; Tracy, TS; Wrighton, SA, 1995)	1.95
"Flurbiprofen is a chiral 2-arylpropionate used clinically as a racemate. "	( Dose-dependency of flurbiprofen enantiomer pharmacokinetics in the rat. Berry, BW; Jamali, F; Wright, MR, 1994)	2.06
"Flurbiprofen (Ansaid) is a new NSAID for the treatment of rheumatoid arthritis and osteoarthritis."	( Nonsteroidal antiinflammatory drug desensitization using flurbiprofen (Ansaid) Brown, JS; Douglas, DM; Ward, L, 1993)	1.25
"Flurbiprofen appears to be an effective drug for the prevention of reinfarction after coronary reperfusion and in reducing the need for secondary revascularization procedures."	( Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Brochier, ML, 1993)	1.37
"Flurbiprofen (1) is an analgesic, antipyretic and antiinflammatory agent which is practically insoluble in water. "	( Formulation of an aqueous injection of flurbiprofen. Gupta, GD; Jain, NK; Jain, S, 1997)	2.01
"Flurbiprofen (Ansaid) is a newly released nonsteroidal antiinflammatory drug (NSAID) that is a potent inhibitor of prostaglandin synthesis. "	( Flurbiprofen (Ansaid) cross-sensitivity in an aspirin-sensitive asthmatic patient. Bosso, JV; Creighton, D; Stevenson, DD, 1992)	3.17
"Flurbiprofen is a water-soluble, non-steroid anti-inflammatory agent and is capable of marked inhibition of prostaglandin synthesis. "	( [Effects of an anti-prostaglandin agent added to the irrigation solution on damage to the anterior segment in monkey eyes induced by pars plana vitrectomy]. Kawamura, A; Matsui, M; Shimada, H; Shingyouchi, F; Shingyouchi, S, 1989)	1.72
"Flurbiprofen appears to be a satisfactory alternative to phenylbutazone in the management of acute gouty arthritis."	( Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Butler, RC; Goddard, DH; Higgens, CS; Hollingworth, P; Pease, CT; Scott, JT; Stodell, MA, 1985)	1.31
"Flurbiprofen appears to be an excellent alternative to phenylbutazone in the management of patients with ankylosing spondylitis."	( Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone. Brinn, EL; Lamborn, KR; Lomen, PL; Sattler, LP; Turner, LF, 1986)	2.44
"Flurbiprofen is an excellent treatment for the control of pain and inflammation in patients with ankylosing spondylitis."	( Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with indomethacin. Brinn, EL; Lamborn, KR; Lomen, PL; Turner, LF, 1986)	2.44

Excerpt	Reference	Relevance
"Flurbiprofen axetil has the efficacy of targeted analgesia."	( Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial. Fang, J; Lian, Y; Wu, Y; Xiang, X; Yuan, X, 2018)	1.46
"Flurbiprofen spray has been successfully used for treatment of oral inflammations, but its effects on postoperative sore throat and hoarseness are unknown."	( Oral flurbiprofen spray for postoperative sore throat and hoarseness: a prospective, randomized, double-blind, placebo-controlled study. Gul, F; Muderris, T; Sancak, M; Tezcan, G; Ugur, G, 2019)	1.75
"Flurbiprofen has been shown to bind more strongly than diclofenac to the same site of albumin."	( Albumin-binding of diclofenac and the effect of a site II inhibitor in the aqueous humor of cataract patients with the instillation of diclofenac. Arimori, K; Ogata, K; Osaki, T; Ozaki, M; Setoguchi, N; Takamura, N; Tokunaga, J, 2014)	1.12
"Flurbiprofen axetil has been reported to reduce the pain of injection."	( Efficacy and safety of flurbiprofen axetil in the prevention of pain on propofol injection: a systematic review and meta-analysis. Bao, H; Luo, Z; Shi, H; Wang, H; Xu, L; Yu, Y; Zhang, L; Zhang, X; Zhang, Y; Zhao, Y; Zhu, J, 2014)	1.43
"Flurbiprofen has been shown to reduce cerebral ischemia/reperfusion injury in both focal and global cerebral ischemia models, but the mechanism remains unclear."	( The Akt/GSK-3β pathway mediates flurbiprofen-induced neuroprotection against focal cerebral ischemia/reperfusion injury in rats. Chen, L; Liu, X; Sun, B; Wei, X; Xiang, Y; Zhang, X, 2011)	1.37
"(R)-flurbiprofen has been generally well tolerated at high doses in clinical trials."	( Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. Geerts, H, 2007)	1.14
"Flurbiprofen has been shown to be effective in relieving symptoms in the degenerative and inflammatory arthritides and side-effects have not proved a problem."	( A long-term assessment of flurbiprofen. Marsh, BD; Sheldrake, FE; Webber, JM, 1977)	1.28
"Flurbiprofen has been introduced more recently and has been accepted largely because of a better patient comfort."	( [Comparison of the anti-miotic effect of 0.03% flurbiprofen with 1% indomethacin in cataract extraction]. Beati, D; Gennari, G; Ortelli, G; Stucchi, CA; Vignanelli, M, 1991)	1.26
"Flurbiprofen has been shown to inhibit cyclo-oxygenase metabolism of arachidonic acid to thromboxane A2 (TxA2), resulting in the inhibition of platelet aggregation. "	( Relative effects of flurbiprofen on platelet 12-hydroxy-eicosatetraenoic acid and thromboxane A2 production: influence on collagen-induced platelet aggregation and adhesion. Buchanan, MR; Van Ryan-McKenna, J, 1989)	2.04
"Flurbiprofen has been compared with phenylbutazone in a double-blind study involving 33 patients with acute gout. "	( Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Butler, RC; Goddard, DH; Higgens, CS; Hollingworth, P; Pease, CT; Scott, JT; Stodell, MA, 1985)	2.03

Excerpt	Reference	Relevance
"Flurbiprofen axetil can inhibit the growth of cervical cancer transplanted tumor in nude mice and this inhibitory effect was maximal in Cf50 group."	( THE INVESTIGATION OF EFFECT OF FLURBIPROFEN AXETIL ON THE TISSUE GROWTH AND THE CONTENT OF PGE2 IN CERVICAL CANCER. Chen, G; Li, K; Lu, J; Sun, X; Wang, S, 2016)	1.44
"R-flurbiprofen was used because it is able to reduce neuropathic pain in young mice in part by increasing anandamide."	( Anandamide deficiency and heightened neuropathic pain in aged mice. Bishay, P; Ferreirós, N; Galve-Roperh, I; Häussler, A; Lim, HY; Oertel, B; Tegeder, I, 2013)	0.95
"Flurbiprofen may increase the concentration of moxifloxacin in aqueous humor."	( Comparative evaluation of aqueous and plasma concentration of topical moxifloxacin alone and with flurbiprofen in patients of cataract surgery. Biswas, S; Dutta, BK; Haldar, M; Halder, S; Mandal, TK; Mondal, KK, )	1.79
"Flurbiprofen axetil can produce preemptive analgesia and reduce the tramadol dose during postoperative PCIA in patients undergoing postburn plastic operations."	( [Effect of preemptive analgesia with flurbiprofen axetil on patient-controlled intravenous analgesia with tramadol in patients undergoing postburn plastic surgery]. Liu, C; Lu, JC; Zhang, XF, 2009)	2.07
"Nitroflurbiprofen was shown to inhibit nitric oxide synthase induction caused by lipopolysaccharide administration, while flurbiprofen had no effect on nitric oxide synthase induction."	( Effect of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils. Adami, A; Benoni, G; Cuzzolin, L; Del Soldato, P; Mariotto, S; Suzuki, H, 1995)	0.99

Excerpt	Reference	Relevance
"Flurbiprofen treatment reduced the expression of immaturely glycosylated SERT and enhanced the expression of maturely glycosylated SERT."	( Effects of flurbiprofen on the functional regulation of serotonin transporter and its misfolded mutant. Adachi, N; Asano, M; Harada, K; Hide, I; Hirakawa, H; Kikkawa, S; Murakawa, S; Noguchi, S; Sakai, N; Taguchi, K; Tanaka, S; Ueyama, T, 2022)	1.83
"The flurbiprofen treatment simultaneously administered."	( Therapeutic potential of flurbiprofen against obesity in mice. Baba, S; Hosoi, T; Ozawa, K, 2014)	1.19
"R-flurbiprofen treatment increased CD4(+)CD25(+)FoxP3(+) regulatory T cells, CTLA4(+) inhibitory T cells and interleukin-10, whereas the EAE-evoked upregulation of pro-inflammatory genes in the spinal cord was strongly reduced."	( R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice. Altmann, C; Bishay, P; de Bruin, N; Ferreirós, N; Geisslinger, G; Häussler, A; Lötsch, J; Männich, J; Parnham, MJ; Schmitz, K; Tegeder, I; Ultsch, A, 2014)	1.68
"The flurbiprofen treatment, 30 min prior to ischemia and 4 h post-reperfusion, afforded significant neuroprotection from ischemic injury as evidenced by reduction in cerebral infarct volume and neurobehavioral deficit."	( Neuroprotective effect of flurbiprofen in focal cerebral ischemia: the possible role of ASIC1a. Mishra, V; Raghubir, R; Verma, R, 2010)	1.14
"Flurbiprofen treatment of ND rats replicated many of the biochemical and physiological abnormalities of EDN, i.e., reduced motor nerve conduction velocity (MNCV), total and endoneurial nerve blood flow (NBF), Na,K-ATPase activity, and myo-inositol (MI) and taurine content."	( Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Greene, DA; Larkin, D; Li, F; Marinescu, V; Pop-Busui, R; Stevens, MJ; Sullivan, K; Van Huysen, C, 2002)	1.04
"Flurbiprofen-treated rats showed severe gastrointestinal ulcerations (bleeding in 3/8 rats) and nefrotoxicity, which was not observed in nitroflurbiprofen-treated cirrhotic rats."	( Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Fevery, J; Laleman, W; Nevens, F; Van der Elst, I; Van Landeghem, L; Zeegers, M, 2007)	1.57
"Flurbiprofen-treated eyes showed a significantly smaller percent (32.6%) decrease in intraocular pressure (IOP) one day after ALT as compared to eyes receiving placebo (43.8%)."	( Nonsteroidal anti-inflammatory agents after argon laser trabeculoplasty. A trial with flurbiprofen and indomethacin. Hotchkiss, ML; Pollack, IP; Quigley, HA; Robin, AL, 1984)	1.21
"Flurbiprofen is a useful treatment for idiopathic detrusor instability and is well tolerated by most patients."	( Evaluation of flurbiprofen in detrusor instability. Cardozo, LD; Hole, D; Robinson, H; Stanton, SL, 1980)	1.34
"In flurbiprofen-treated dogs regional function returned to normal within 5 min of reperfusion in both the subendocardium (%SS preocclusion = 17.2+/-2.0%; 5 min reperfusion = 17.8+/-3.1%; P = NS) and in the midmyocardium (%SS preocclusion = 17.8+/-2.2%; 5 min reperfusion = 17.9+/-2.3%; P = NS) and was not significantly different after 5 h of reperfusion from what it was before coronary occlusion."	( Early recovery of regional performance in salvaged ischemic myocardium following coronary artery occlusion in the dog. Braunwald, E; Darsee, JR; Kloner, RA, 1981)	0.78
"When flurbiprofen-treated cells were exposed to melphalan there was no protection against cytotoxicity."	( Flurbiprofen, a non-steroid anti-inflammatory agent, protects cells against hypoxic cell radiosensitizers in vitro. Jinks, S; Millar, BC; Powles, TJ, 1981)	2.16
"Flurbiprofen-treated patients achieved good Snellen visual acuity (better than 20/40) sooner than vehicle-treated patients.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen-CME Study Group I. Solomon, LD, 1995)	1.34
"Flurbiprofen treatment improved contrast sensitivity in patients with and without CME significantly at 12 cycles per degree."	( Effects of flurbiprofen and indomethacin on acute cystoid macular edema after cataract surgery: functional vision and contrast sensitivity. Abelson, M; Cheetham, JK; DeGryse, RE; Ginsburg, AP, 1995)	1.4
"Flurbiprofen-treated patients however, demonstrated a significantly greater proportion of sites (8.0%) with bone gain when compared to the placebo group (3.3%)."	( The use of topical flurbiprofen as an adjunct to non-surgical management of periodontal disease. Aitken, D; Benn, DK; Heasman, PA; Kelly, PJ; Seymour, RA, 1993)	1.34
"The flurbiprofen-treated group served as the control group."	( Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Apple, DJ; Solomon, KD; Stewart, JA; Turkalj, JW; Whiteside, SB, 1997)	1.06
"Flurbiprofen co-treatment markedly attenuated these actions of pentoxifylline on nerve conduction and blood flow whereas NG-nitro-L-arginine was without effect."	( Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats. Cameron, NE; Cotter, MA; Flint, H, 2000)	1.03
"In flurbiprofen-treated animals, values were 42 +/- 8 and 160 +/- 18 nmol/gm at day 4, significantly attenuated from burn alone."	( Topical flurbiprofen decreases burn wound-induced hypermetabolism and systemic lipid peroxidation. Daryani, R; Demling, RH; Knox, J; LaLonde, C; Neumann, M; Zhu, DG, 1991)	1.23
"Flurbiprofen treatment resulted in a significant reduction of the maximum intensity of stromal opacity in some experiments, whereas in other experiments the effect was not statistically significant."	( The effect of flurbiprofen on herpes simplex virus type 1 stromal keratitis in mice. Barfknecht, CF; Epstein, RJ; Hendricks, RL; Schoenwald, RD; Sugar, J, 1990)	1.36
"The flurbiprofen-treated patients experienced less severe symptoms, demonstrating maximum benefit 3 to 5 days into the drug trial with some loss of effect thereafter."	( Hay fever treatment with combined antihistamine and cyclooxygenase-inhibiting drugs. Brooks, CD; Karl, KJ, 1988)	0.76
"Flurbiprofen treatment was rated as "excellent" or "good" by approximately half of the patients and physicians following both BID or QID dosing."	( Comparison of two dosing schedules of flurbiprofen for patients with rheumatoid arthritis. Twice-daily versus four-times-a-day schedules. Brown, BL; Daenzer, CL; Hearron, MS; Johnson, JH, 1986)	1.26
"Many flurbiprofen-treated patients (46 percent) completing the trial followed a relatively low dosage regimen of 50 mg twice daily for more than half the study."	( Treatment of osteoarthritis of the knee. A comparison of flurbiprofen and aspirin. Brinn, EL; Lamborn, KR; Lomen, PL; Porter, GH; Turner, LF, 1986)	0.97
"Sham treatment and flurbiprofen treatment did not affect Aβ pathology, and a low dose HCT 1026 (10 mg/kg; a nitric oxide-donating flurbiprofen analog that has additional useful properties, including a remarkable gastrointestinal safety) did not affect pathology either, however a higher dose of HCT 1026 (30 mg/kg) did reduce the Aβ load."	( Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology. Kadish, I; Miettinen, P; van Groen, T, 2011)	0.69
"Pretreatment with flurbiprofen and thymoxamine appeared to enhance this effect but this was not statistically demonstrated by the study."	( Unoprostone isopropyl ester darkens iris color in pigmented rabbits with sympathetic denervation. Camras, CB; Meza, JL; Toris, CB; Zhan, GL, 2003)	0.64
"Sham treatment, flurbiprofen, and the low-dose HCT 1026 did not affect pathology; however, a higher dose of HCT 1026 reduced both A load and amount of microglial activation surrounding plaques."	( Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Kadish, I; van Groen, T, 2005)	0.66
"Eyes treated with flurbiprofen and indomethacin showed significantly less conjunctival injection following ALT."	( Nonsteroidal anti-inflammatory agents after argon laser trabeculoplasty. A trial with flurbiprofen and indomethacin. Hotchkiss, ML; Pollack, IP; Quigley, HA; Robin, AL, 1984)	0.81
"Pretreatment with flurbiprofen completely abolished the febrile reactions to endotoxin."	( Endotoxin-induced fever and associated haematological and blood biochemical changes in the goat: the effect of repeated administration and the influence of flurbiprofen. Schotman, AJ; van Duin, CT; van Miert, AS; Verheijden, JH, 1982)	0.79
"Eyes treated with flurbiprofen were compared with controls."	( Does topical flurbiprofen affect the pupillary response to acetylcholine? Jackson, H; Mathalone, BM; Patel, CK; Thompson, GM; Westcott, M, 1994)	0.98
"Pretreatment with flurbiprofen partly antagonized the febrile reactions to r.HuIL-1 alpha."	( Effects of flurbiprofen on recombinant human IL-1 alpha-induced fever and associated clinical, haematological and blood biochemical changes in the dwarf goat. Van Duin, CT; Van Miert, AS; Wensing, T, 1994)	1
"The treatment with flurbiprofen and indomethacin administered subcutaneously every 12 hours, commenced on the day of S-antigen injection and was continued until the termination of the experiment (12 days)."	( Modulation of immune responses by cyclo-oxygenase inhibitors during intraocular inflammation. Bhattacherjee, P; Jaramillo, A; Paterson, CA; Sonnenfeld, G, 1992)	0.6
"Pretreatment with flurbiprofen did not affect the IOP lowering that was obtained with timolol or apraclonidine administration."	( Effects of topical flurbiprofen on the intraocular pressure lowering effects of apraclonidine and timolol. Arkin, LM; Cummings, HL; Robin, AL; Sulewski, ME, 1991)	0.93
"Treatment with flurbiprofen (100 mg twice a day for 5 days), tranexamic acid (1.5 gm three times a day for 3 days and 1 gm twice a day for another 2 days), and an intrauterine contraceptive device releasing 20 micrograms levonorgestrel per day was compared in women with idiopathic menorrhagia. "	( A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Andersch, B; Andersson, K; Milsom, I; Rybo, G, 1991)	0.98
"Treatment with flurbiprofen appeared to decrease the severity of inflammation following cataract extraction surgery."	( Reduction of inflammation following cataract surgery by the nonsteroidal anti-inflammatory drug, flurbiprofen. Cheetham, JK; DeGryse, R; Duzman, E; Osterle, C; Sabiston, D; Sumers, K; Tessler, H, 1987)	0.83

Excerpt	Reference	Relevance
" The other photoproducts, Butibufen and Flurbiprofen did not produce observable toxic effects on cells."	( Phototoxicity of non-steroidal anti-inflammatory drugs: in vitro testing of the photoproducts of Butibufen and Flurbiprofen. Castell, JV; Gómez-Lechón, MJ; Miranda, MA; Morera, IM, 1992)	0.76
"Data from 58 premarketing studies of the nonsteroidal antiinflammatory drug flurbiprofen were pooled for analyses of adverse drug reactions (ADRs)."	( Clinical safety of flurbiprofen. Assenzo, JR; Brooks, CD; Defesche, CL; Johnson, JH; Linet, OI; Schellenberg, D; Teoh, KW; Turner, LF, 1990)	0.84
"5 X 10(-3) M was toxic to all cell lines."	( Lymphotoxic activity of methyl prednisolone in vitro--I. Comparative toxicity of methyl prednisolone in human cell lines of B and T origin. Bell, JB; Hall, JG; Hobbs, SM; Jackson, E; Millar, BC, 1987)	0.27
" Toxic effects were observed for all three drugs at 10 times the therapeutic plasma concentration."	( A study of the relative hepatotoxicity in vitro of the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and butibufen. Castell, JV; Gómez-Lechón, MJ; Larrauri, A, 1988)	0.49
"Sustained release formulations of flurbiprofen demonstrate reduced gastroduodenal permeability but shift the site of this side-effect to the more distal intestine."	( Influence of dosage form on the gastroenteropathy of flurbiprofen in the rat: evidence of shift in the toxicity site. Davies, NM; Jamali, F, 1997)	0.83
" They differ mainly in their adverse effects and costs."	( Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account. , 2000)	0.31
"Since assessment of the acute gastrotoxicity of nonsteroidal antiinflammatory drugs (NSAIDs) in rats requires high doses of the drugs, we sought to establish an experimental model with which this adverse NSAID effect can be estimated at therapy-relevant doses."	( Estimation of acute flurbiprofen and ketoprofen toxicity in rat gastric mucosa at therapy-relevant doses. Cabré, F; Holzer, P; Jocic, M; Mauléon, D, 2001)	0.63
" There was no significant difference in the gastrotoxicity of FBP when the drug was administered subcutaneously or IG, whereas subcutaneously injected R/S-KP was slightly more toxic than IG R/S-KP."	( Estimation of acute flurbiprofen and ketoprofen toxicity in rat gastric mucosa at therapy-relevant doses. Cabré, F; Holzer, P; Jocic, M; Mauléon, D, 2001)	0.63
"Retrospective analysis of adverse event databases."	( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Hartnell, NR; Wilson, JP, 2004)	0.32
"Reports of adverse events submitted to the FDAs Spontaneous Reporting System and the Adverse Event Reporting System from January 1969-December 2000 for these drugs were analyzed according to the number of adverse events reported for each drug per year from the time the drug was approved until December 2000."	( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Hartnell, NR; Wilson, JP, 2004)	0.32
" Various other factors affected spontaneous reporting of adverse events, as peaks in the number of reports were seen numerous times for each drug after the initial 5-year marketing period."	( Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Hartnell, NR; Wilson, JP, 2004)	0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"Our results establish that the neurotoxicity related to the Abeta peptide can be captured in vivo by functional imaging and suggest hippocampal subregions most vulnerable to its toxic effects."	( Imaging the Abeta-related neurotoxicity of Alzheimer disease. Brickman, A; Brown, TR; Lee, T; Mayeux, R; Moreno, H; Small, SA; Wu, WE, 2007)	0.34
" The most common adverse events were diarrhoea (in seven, nine, and five patients in the 800 mg, 400 mg, and placebo groups, respectively), nausea (in seven, seven, and four patients), and dizziness (in five, nine, and four patients)."	( Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Black, SE; Hendrix, SB; Laughlin, MA; Swabb, EA; Wilcock, GK; Zavitz, KH, 2008)	0.35
" Tarenflurbil (R-flurbiprofen, MPC-7869, Myriad Pharmaceuticals) is an attractive compound because its usage is not associated with the adverse side effects of NSAIDs."	( Tarenflurbil protection from cytotoxicity is associated with an upregulation of neurotrophins. Andrews, PM; Hoe, HS; Rebeck, GW; Zhao, X, 2008)	0.69
"Short-term exposure of transformed cells to cisplatin reduced the clonogenic survival in low-density cultures (without gap junction formation) and in high density (with gap junction formation), but the toxic effect was greater at high density."	( Tramadol and flurbiprofen depress the cytotoxicity of cisplatin via their effects on gap junctions. Harris, AL; He, B; Hong, X; Liu, B; Tao, L; Tong, X; Wang, L; Wang, Q; Ye, H, 2009)	0.72
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
"Pain on injection is an acknowledged adverse effect (AE) of propofol administration for the induction of general anesthesia."	( Efficacy and safety of flurbiprofen axetil in the prevention of pain on propofol injection: a systematic review and meta-analysis. Bao, H; Luo, Z; Shi, H; Wang, H; Xu, L; Yu, Y; Zhang, L; Zhang, X; Zhang, Y; Zhao, Y; Zhu, J, 2014)	0.71
" In terms of drug safety, there were no adverse effects (AEs) reported between flurbiprofen axetil-based regimens and placebo regimens."	( Efficacy and safety of flurbiprofen axetil in the prevention of pain on propofol injection: a systematic review and meta-analysis. Bao, H; Luo, Z; Shi, H; Wang, H; Xu, L; Yu, Y; Zhang, L; Zhang, X; Zhang, Y; Zhao, Y; Zhu, J, 2014)	0.94
" More studies are required to assess its adverse effects."	( Efficacy and safety of flurbiprofen axetil in the prevention of pain on propofol injection: a systematic review and meta-analysis. Bao, H; Luo, Z; Shi, H; Wang, H; Xu, L; Yu, Y; Zhang, L; Zhang, X; Zhang, Y; Zhao, Y; Zhu, J, 2014)	0.71
" The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46."	( The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016)	0.73
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" It is concluded that the synthesized prodrugs have promising pharmacological activities with reduced GI adverse effects than the parent drug."	( Flurbiprofen-antioxidant mutual prodrugs as safer nonsteroidal anti-inflammatory drugs: synthesis, pharmacological investigation, and computational molecular modeling. Abdullah, S; Ahsan, H; Ashraf, Z; Hassan, M; Kanwal, M; Kim, SJ; Waheed, M, 2016)	1.88
" CDDP-induced nephrotoxicity (CIN) is one of the most severe adverse events associated with the use of CDDP."	( Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo. Furugen, A; Iseki, K; Kobayashi, M; Narumi, K; Okamoto, K; Saito, Y, 2020)	0.56
" No serious adverse events/deaths were reported."	( Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers. Brantley, SJ; Dai, X; Goulet, MT; Hard, ML; Hitron, M; Karol, MD; McLaughlin, CF, 2021)	0.62
" Adverse events (AEs) were evaluated as the safety outcome."	( Efficacy and safety of S-flurbiprofen plaster in knee osteoarthritis patients: A 2-week randomized controlled Phase III clinical trial compared to diclofenac gel. Fuady, A; Matsumoto, H; Tomatsu, K; Yasuda, S, 2022)	1.02
" Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic."	( Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years. Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC, 2022)	0.72
" The incidence of adverse drug reactions was 55% in the SFPP group, which is not significantly different from 50% incidence in the control group."	( Comparison of efficacy and safety in the combination therapies of duloxetine and S-flurbiprofen plaster, and of duloxetine and conventional NSAIDs for chronic pain in patients with osteoarthritis (OASIS DUAL study). Koyama, K, 2022)	0.95
" There were four secondary outcomes, including the extent of pain relief, the change trends of VAS scores, joint function scores measured by the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and adverse events."	( Efficacy and safety of flurbiprofen cataplasms versus loxoprofen sodium cataplasms in knee osteoarthritis: a randomized controlled trial. Cheng, Y; Guan, Z; Jia, J; Kan, J; Li, D; Liu, J; Wang, Z; Wu, Z; Xue, T; Yuan, P; Zhai, S; Zhang, G; Zhang, H; Zhang, K, 2023)	1.22
" In addition, the FPC group experienced a significantly lower incidence of adverse events (5."	( Efficacy and safety of flurbiprofen cataplasms versus loxoprofen sodium cataplasms in knee osteoarthritis: a randomized controlled trial. Cheng, Y; Guan, Z; Jia, J; Kan, J; Li, D; Liu, J; Wang, Z; Wu, Z; Xue, T; Yuan, P; Zhai, S; Zhang, G; Zhang, H; Zhang, K, 2023)	1.22

Excerpt	Reference	Relevance
" Only minor differences in the pharmacokinetic parameters were observed between the younger and elderly patients."	( The pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis. Antal, EJ; Buchanan, WW; Cauvier, H; Grace, EM; Kean, WF; Rischke, J, 1992)	0.59
" Flurbiprofen half-life and Tmax were not different."	( Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. Cefali, EA; Cox, S; Poynor, WJ; Sica, D, 1991)	1.48
" Pharmacokinetic parameters showed considerable variability within the group of patients, although differences in S(+)/R(-) plasma concentration ratios were small."	( The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. Aarons, L; Toon, S; Young, MA, 1991)	0.54
"The pharmacokinetic profile of 200 mg sustained-release flurbiprofen capsules was compared in nine elderly (mean age 84."	( A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. Bird, A; Hamdy, RC; Hill, J; Hind, ID; Le Gallez, P, 1990)	0.75
" The relative pharmacokinetic parameters of total flurbiprofen determined from plasma samples were Cmax, tmax, Kel, t1/2, and AUC infinity."	( Pharmacokinetic interaction between flurbiprofen and antacids in healthy volunteers. Caillé, G; du Souich, P; Pollock, SR; Stalker, DJ; Vézina, M, )	0.66
"50 L/h), but an equal half-life (4."	( Stereoselective pharmacokinetics of flurbiprofen in humans and rats. Berry, BW; Jamali, F; Russell, AS; Tehrani, MR, 1988)	0.55
" No significant differences in elimination rate constant, peak concentration, time to peak concentration, volume of distribution, or elimination half-life were noted among treatments."	( Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Cox, SR; Rock, WL; Small, RE; Sullivan, KM; Willis, HE, 1986)	0.51
" The applicability of the method was demonstrated in a pharmacokinetic ibuprofen experiment in an adult person."	( Rapid HPLC-determination of ibuprofen and flurbiprofen in plasma for therapeutic drug control and pharmacokinetic applications. Askholt, J; Nielsen-Kudsk, F, 1986)	0.54
" Drug absorption is rapid, drug disappearance half-life is independent of oral dose, and the area under the plasma drug concentration versus time curve increases with increasing oral dose."	( Pharmacokinetics of flurbiprofen. Brooks, CD; Kaiser, DG; Lomen, PL, 1986)	0.59
" Half-life (2."	( Pharmacokinetics of oral and rectal flurbiprofen in children. Benvenuti, C; D'Amico, E; Hind, ID; Mazzoni, PL; Scaroni, C, 1984)	0.54
" Plasma concentrations of flurbiprofen and urinary concentrations of the NSAID and its metabolites were measured by high-performance liquid chromatography assay, to enable comparison of the pharmacokinetic parameters for delivery of the drug by both routes."	( Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. Glass, RC; Leutenegger, E; Singlas, E; Taburet, AM; Thomas, F, 1995)	0.83
" Sustained release dosage forms are available, which may be beneficial due to the short terminal phase elimination half-life of conventional immediate release flurbiprofen (3 to 6 hours)."	( Clinical pharmacokinetics of flurbiprofen and its enantiomers. Davies, NM, 1995)	0.78
" This pharmacokinetic study was an effort to understand the pharmacodynamic difference between the two routes of administration observed when the same dose range of drug, given as single daily doses, had been employed in both studies."	( Chiral pharmacokinetics of Rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. Bigornia, AE; Jee, WS; Murray, ED; Wechter, WJ, 1994)	0.57
" Previously a significant pharmacokinetic interaction between the enantiomers of flurbiprofen has been reported in both rats and humans."	( Dose-dependency of flurbiprofen enantiomer pharmacokinetics in the rat. Berry, BW; Jamali, F; Wright, MR, 1994)	0.84
" bolus administration of flurbiprofen to the mouse (n = 4) and the rat (n = 6) with on-line HPLC analysis of microdialysates to unbound concentrations using the in vivo loss of flurbiprofen by retrodialysis carried out just before the start of the pharmacokinetic experiment."	( Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. Deridder, G; Evrard, PA; Verbeeck, RK, 1996)	0.6
"The developed techniques can be used to carry out routine pharmacokinetic studies in the mouse and the rat illustrated by our experiments with flurbiprofen, a compound with very high plasma protein binding."	( Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. Deridder, G; Evrard, PA; Verbeeck, RK, 1996)	0.49
" The pharmacokinetic data of the S-enantiomer was linked to the effect data using a hypothetical effect compartment."	( Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Derendorf, H; Grundy, BL; Suri, A, 1997)	0.53
" The conjugates of FP, an NSAID, with histamine H(2) antagonists were synthesized, in order to investigate the reduction in gastric damage by NSAID, and their pharmaceutical, pharmacokinetic and pharmacological properties were examined."	( Improving the pharmacokinetic and pharmacodynamic properties of a drug by chemical conversion to a chimera drug. Fukuhara, A; Imai, T; Otagiri, M, 1999)	0.3
" There was no significant difference among pharmacokinetic parameters (AUC, CL, t(1/2z), Vd) for total or unbound flurbiprofen determined after intraperitoneal and intravenous administration."	( Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. Mathy, FX; Preat, V; Verbeeck, RK, 2001)	0.75
"To determine the effect of arthritis on the disposition of flurbiprofen (FP) and its acyl glucuronide (FPG) as well as formation of covalent adducts with plasma protein, a pharmacokinetic study was carried out in adjuvant-induced arthritic (AA) rats."	( Stereoselective pharmacokinetics of flurbiprofen and formation of covalent adducts with plasma protein in adjuvant-induced arthritic rats. Iwaki, M; Nagao, T; Tanino, T, 2003)	0.84
" Plasma and urine samples were collected over 24 h, and flurbiprofen and 4'-hydroxyflurbiprofen pharmacokinetic data were compared across genotypes."	( Differences in flurbiprofen pharmacokinetics between CYP2C91/1, 1/2, and 1/3 genotypes. Blaisdell, JA; Frye, RF; Goldstein, JA; Hinderliter, AL; Lee, CR; Pieper, JA, 2003)	0.92
" After the administration of the FBP racemate and individual enantiomers no differences were observed between pharmacokinetic parameters [t(1/2beta) (h), Cl (L/h."	( Pharmacokinetics and synovial fluid concentrations of flurbiprofen enantiomers in horses: chiral inversion. Garcia, J; Soraci, AL; Tapia, O, 2005)	0.58
" In cows, stereoselectivity was observed in Cl(B) and elimination half-life (t(1)/2) only in the early lactation group."	( Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. Auza, N; Igarza, L; Soraci, A; Zeballos, H, 2006)	0.59
" Chemical and plasmatic stability of prodrugs 6a- e as well as pharmacokinetic distribution studies for the prodrugs 6b and 6d were carried out."	( Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. Barrio, JR; Bersani, S; Kepe, V; Pantò, V; Pignatello, R; Pistarà, V; Puglisi, G; Salmaso, S, 2008)	1.79
"To evaluate the safety and tolerability and pharmacokinetic properties of R-flurbiprofen (Tarenflurbil) in normal elderly individuals and to determine the effect of the drug on amyloid beta 42 (Abeta42) levels, we conducted a double-blind, placebo-controlled study of 48 healthy subjects aged 55 to 80."	( Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Cottrell, BA; Galasko, DR; Golde, TE; Graff-Radford, N; Hendrix, S; Koo, EH; Laughlin, M; Mather, G; May, S; Murphy, MP; Sagi, SA; Swabb, E; Zavitz, KH, )	0.58
" After strict validation, the method indicated good performance in terms of reproducibility, specificity, linearity, precision and accuracy, and it was successfully applied to the pharmacokinetic study of flurbiprofen in rats after oral and transdermal administration."	( Cloud point extraction-HPLC method for determination and pharmacokinetic study of flurbiprofen in rat plasma after oral and transdermal administration. Han, F; Jia, Q; Li, SM; Liu, HZ; Shi, XL; Xu, L; Yao, HM; Yin, R, 2008)	0.76
"The aim of the study was to compare the pharmacokinetic properties and bioequivalence of flurbiprofen 50-mg ODT (test) with a conventional flurbiprofen 50-mg tablet (reference) under fasting conditions in healthy volunteers."	( Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Li, XN; Liu, GY; Liu, Y; Liu, YM; Lu, C; Yu, C; Zhang, MQ; Zhang, YM, 2009)	0.78
" Pharmacokinetic parameters, including C(max), T(max), t(1/2), AUC(0-24), and AUC(0-infinity), were calculated and analyzed statistically."	( Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male volunteers. Jia, JY; Li, SJ; Li, XN; Liu, GY; Liu, Y; Liu, YM; Lu, C; Yu, C; Zhang, MQ; Zhang, YM, 2009)	0.56
"This study compared the pharmacokinetic parameters and bioavailability of flurbiprofen from the investigational enteric-coated tablet (test) and from a film-coated immediate-release tablet compounded for the purposes of this study (reference)."	( Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers. Ahmad, M; Pervaiz, F, 2010)	0.8
" Plasma concentrations of the 2 formulations were determined, and pharmacokinetic parameters were compared using noncompartmental analysis."	( Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers. Ahmad, M; Pervaiz, F, 2010)	0.57
"In this small study in healthy Pakistani male subjects, there were significant differences in the bioavailability and pharmacokinetic parameters of the enteric- and film-coated tablet formulations of flurbiprofen."	( Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers. Ahmad, M; Pervaiz, F, 2010)	0.76
" A population pharmacokinetic model was built using the NONMEM software package."	( Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. Hooker, A; Kokki, H; Kokki, M; Kumpulainen, E; Lehtonen, M; Ranta, VP; Välitalo, P, 2010)	0.61
" Blood samples were collected periodically in both phases and analyzed for parent drugs and metabolites (dextrorphan, 4'-hydroxy-flurbiprofen and 1'-hydroxy-midazolam) to calculate pharmacokinetic parameters."	( Drug metabolism in hemorrhagic shock: pharmacokinetics of selective markers of cytochrome-P450 2C9, 2D6, and 3A4 enzyme activities in a porcine model. Beilman, GJ; Kumar, A; Mann, HJ; Remmel, RP, 2011)	0.57
" The on-line DBS automated system was then successfully applied to a pharmacokinetic study performed on healthy male volunteers after oral administration of a single 50-mg dose of FLB."	( Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite. Daali, Y; Dayer, P; Déglon, J; Desmeules, J; Lauer, E; Mangin, P; Samer, C; Staub, C; Thomas, A, 2011)	0.58
" The pharmacokinetic parameters observed in Pakistani subjects when compared with other populations (USA, UK, Canadian, French, and Indian) did not show considerable ethnic differences."	( Determination of pharmacokinetics of flurbiprofen in Pakistani population using modified HPLC method. Farooqi, ZU; Najmi, MH; Qayyum, A, 2011)	0.64
"The paper is to report the establishment of a population pharmacokinetic model for flurbiprofen (FP), an active metabolite of flurbiprofen axetil (FA)."	( [Population pharmacokinetic modeling of flurbiprofen]. Gong, SJ; Huang, PF; Lin, WW; Wang, CL, 2010)	0.85
"This was an open, randomised, two-period, crossover, pharmacokinetic (PK) study in which flurbiprofen plasma levels were compared in 12 healthy volunteers after the administration of single doses (8."	( A randomised, two-period, cross-over, open-label study to evaluate the pharmacokinetic profiles of single doses of two different flurbiprofen 8.75-mg lozenges in healthy volunteers. Annoni, O; Brunner, M; Burian, A; Lauro, V; Martin, W; Matzneller, P; Tacchi, R; Zeitlinger, M, 2012)	0.81
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."	( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach. Kumar, M; Sinha, VR; Thareja, S, 2012)	0.38
" The aim of this study was to determine whether a commercially available curcuminoid/piperine extract alters the pharmacokinetic disposition of probe drugs for these enzymes in human volunteers."	( Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Badmaev, V; Court, MH; Greenblatt, DJ; Hanley, MJ; Harmatz, JS; Hazarika, S; Majeed, M; Masse, G; Volak, LP, 2013)	0.62
" The formulation is optimized based on the in vitro drug release study and further evaluated by X-ray imaging and pharmacokinetic studies in healthy humans for colonic delivery."	( Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. Veerareddy, PR; Vemula, SK, 2012)	0.6
" Plasma, urine, and cerebrospinal fluid (CSF) samples were collected for measuring drug and main metabolite concentrations and potential biomarkers of pharmacodynamic activity (β-amyloid1-40, β-amyloid1-42, soluble CD40 ligand, and tumor necrosis factor-α)."	( Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. Breda, M; Calzà, L; Casula, D; Fernandez, M; Fiorentini, F; Frigerio, E; Giardino, L; Imbimbo, BP; Norris, D; Shenouda, M; Sivilia, S, )	0.13
" The studies provide no evidence for concern about clinically important pharmacokinetic drug interactions of BBJ with substrate drugs metabolized by CYP3A or CYP2C9."	( Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. Cancalon, PF; Court, MH; Dolnikowski, GG; Greenblatt, DJ; Hanley, MJ; Harmatz, JS; Masse, G, 2013)	0.64
" Despite inhibition of CYP2C9 in vitro, pomegranate juice and extract had no effect on CYP2C9 activity in human subjects, and can be consumed by patients taking CYP2C9 substrate drugs with negligible risk of a pharmacokinetic interaction."	( Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results. Court, MH; Greenblatt, DJ; Hanley, MJ; Harmatz, JS; Masse, G, 2012)	0.61
" Pharmacokinetic parameters like AUC(0-t), AUC(0-oo), Cmax, Tmax, t½, Vd and clearance were determined."	( Comparative bioavailability and pharmacokinetics of two oral formulations of flurbiprofen: a single-dose, randomized, open-label, two-period, crossover study in Pakistani subjects. Abbas, M; Najmi, MH; Qayyum, A, 2013)	0.62
" Then the tablets were optimized with the support of in vitro dissolution studies, and further it was proved by pharmacokinetic studies."	( Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. Bontha, VK; Vemula, SK, 2013)	0.64
" The formulation is optimized based on the in vitro drug release study and further evaluated by X-ray imaging and pharmacokinetic studies in healthy humans for colonic delivery."	( Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets. Devadasu, VR; Veerareddy, PR; Vemula, SK, 2015)	0.66
" Then the formulations were evaluated for different physical parameters, solubility studies, DSC, FTIR studies and in vitro dissolution studies to select the best formulation that shows rapid dissolution rate and finally subjected to pharmacokinetic studies."	( Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. Daravath, B; Tadikonda, RR; Vemula, SK, 2015)	0.65
" From the pharmacokinetic evaluation, the control tablets produced peak plasma concentration (Cmax) of 9140."	( Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. Daravath, B; Tadikonda, RR; Vemula, SK, 2015)	0.65
" This assay was applied to determine the pharmacokinetic parameters of flurbiprofen in healthy Turkish volunteers who had been given 100 mg of flurbiprofen."	( Determination of flurbiprofen in human plasma by gas chromatography with mass spectrometry and its pharmacokinetics. Akba, V; Erdem, AF; Sahin, H; Yilmaz, B, )	0.7
"In order to assess the preliminary safety and effectiveness of nanostructured lipid carriers-based flurbiprofen gel (FP NLC-gel), the acute irritation test, in vivo pharmacodynamics evaluation and pharmacokinetic study were investigated after topical application."	( Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and percutaneous absorption mechanism. Han, F; Li, S; Song, A; Su, Z, 2015)	0.91
"The study aimed to prepare a transdermal patch for flurbiprofen using isopulegol decanoate (ISO-C10) as a permeation enhancer, and to evaluate the in-vitro and in-vivo percutaneous permeation of the drug, as well as the pharmacodynamic efficacy of the formulation."	( Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. Chen, Y; Cun, D; Fang, L; Guo, W; Liu, X; Quan, P; Song, W; Wang, Z, 2015)	0.95
"The permeation experiments were conducted on rabbit skin, and the pharmacokinetic profiles and synovial fluid drug concentration were measured after in-vivo transdermal administration."	( Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. Chen, Y; Cun, D; Fang, L; Guo, W; Liu, X; Quan, P; Song, W; Wang, Z, 2015)	0.7
" Meanwhile, the ISO-C10 contained patches increased the drug disposition in synovial fluid and enhanced the pharmacodynamic efficacy of the formulation."	( Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. Chen, Y; Cun, D; Fang, L; Guo, W; Liu, X; Quan, P; Song, W; Wang, Z, 2015)	0.7
" Then, the tablets were evaluated for both physical evaluation and drug-release studies, and to prove these results, in vivo pharmacokinetic studies in human volunteers were conducted."	( A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. Vemula, SK, 2015)	0.74
" Cmax and AUC0-∞ were dose-proportional."	( Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans. Hoshino, Y; Kamezawa, M; Matsumoto, H; Matsushita, I; Otsuka, N; Sasaki, S; Uebaba, K; Yamada, I; Yataba, I, 2016)	0.68
"No adverse events were observed during pharmacokinetic assessment."	( Pharmacokinetics and efficacy of intraocular flurbiprofen. Blazaki, S; Naoumidi, E; Tsatsakis, A; Tsatsanis, C; Tsika, C; Tsilimbaris, MK; Tzatzarakis, M, 2017)	0.71
" However, the half-life of the drug remains short, necessitating further research to prolong its presence in the vitreous cavity."	( Pharmacokinetics and efficacy of intraocular flurbiprofen. Blazaki, S; Naoumidi, E; Tsatsakis, A; Tsatsanis, C; Tsika, C; Tsilimbaris, MK; Tzatzarakis, M, 2017)	0.71
" Additionally, the effect of each method on a simulated in vivo pharmacokinetic profile was studied using advanced PBPK modelling."	( A comparison of two biorelevant in vitro drug release methods for nanotherapeutics based on advanced physiologically-based pharmacokinetic modelling. Gao, F; Jung, F; Nothnagel, L; Thurn, M; Vogel, V; Wacker, MG, 2018)	0.48
"The objective of this study was to optimize the Flurbiprofen (FB) nanosuspension (NS) based gel and to investigate the in vitro release, ex vivo permeation, the plasma concentration-time profile and pharmacokinetic parameters."	( Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. Celebi, N; Ilbasmis-Tamer, S; Oktay, AN; Uludag, O, 2021)	1.17
" Then the in-vitro release, ex vivo permeation studies were performed, and pharmacokinetic studies were evaluated on rats."	( Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. Celebi, N; Ilbasmis-Tamer, S; Oktay, AN; Uludag, O, 2021)	0.92
" The optimized FB nanosuspension gel provided better permeation and pharmacokinetic performance compared to FB coarse suspension gel."	( Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. Celebi, N; Ilbasmis-Tamer, S; Oktay, AN; Uludag, O, 2021)	0.92
" Therefore, it is of great significance to compare the in vivo pharmacokinetic behaviors of R-FP and S-FP."	( Comparison of in vivo pharmacokinetic behaviors of R- and S-flurbiprofen after intravenous injection of flurbiprofen axetil. He, Y; Li, M; Qin, F; Qin, M; Tian, B; Zhi, D, 2023)	1.15
" This study covers the formulation and pharmacokinetic study of fast-dissolving flurbiprofen tablets using PEG 6000 (hydrophilic carrier) and lactose (adsorbent)."	( Quality by design (QbD) approach to develop fast-dissolving tablets using melt-dispersion paired with surface-adsorption method: formulation and pharmacokinetics of flurbiprofen melt-dispersion granules. Daravath, B; Repka, M; Vemula, SK, 2023)	1.33

Excerpt	Reference	Relevance
" However, one study did demonstrate differences in the pharmacokinetics of 7-hydroxy-methotrexate, the active metabolite of MTX, when MTX was administered with aspirin."	( Methotrexate and nonsteroidal antiinflammatory drug interactions. Frenia, ML; Long, KS, 1992)	0.28
" In the present study, we have investigated the effect of oral terfenadine 180 mg, flurbiprofen 100 mg, and the drug combination on AMP-induced bronchoconstriction in eight nonatopic asthmatic subjects with a mean age of 53."	( The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate in nonatopic asthma. Holgate, ST; Phillips, GD, 1989)	0.74
"Two patients with orthostatic hypotension, complicating diabetes mellitus, were treated with dopaminergic antagonist metoclopramide alone or combined with the nonsteroidal anti-inflammatory agent flurbiprofen."	( Metoclopramide alone or combined with flurbiprofen in the treatment of orthostatic hypotension associated with diabetes mellitus. Beretta-Piccoli, C; Weidmann, P, 1982)	0.72
"3 variant exhibits marked decreases in substrate turnover compared with the wild-type enzyme, but little is known regarding the effect this variant form may have on the occurrence of drug-drug interactions."	( CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Gannett, PM; Hummel, MA; Locuson, CW; Mosher, CM; Rettie, AE; Rock, DA; Tracy, TS, 2005)	0.33
"To observe the effect of propofol combined with flurbiprofen axetil for abortion anesthesia."	( [Clinical observation of propofol combined with flurbiprofen axetil for induced abortion anesthesia]. Guo, QL; Xie, YQ; Yang, HW, 2006)	0.85
"Propofol combined with flurbiprofen axetil gives more efficient anesthesia for induced abortion patients in gynecology department."	( [Clinical observation of propofol combined with flurbiprofen axetil for induced abortion anesthesia]. Guo, QL; Xie, YQ; Yang, HW, 2006)	0.9
"To investigate the effect of flurbiprofen preemptive analgesia combined with intravenous propofol anesthesia in induced abortion."	( [Application of flurbiprofen preemptive analgesia combined with intravenous propofol anesthesia in induced abortion]. Lao, JX; Liu, WX; Tan, SX; Zhang, YF, 2008)	0.98
"Flurbiprofen preemptive analgesia combined with intravenous propofol is safe and effective for anesthesia during induced abortion."	( [Application of flurbiprofen preemptive analgesia combined with intravenous propofol anesthesia in induced abortion]. Lao, JX; Liu, WX; Tan, SX; Zhang, YF, 2008)	2.13
"a To observe the analgesic effect of fentanyl combined with flurbiprofen axetil for postoperative analgesia after gynecologic surgery."	( [Postoperative analgesia with fentanyl combined with flurbiprofen axetil following gynecologic surgery for turnor]. Bai, XH; Cao, LH; Lin, WQ; Wen, LL; Zhong, ZJ, 2009)	0.84
"Flurbiprofen axetil combined with fentanyl for postoperative analgesia can significantly reduce fentanyl dose and the incidence of adverse effects associated with fentanyl without obviously affecting the coagulation and gastrointestinal functions."	( [Postoperative analgesia with fentanyl combined with flurbiprofen axetil following gynecologic surgery for turnor]. Bai, XH; Cao, LH; Lin, WQ; Wen, LL; Zhong, ZJ, 2009)	2.05
" While grapefruit juice has been extensively studied with respect to its drug-drug interaction potential, numerous other fruit juices such as cranberry juice, orange juice, grape juice, pineapple juice and pomegranate juice have also been investigated for its potential to show drug-drug interaction of any clinical relevance."	( Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence. Srinivas, NR, 2013)	0.39
"EA intervention combined with anesthetics is effective in reducing the dosage of the supplemented Sauteralgyl and the degree of postoperative nausea, and in improving postoperative gastrointestinal functional recovery in patients undergoing pneumectomy."	( [Electroacupuncture Intervention Combined with Anesthetics for Analgesia and Post-surgical Gastrointestinal Recovery in Pneumectomy Patients]. Chen, TY; Ma, W; Wang, K; Wu, YY; Xu, JJ; Zhou, J, 2015)	0.42
" To further validate this cocktail, in this study, we have verified whether probe drugs contained in the latter cause mutual drug-drug interactions."	( Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method. Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Thomas, A; Walder, B, 2016)	0.43
" We hypothesize that different doses of oxycodone hydrochloride combined with flurbiprofen axetil would generate great results on postoperative intravenous analgesia in lower abdominal patients."	( Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial. Fang, J; Lian, Y; Wu, Y; Xiang, X; Yuan, X, 2018)	0.96
"75 mg/kg oxycodone hydrochloride combined with flurbiprofen axetil can provide safe and effective postoperative analgesia for lower abdominal patients, with fewer adverse reactions."	( Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial. Fang, J; Lian, Y; Wu, Y; Xiang, X; Yuan, X, 2018)	0.99
"To evaluate the anesthetic effect of ultrasound-guided (USG) ilioinguinal/iliohypogastric nerve (II/IHN) block combined with genital branch of genitofemoral nerve (GFN) block in the elderly undergoing inguinal hernia repair, 54 old patients (aged 60-96years, ASA I-III) with indirect hernia were enrolled and scheduled for unilateral tension-free herniorrhaphy."	( Evaluation of Ultrasound-guided Genitofemoral Nerve Block Combined with Ilioinguinal/iliohypogastric Nerve Block during Inguinal Hernia Repair in the Elderly. Huang, Z; Ke, JY; Peng, XH; Wang, W; Xia, W, 2019)	0.51
" Nonetheless, only few studies have evaluated the clinical therapeutic effects of lidocaine combination with flurbiprofen axetil to prevent pain on injection of propofol."	( Clinical therapeutic effects of lidocaine combination with flurbiprofen axetil for reducing propofol-induced pain in adults: A protocol for systematic review and meta-analysis. Fu, J; Lu, G; Sun, W; Ye, X; Yu, J, 2020)	1.01
"This study will provide high-quality evidence for the clinical therapeutic effects of lidocaine combination with flurbiprofen axetil for reducing pain on injection of propofol in adult patients."	( Clinical therapeutic effects of lidocaine combination with flurbiprofen axetil for reducing propofol-induced pain in adults: A protocol for systematic review and meta-analysis. Fu, J; Lu, G; Sun, W; Ye, X; Yu, J, 2020)	1.01
"To evaluate the safety and efficacy of sedation and analgesia using dexmedetomidine combined with flurbiprofen axetil in multiple complex teeth extraction under local anesthesia."	( [Evaluation of the application of dexmedetomidine combined with flurbiprofen axetil in extraction of multiple complex teeth under local anesthesia]. He, H; Liu, H; Qi, M; Shao, Y; Sheng, L, 2021)	1.08
"According to the inclusion and exclusion criteria of the study, 40 patients scheduled for multiple complex teeth (4-6) extraction were randomly divided into 2 groups: experimental group (sedation and analgesia using dexmedetomidine combined with flurbiprofen axetil in addition to local anesthesia, n=20) and control group (local anesthesia, n=20)."	( [Evaluation of the application of dexmedetomidine combined with flurbiprofen axetil in extraction of multiple complex teeth under local anesthesia]. He, H; Liu, H; Qi, M; Shao, Y; Sheng, L, 2021)	1.04
"Sedation and analgesia using dexmedetomidine combined with flurbiprofen axetil in addition to local anesthesia is a safe and effective approach in multiple complex teeth extraction."	( [Evaluation of the application of dexmedetomidine combined with flurbiprofen axetil in extraction of multiple complex teeth under local anesthesia]. He, H; Liu, H; Qi, M; Shao, Y; Sheng, L, 2021)	1.1
"To explore the effect of dexmedetomidine combined with flurbiprofen axetil on postoperative analgesia and immune function in patients with lung cancer after radical operation."	( Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. Chen, Y; Du, J; Tao, H; Zong, S, )	0.63
"60 lung cancer patients undergoing open chest radical surgery were selected and randomly divided into D & F Group (dexmedetomidine combined with flurbiprofen axetil) and F Group (flurbiprofen axetil), with 30 cases in each group."	( Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. Chen, Y; Du, J; Tao, H; Zong, S, )	0.58
"Flurbiprofen axetil can improve postoperative pain, but combined with dexmedetomidine better effect, postoperative comfort and immune function of patients were significantly improved."	( Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. Chen, Y; Du, J; Tao, H; Zong, S, )	1.82
"To investigated the effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine for patient-controlled intravenous analgesia (PCIA) on patients after open gastrointestinal tumor surgery, and compared this combination with traditional PCIA with pure opioids or epidural analgesia (PCEA)."	( Analgesic effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine after open gastrointestinal tumor surgery: a retrospective study. Chen, YJ; Huang, J; Li, TT; Liu, F; Wang, TH; Xiong, LL; Yin, L, 2022)	1.21
"The analgesic effects of PCIA with sufentanil in combination with flurbiprofen axetil and dexmedetomidine on postoperative analgesia was better than that of traditional pure opioids PCIA, and similar with that of PCEA."	( Analgesic effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine after open gastrointestinal tumor surgery: a retrospective study. Chen, YJ; Huang, J; Li, TT; Liu, F; Wang, TH; Xiong, LL; Yin, L, 2022)	1.21
" This study aimed to compare the analgesic effects of tramadol alone and combined with butorphanol or flurbiprofen axetil after a cesarean section."	( Analgesic outcomes of tramadol alone and in combination with Butorphanol or Flurbiprofen Axetil after cesarean section: a retrospective study with propensity score matching analysis. Bao, X; Deng, Q; Li, H; Liang, Y; Liu, W; Peng, J; Tan, D; Wu, Z; Yan, G; Yang, G, 2022)	1.17
"To determine the analgesic effect of flurbiprofen axetil (FBA) combined with half standard-dose opioids in patients undergoing primary unilateral total knee arthroplasty (TKA)."	( Analgesia with reduced incidence of adverse reactions using flurbiprofen axetil in combination with half standard-dose opioids in primary total knee arthroplasty. Cai, H; Lin, Q; Liu, J; Shen, J; Wu, X; Xiao, J; Zhao, C; Zhu, J, 2023)	1.43
" All patients received the same dose of FBA in the form of a patient-controlled intravenous analgesia but in the control group this was combined with a standard-dose of opioids and in the experimental group with a half standard-dose of opioids."	( Analgesia with reduced incidence of adverse reactions using flurbiprofen axetil in combination with half standard-dose opioids in primary total knee arthroplasty. Cai, H; Lin, Q; Liu, J; Shen, J; Wu, X; Xiao, J; Zhao, C; Zhu, J, 2023)	1.15
"The analgesic effect of FBA in combination with half standard-dose opioids was similar to that of FBA in combination with conventional standard-dose opioids, but the incidence of adverse effects involving nausea/vomiting in the experimental group were significantly reduced."	( Analgesia with reduced incidence of adverse reactions using flurbiprofen axetil in combination with half standard-dose opioids in primary total knee arthroplasty. Cai, H; Lin, Q; Liu, J; Shen, J; Wu, X; Xiao, J; Zhao, C; Zhu, J, 2023)	1.15
" Plant-based therapeutic agents including essential oils in combination with low-dose synthetic drugs have been shown to produce synergistic effects and reduce complications of synthetic drugs."	( Anti-inflammatory mechanisms of eucalyptol rich Eucalyptus globulus essential oil alone and in combination with flurbiprofen. Arooj, B; Asghar, S; Asif, M; Chohan, T; Khalid, SH; Khan, IU; Saleem, M; Yaseen, HS; Zubair, HM, 2023)	1.12

Excerpt	Reference	Relevance
"In this randomized, crossover study comparing the bioavailability of a film-coated (Ansaid) with a sugar-coated (Froben) 100 mg tablets of racemic flurbiprofen in 23 healthy young men, no significant differences were found for Cmax, tmax or AUC, using a nonstereoisomeric assay for flurbiprofen."	( Comparative bioavailability of two flurbiprofen products: stereospecific versus conventional approach. Berry, BW; Cheung, H; Cheung, R; Collins, DS; Jamali, F; McColl, K; Molder, S, )	0.61
" After rectal administration, the rate of absorption evaluated through tmax and calculation of mean absorption times was always slower than after oral dosing."	( Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. Guentert, TW; Schmitt, M, 1990)	0.28
" Dialysis was carried out using plasma samples obtained from five of 15 subjects participating in a crossover bioavailability study."	( Pharmacokinetics of flurbiprofen in man. II. Plasma protein binding. Albert, KS; Szpunar, GJ; Wagner, JG, 1989)	0.6
"The bioavailability of granules and tablet flurbiprofen in 100 mg single dose was crossover compared in 6 healthy volunteers (mean aged 26."	( Single-dose pharmacokinetics of flurbiprofen granules and tablets in healthy volunteers. Bandi, G; Benvenuti, C; Gambaro, V; Lodi, F; Scaroni, C; Valenti, M, 1989)	0.82
" Flurbiprofen was buccally absorbed by a passive diffusional mechanism and the rate of absorption was pH dependent."	( Human buccal absorption of flurbiprofen. Adkins, EL; Barsuhn, CL; Gleason, DD; Ho, NF; Olanoff, LS, 1988)	1.48
"The ocular bioavailability of radiolabeled flurbiprofen was determined after single or multiple topical dosing of rabbits."	( Multiple dosing increases the ocular bioavailability of topically administered flurbiprofen. Anderson, JA; Chen, CC, 1988)	0.77
" Following a single oral dose of 100 mg of flurbiprofen, drug bioavailability is equivalent using regimens of four 25-mg tablets, two 50-mg tablets, or one 100-mg tablet once daily."	( Pharmacokinetics of flurbiprofen. Brooks, CD; Kaiser, DG; Lomen, PL, 1986)	0.86
" Flurbiprofen showed equivalent bioavailability after oral and rectal administration and the same pharmacokinetic profile was confirmed in children as observed in adults."	( Pharmacokinetics of oral and rectal flurbiprofen in children. Benvenuti, C; D'Amico, E; Hind, ID; Mazzoni, PL; Scaroni, C, 1984)	1.45
" The method is applicable to human bioavailability and pharmacokinetic studies with flurbiprofen."	( Determination of flurbiprofen in human serum by reverse-phase high-performance liquid chromatography with fluorescence detection. Albert, KS; Garry, M; Gillespie, WR; Raabe, A, 1984)	0.83
" The ocular bioavailability of the ophthalmic dose was defined by using intracameral administration as a standard measurement."	( Ocular and systemic bioavailability of ophthalmic flurbiprofen. Liu, SS; Tang-Liu, DD; Weinkam, RJ, 1984)	0.52
"In a study of the ocular absorption and elimination of a topically applied non-steroidal anti-inflammatory drug (NSAID), flurbiprofen, the compound was well absorbed into rabbit ocular tissues and was highly concentrated in the rabbit cornea."	( Disposition of topical flurbiprofen in normal and aphakic rabbit eyes. Anderson, JA; Chen, CC; Shackleton, M; Vita, JB, 1982)	0.78
" Flurbiprofen did not seem to alter the bioavailability of the chemotherapeutic agents."	( Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy. Bennett, A; Berstock, DA; Carroll, MA, 1982)	1.17
" The enhanced bioavailability of flurbiprofen suggests the possible utility of tri-O-methyl-beta-cyclodextrin in pharmaceutical formulation."	( Enhanced oral bioavailability of antiinflammatory drug flurbiprofen in rabbits by tri-O-methyl-beta-cyclodextrin complexation. Imai, T; Otagiri, M; Uekama, K, 1982)	0.79
" These methods were applied to bioavailability studies in dogs."	( Determination of flurbiprofen and ibuprofen in dog serum with automated sample preparation. Beaubien, LJ; Rahn, PD; Sears, DJ; Snider, BG, 1981)	0.6
" The absorption rate constant was increased significantly after multiple administration as compared to that of single administration."	( Effect of oral multiple-dose administration of anti-inflammatory flurbiprofen chimera drug on gastric lesion, other toxicities and disposition kinetics. Fukuhara, A; Imai, T; Inoue, K; Otagiri, M, 1995)	0.53
" Although with these preparations the peak plasma drug concentration is reduced and time taken to achieve peak concentrations is prolonged, the bioavailability is the same as that with regular release counterparts."	( Clinical pharmacokinetics of flurbiprofen and its enantiomers. Davies, NM, 1995)	0.58
"To compare the bioavailability and pupillary effect of flurbiprofen and indomethacin during phacoemulsification and intraocular lens implantation."	( Intraocular availability and pupillary effect of flurbiprofen and indomethacin during cataract surgery. Cheetham, JK; DeGryse, R; Garcia, CG; Gimbel, H; Van Westenbrugge, J, 1996)	0.8
" In humans, the bioavailability of racemic flurbiprofen absorbed from the oral cavity has been studied measuring the total concentration of S- and R-flurbiprofen, and the pharmacokinetics of S- and R-flurbiprofen have been studied after oral administration of racemic flurbiprofen."	( Human plasma concentrations of R, S, and racemic flurbiprofen given as a toothpaste. Arnett, RL; Clifford, KH; Cutler, RE; Forland, SC; Wechter, WJ; Witchwoot, S, 1996)	0.81
" Although food did not affect the bioavailability of this formulation, there was a statistically significant increase in the mean (+/-SE) concentration of the first peak (Cpeak 1) from 14."	( The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. Kelkar, MG; Nayak, PJ; Pargal, A, 1996)	0.54
"The interactions between flurbiprofen (FB) and different polymers are studied in order to improve the bioavailability of FB."	( An investigation of FB interactions with poly(ethylene glycol) 6000, poly(ethylene glycol) 4000, and poly-epsilon-caprolactone by thermoanalytical and spectroscopic methods and modeling. Chauvet, A; Egea, MA; Garcia, ML; Lacoulonche, F; Masse, J, 1998)	0.6
" Thus, alterations in both plasma extravasation and tissue pH seem to be relevant factors regulating the delivery and bioavailability of this nonsteroidal anti-inflammatory drug to dental pulp."	( Effect of inflammation on the delivery of drugs to dental pulp. Bunczak-Reeh, MA; Hargreaves, KM, 1998)	0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" FP (1%) gel containing ethanol (25%) and l-menthol (3%) as penetration enhancers was applied to rabbit dorsal skin and the in vivo absorption rate of FP was compared with the in vitro penetration rate through excised skin."	( Effect of l-menthol-ethanol-water system on the systemic absorption of flurbiprofen after repeated topical applications in rabbits. Hayashi, T; Kawabata, S; Morimoto, Y; Seki, T; Sugibayashi, K, 2000)	0.54
" The oral bioavailability of Flu from Flu or Flu/beta-CD at doses of 1, 3, 10, and 30 mg/kg (as Flu) was examined in rats."	( Evaluation of the bioavailability of flurbiprofen and its beta-cyclodextrin inclusion complex in four different doses upon oral administration to rats. Machida, Y; Muraoka, A; Tokumura, T, 2004)	0.6
" The bioavailability of drug when administered as SD was evaluated in humans."	( Formulation studies and in vivo evaluation of a flurbiprofen-hydroxypropyl beta-cyclodextrin system. Govindarajan, R; Nagarsenker, MS, 2005)	0.58
" Therefore, a semi-solid dispersion of flurbiprofen with Gelucire and Labrasol may have the potential of improved bioavailability because of the enhanced in vitro properties."	( Preparation and in vitro characterization of a semi-solid dispersion of flurbiprofen with Gelucire 44/14 and Labrasol. Khan, MA; Soliman, MS, 2005)	0.83
" In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system."	( Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. Bigogno, C; Biscaioli, M; Bolzoni, PT; Caruso, P; Catinella, S; Cenacchi, V; Del Giudice, E; Dondio, G; Facchinetti, F; Fontanella, L; Imbimbo, BP; Marchetti, S; Misiano, P; Moretto, N; Parini, C; Peretto, I; Puccini, P; Radaelli, S; Raveglia, LF; Riccardi, B; Rizzi, A; Rondelli, I; Villetti, G; Zandi, M, 2005)	0.6
"84% relative bioavailability compared to immediate release tablet of flurbiprofen."	( Wet process-induced phase-transited drug delivery system: a means for achieving osmotic, controlled, and level A IVIVC for poorly water-soluble drug. Pathak, K; Philip, AK, 2008)	0.58
"Improvement of the oral bioavailability of flurbiprofen (Flu) after oral administration of flurbiprofen/beta-cyclodextrin inclusion complex (Flu/beta-CD) by the action of cinnarizine (CN) was investigated."	( Improvement of oral bioavailability of flurbiprofen from flurbiprofen/beta-cyclodextrin inclusion complex by action of cinnarizine. Machida, Y; Muraoka, A; Tokumura, T, 2009)	0.88
"The main purpose of this study was to evaluate the effect of a mixed drug solution containing a surfactant and beta-cyclodextrin (beta-CD) on the solubility and bioavailability of a poorly water soluble drug, flurbiprofen."	( Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound. Balakrishnan, P; Choi, HG; Han, MJ; Joe, JH; Kim, JO; Li, DX; Oh, DH; Park, SM; Seo, Y; Yan, YD; Yong, CS, 2010)	0.83
"The feasibility of alpha-glucosyl hesperidin (Hsp-G) to improve the dissolution and bioavailability of poorly water-soluble drug was investigated."	( Improvement of dissolution and absorption properties of poorly water-soluble drug by preparing spray-dried powders with alpha-glucosyl hesperidin. Imono, M; Takeuchi, H; Tozuka, Y; Uchiyama, H, 2010)	0.36
"This study compared the pharmacokinetic parameters and bioavailability of flurbiprofen from the investigational enteric-coated tablet (test) and from a film-coated immediate-release tablet compounded for the purposes of this study (reference)."	( Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers. Ahmad, M; Pervaiz, F, 2010)	0.8
"In this small study in healthy Pakistani male subjects, there were significant differences in the bioavailability and pharmacokinetic parameters of the enteric- and film-coated tablet formulations of flurbiprofen."	( Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers. Ahmad, M; Pervaiz, F, 2010)	0.76
"The capability of transglycosylated materials, α-glycosyltransferase-treated stevia (Stevia-G) and α-glycosyl hesperidin (Hsp-G), to enhance the bioavailability of poorly water-soluble drugs was investigated."	( Transglycosylated stevia and hesperidin as pharmaceutical excipients: dramatic improvement in drug dissolution and bioavailability. Imono, M; Takeuchi, H; Tozuka, Y; Uchiyama, H, 2010)	0.36
" These results suggest that FP from LM chitosan kneaded mixture increases the dissolution rate and improves the bioavailability of the drug by the formation of a water-soluble complex."	( Enhancement of dissolution and bioavailability of flurbiprofen by low molecular weight chitosans. Anraku, M; Arahira, M; Imai, T; Khaled, KA; Mady, FM; Otagiri, M; Seo, H; Yamasaki, K, 2010)	0.61
" The dissolution and bioavailability in rats were evaluated compared to commercial product."	( Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change. Choi, HG; Kang, JH; Oh, DH; Park, YJ; Yong, CS, 2011)	0.61
" The apparent bioavailability of oral flurbiprofen syrup was 81%."	( Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. Hooker, A; Kokki, H; Kokki, M; Kumpulainen, E; Lehtonen, M; Ranta, VP; Välitalo, P, 2010)	0.88
"9 times higher than that of the flurbiprofen sodium eye drops respectively, which meant that the ocular bioavailability was improved greatly by the novel preparation."	( [Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil]. Gan, L; Gan, Y; Shen, JQ; Zhu, CL; Zhu, JB, 2010)	0.88
" To improve the solubility and bioavailability of flurbiprofen (poor water solubility), a solid dispersion was spray dried with a solution of flurbiprofen and cycloamylose at a weight ratio of 1:1."	( Enhanced solubility and bioavailability of flurbiprofen by cycloamylose. Baek, HH; Choi, HG; Hah, JM; Kim, YR; Kwon, SY; Lee, WS; Rho, SJ; Yang, HJ; Yong, CS, 2011)	0.89
"α-Glucosylhesperidin (Hsp-G), a functional food additive, significantly enhances the solubility and bioavailability of poorly water-soluble drugs despite little surface activity."	( NMR investigation of a novel excipient, α-glucosylhesperidin, as a suitable solubilizing agent for poorly water-soluble drugs. Higashi, K; Moribe, K; Takeuchi, H; Tozuka, Y; Uchiyama, H; Yamamoto, K; Zhang, J, 2011)	0.37
" Similarly, they greatly improved the dissolution rate and oral bioavailability of flurbiprofen in rats due to the fast spontaneous emulsion formation and the decreased droplet size."	( Comparison of solid self-microemulsifying drug delivery system (solid SMEDDS) prepared with hydrophilic and hydrophobic solid carrier. Choi, HG; Kang, JH; Kim, DW; Kim, JO; Lee, BJ; Oh, DH; Yong, CS, 2011)	0.59
"In order to investigate the effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in a solid self-nanoemulsifying drug delivery system (solid SNEDDS), different solid SNEDDS formulations were prepared by spray-drying the solutions containing liquid SNEDDS and various carriers."	( Effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in solid self-nanoemulsifying drug delivery system (solid SNEDDS). Choi, HG; Kang, JH; Oh, DH; Oh, YK; Yong, CS, 2012)	0.81
"To develop a novel flurbiprofen-loaded solid self-microemulsifying drug delivery system (solid SMEDDS) with improved oral bioavailability using gelatin as a solid carrier, the solid SMEDDS formulation was prepared by spray-drying the solutions containing liquid SMEDDS and gelatin."	( Development of novel flurbiprofen-loaded solid self-microemulsifying drug delivery system using gelatin as solid carrier. Choi, HG; Kang, JH; Kim, DW; Oh, DH; Yong, CS, 2012)	1.03
"2-fold increase in relative oral bioavailability compared with that of the suspension."	( Development and optimization of self-nanoemulsifying drug delivery system with enhanced bioavailability by Box-Behnken design and desirability function. Choi, HG; Kim, JO; Marasini, N; Poudel, BK; Yan, YD; Yong, CS, 2012)	0.38
" Therefore, these flurbiprofen-loaded nanoparticles can be convenient for distributing a poorly water-soluble flurbiprofen with improved bioavailability using uniform nano-sized particles."	( Flurbiprofen-loaded nanoparticles prepared with polyvinylpyrrolidone using Shirasu porous glass membranes and a spray-drying technique: nano-sized formation and improved bioavailability. Choi, HG; Din, FU; Kim, DW; Kim, JO; Oh, DH; Yong, CS, 2013)	2.17
" Furthermore, dissolution and bioavailability in rats were evaluated compared to a flurbiprofen-loaded commercial product."	( Development of flurbiprofen-loaded nanoparticles with a narrow size distribution using sucrose. Choi, HG; Kim, DW; Kim, JO; Oh, DH; Yan, YD; Yong, CS, 2014)	0.98
" The bioavailability of flurbiprofen from optimized nanoparticles was assessed in male Wistar rats at a dose of 15 mg/kg."	( Enhanced bioavailability of orally administered flurbiprofen by combined use of hydroxypropyl-cyclodextrin and poly(alkyl-cyanoacrylate) nanoparticles. Li, W; Luo, Q; Zhang, X; Zhao, X, 2014)	0.96
"Comparative bioavailability studies are conducted to establish the bioequivalence of generic formulation with that of branded reference formulation, providing confidence to clinicians to use these products interchangeably."	( Comparative bioavailability and pharmacokinetics of two oral formulations of flurbiprofen: a single-dose, randomized, open-label, two-period, crossover study in Pakistani subjects. Abbas, M; Najmi, MH; Qayyum, A, 2013)	0.62
"This study aimed to develop an oral delivery system using clay-based organic-inorganic hybrid materials to improve the bioavailability of the drug, flurbiprofen, which is poorly soluble in water."	( 3-aminopropyl functionalized magnesium phyllosilicate as an organoclay based drug carrier for improving the bioavailability of flurbiprofen. Choi, SK; Han, HK; Shin, HJ; Yang, L, 2013)	0.8
"Development of solid dispersions is to improve the therapeutic efficacy by increasing the drug solubility, dissolution rate, bioavailability as well as to attain rapid onset of action."	( Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. Daravath, B; Tadikonda, RR; Vemula, SK, 2015)	0.65
"From the above results, it is concluded that the formulation of gelucire 44/14 solid dispersions is able to improve the solubility, dissolution rate as well as the absorption rate of flurbiprofen than pure form of drug."	( Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. Daravath, B; Tadikonda, RR; Vemula, SK, 2015)	0.85
" In this study, we have investigated the bioavailability of a new generic formulation of flurbiprofen lozenges developed by Epifarma Srl, compared to the originator Benactiv Gola® taken as reference."	( Influence of the oral dissolution time on the absorption rate of locally administered solid formulations for oromucosal use: the flurbiprofen lozenges paradigm. De Gregori, S; Imberti, R; Lisi, L; Navarra, P, 2014)	0.83
"The purpose of this study was to develop novel solid lipid nanoparticle (SLN)-loaded dual-reverse thermosensitive hydrogel (DRTH) for rectal administration of flurbiprofen with improved bioavailability and reduced initial burst effect."	( Novel dual-reverse thermosensitive solid lipid nanoparticle-loaded hydrogel for rectal administration of flurbiprofen with improved bioavailability and reduced initial burst effect. Choi, HG; Choi, JY; Din, FU; Kim, DW; Kim, JO; Ku, SK; Mustapha, O; Park, JH; Rashid, R; Yong, CS, 2015)	0.83
" The relative bioavailability of FP-HP-β-CD COE loaded liposomes was 420%, 201% and 402% compared with FP solution, FP-HP-β-CD and FP-liposomes, respectively."	( Drug-in-cyclodextrin-in-liposomes: A novel drug delivery system for flurbiprofen. Chen, F; Lin, C; Pan, W; Wang, X; Yang, X; Zhang, L; Zhang, Q; Zhang, W, 2015)	0.65
"In this study, a novel controlled release osmotic pump capsule consisting of pH-modulated solid dispersion for poorly soluble drug flurbiprofen (FP) was developed to improve the solubility and oral bioavailability of FP and to minimize the fluctuation of plasma concentration."	( A novel osmotic pump-based controlled delivery system consisting of pH-modulated solid dispersion for poorly soluble drug flurbiprofen: in vitro and in vivo evaluation. Li, S; Liu, D; Pan, W; Wang, X; Wang, Y; Yang, X; Zhang, L; Zhao, Q, 2015)	0.83
" The LCT-SNEDDS was considered to be superior for enhancement of the drug bioavailability when compared with other SNEDDS formulations and market product."	( Studies on self-nanoemulsifying drug delivery system of flurbiprofen employing long, medium and short chain triglycerides. Daar, J; Khan, A; Khan, GM; Khan, J, 2017)	0.7
" A significant higher bioavailability of gabapentin administered 30min after meal, compared to fasting conditions or to dose administration 10min before meal, argued in favor of the gastro-retention of gabapentin prolonged release layer."	( Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect. Barchielli, M; Bettini, R; Buttini, F; Colombo, G; Colombo, P; Conti, C; Leoni, B; Loprete, L; Rossi, A; Sonvico, F, 2017)	0.7
"A novel Flurbiprofen (FLB)-in-liposome-in-hydrogel formulation was developed, as a method to sustain the release and increase the ocular bioavailability of FLB following intravitreal injection."	( Sustained release of intravitreal flurbiprofen from a novel drug-in-liposome-in-hydrogel formulation. Antimisiaris, SG; Blazaki, S; Klepetsanis, P; Naoumidi, E; Pachis, K; Tsilimbaris, M; Tzatzarakis, M, 2017)	1.17
" In this study, we evaluated the intravitreal bioavailability and anti-inflammatory efficacy of flurbiprofen in rabbit eyes."	( Pharmacokinetics and efficacy of intraocular flurbiprofen. Blazaki, S; Naoumidi, E; Tsatsakis, A; Tsatsanis, C; Tsika, C; Tsilimbaris, MK; Tzatzarakis, M, 2017)	0.93
"A major challenge in ocular therapeutics is poor bioavailability of drug, 1% or even less of the instilled dose is absorbed and frequent administration of conventional products leads to poor adherence to therapy."	( Preparation and Evaluation of N-Trimethyl Chitosan Nanoparticles of Flurbiprofen for Ocular Delivery. Jain, DD; Joshi, PN; Shinde, UA; Singh, K, 2019)	0.75
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"Flurbiprofen (FP) is one of the most potent nonsteroidal anti-inflammatory drugs with very low bioavailability of approximately 12% following transdermal administration, compared to that after oral administration."	( Development of galangal essential oil-based microemulsion gel for transdermal delivery of flurbiprofen: simultaneous permeability evaluation of flurbiprofen and 1,8-cineole. Chen, J; Dong, J; Dong, YF; Feng, H; Gu, W; Wu, FY; Yang, BQ; Zhu, XM, 2020)	2.22
" Absolute bioavailability was 33% and 58% for microparticles and pellets, respectively."	( Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation. Balafas, E; Banella, S; Bortolotti, F; Colombo, G; Colombo, P; Kostomitsopoulos, N; Manniello, MD; Napoli, L; Papakyriakopoulou, P; Quarta, E; Rekkas, DM; Russo, P; Tiozzo Fasiolo, L; Valsami, G, 2021)	2.06
" In the rat model, in vivo pharmacokinetic parameters confirmed the improved relative bioavailability of reduced graphene oxide hydrogel when compared with the control hydrogel (without reduced graphene oxide) and marketed transdermal patch."	( Transdermal delivery of flurbiprofen from polyoxypropylene-polyoxyethylene block copolymer stabilized reduced graphene oxide to manage pain in spondylitis: In vitro and in vivo studies. Li, T; Yang, C, 2021)	0.93
" Thereby, the increase in the drug bioavailability and efficiency must come from the mucoadhesion optimization of the drug delivery system."	( Parametric Drug Release Optimization of Anti-Inflammatory Drugs by Gold Nanoparticles for Topically Applied Ocular Therapy. Boisselier, E; Loiseau, A; Maranda, C; Poliquin, A; Raiche-Marcoux, G, 2022)	0.72

Excerpt	Relevance	Reference
" To date, 1220 patients have received the drug in a dosage varying from 75 mg to 400 mg daily."	( A long-term assessment of flurbiprofen. Marsh, BD; Sheldrake, FE; Webber, JM, 1977)	0.56
"Fifteen patients with seropositive rheumatoid arthritis were treated for 2-weeks periods with 150 mg flurbiprofen daily and with flubriprofen in the same dosage plus 3 g aspirin daily, the treatments being administered in random allocation."	( Flurbiprofen-aspirin interaction: a double-blind crossover study. Brooks, PM; Khong, TK, 1977)	1.92
" After dosing with [14C]flurbiprofen, tissue levels of radioactivity in dog and baboon were similar to that in plasma."	( The disposition and metabolism of flurbiprofen in several species including man. Adams, SS; Crampton, EL; Marchant, B; Risdall, PC, 1978)	0.84
" During the first week, the patients' steroid dosage was stabilized at the minimum necessary to control symptoms."	( Steroid-sparing action of flurbiprofen: use of an additional parameter of joint scans with 99m technetium. Desai, MM; Joshi, VR; Lele, RD; Nagarwala, HK; Pispati, PK; Virani, AR, 1977)	0.56
" It was planned that, unless withdrawn, patients from matched pairs received either flurbiprofen (150 mg to 300 mg daily) or indomethacin (75 mg to 150 mg daily) over a minimum period of 6 months, dosage being adjusted to suit exacerbations and remission of disease."	( A comparative study of the long-term efficacy of flurbiprofen and indomethacin in the treatment of rheumatoid arthritis, with special reference to iron metabolism. Bulgen, DY; Hazleman, BL, 1977)	0.74
" 2 Each patient was given a long-term supply of drug and was asked to vary their own dosage within simple limits, according to the severity of their symptoms."	( Continued use of non-steroidal anti-inflammatory drugs: an index of clinical efficacy. Buchanan, WW; Capell, HA; Dick, WC; Paterson, S; Rooney, PJ, 1978)	0.26
" Superfusion of the arterial segment with PGI2 demonstrates a dose-response related inhibition of ADP-induced thrombosis."	( The role of prostaglandins in platelet-vessel wall interaction. Andries, R; Bourgain, RH; Finne, E, 1979)	0.26
" Ibuprofen showed suppression in most tissues three hours after dosing with a return to control values by twenty-four hours."	( In vivo suppression of prostaglandin biosynthesis by non-steroidal anti-inflammatory agents. Fitzpatrick, FA; Wynalda, MA, 1976)	0.26
" The very shallow dose-response curves for flurbiprofen compared with acetylsalicylic acid, especially in the mouse and the rat test systems, are not due to an unreliable or abnormal absorption, which suggests that in these species the mode of action of flurbiprofen is not identical with that of acetylsalicylic acid."	( Some biological properties of flurbiprofen, an anti-inflammatory, analgesic and antipyretic agent. Adams, SS; McCullough, KF; Nicholson, JS, 1975)	0.81
" The effects of different polymer ratios of Eudragit RS30D and Eudragit RL30D, different particle sizes, and different combination of various formulations of solid dispersions on the in vitro release kinetics of drugs from the dosage forms were investigated."	( Development of extended-release solid dispersions of nonsteroidal antiinflammatory drugs with aqueous polymeric dispersions: optimization of drug release via a curve-fitting technique. Ho, C; Hwang, GC, 1992)	0.28
" The disposition of flurbiprofen enantiomers was not changed upon multiple dosing and no evidence of futile cycling was found."	( Stereoselective disposition of flurbiprofen in uraemic patients. Brater, DC; Hall, SD; Knadler, MP, 1992)	0.89
"The pharmacokinetics of flurbiprofen (Ansaid Tablets, Upjohn Company of Canada, Don Mills, Ontario) were evaluated in both younger (40 to 60 years) and elderly (65 to 83 years) rheumatoid arthritic patients after both a 100-mg single-dose administration and at steady state during a 100-mg twice-a-day dosage regimen."	( The pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis. Antal, EJ; Buchanan, WW; Cauvier, H; Grace, EM; Kean, WF; Rischke, J, 1992)	0.9
" For preliminary dose-response studies, antibiotic sensitivity blank disks loaded with 10 microliters of flurbiprofen 250 micrograms, 50 micrograms and 5 micrograms, or ibuprofen 500 micrograms, 50 micrograms and 5 micrograms were placed on the seeded agar plates."	( Antimicrobial activity of flurbiprofen and ibuprofen in vitro against six common periodontal pathogens. Fleury, AA; Hammond, BF; Hersh, EV, 1991)	0.8
" Flurbiprofen in 50 mg and 100 mg dosages demonstrated effective analgesic activity with the 100 mg dosage being at least as effective as the acetaminophen/codeine combination."	( The analgesic efficacy of flurbiprofen compared to acetaminophen with codeine. Cooper, SA; Kupperman, A, 1991)	1.49
" On d 21 and 28, serum and CF samples were taken prior to dosing and afterwards at 1, 2, 4 and 6 hours."	( Flurbiprofen in human crevicular fluid analyzed by high-performance liquid chromatography. Barrett, AW; Edwards, G; Heasman, PA; Seymour, RA; Ward, A, 1990)	1.72
" No significant difference in rates of absorption of carprofen from rectal solution and suppository was seen; this allowed the conclusion that drug release from the semi-solid dosage form was not the rate-limiting step in carprofen absorption from the suppository."	( Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. Guentert, TW; Schmitt, M, 1990)	0.28
" This investigation focuses on the changes in CO metabolites which occur during disease progression of ligature-induced periodontitis and on the dose-response relationship of flurbiprofen, as it relates to disease inhibition and the suppression of ARA metabolites within the crevicular fluid (CF)."	( Changes in cyclooxygenase metabolites in experimental periodontitis in Macaca mulatta. Braswell, LD; Green, MD; Hall, CM; Johnson, HG; McClure, H; Odle, BM; Offenbacher, S; Orkin, JL; Strobert, EA, 1989)	0.47
" This was conducted, first as a dose-response study and, second, as a time-course study."	( Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen. Evidence for the predominant role of histamine. Finnerty, JP; Holgate, ST; Wilmot, C, 1989)	0.5
" There was a significant dose-response regression between flurbiprofen 25 mg and both of the higher dosages."	( An evaluation of flurbiprofen, aspirin, and placebo in postoperative oral surgery pain. Beaver, WT; Forbes, JA; Rosenmertz, SK; Selinger, LR; Yorio, CC, 1989)	0.86
" Paired milk and plasma samples were obtained during this period of dosing as well as after the last dose."	( Flurbiprofen in post-partum women: plasma and breast milk disposition. Brown, RD; Cook, SM; Hinson, JL; Johnson, VA; Smith, IJ; Whitt, RT; Wilson, JT, 1989)	1.72
" Flurbiprofen showed a linear dose-response relationship with respect to gastric injury and serum drug levels."	( The effects of flurbiprofen, aspirin, cimetidine, and antacids on the gastric and duodenal mucosa of normal volunteers. An endoscopic and photographic study. Friedman, H; Lanza, FL; Royer, GL; Schwartz, JH; Seckman, CE; Stubbs, CM, 1989)	1.54
" Increased dosage did not produce a proportional increase in the permeation and maximizing the skin-drug contact did not increase penetration: both factors indicate that absorption from deposited drug films was dissolution rate-limited."	( Absorption through human skin of ibuprofen and flurbiprofen; effect of dose variation, deposited drug films, occlusion and the penetration enhancer N-methyl-2-pyrrolidone. Akhter, SA; Barry, BW, 1985)	0.53
" Flurbiprofen, a potent non-steroidal anti-inflammatory drug, administered intramuscularly on 3 successive days following the combined infection at a dosage of 1 mg/kg/12 h was without beneficial effect on diarrhoea or mortality."	( Pathophysiology of diarrhoea induced by a combined infection with transmissible gastroenteritis virus and enterotoxigenic Escherichia coli in newly-weaned piglets and the effect of flurbiprofen treatment. Cools, V; Cox, E; Houvenaghel, A, 1988)	1.38
"Forty patients with classic or definite rheumatoid arthritis were entered into a double-blind, randomized, multiple crossover, sequential trial comparing two doses (300 mg vs 150 mg per day) and two dosing schedules (b."	( A comparative analysis of two dosing strategies of flurbiprofen in rheumatoid arthritis: an application of sequential trial design. Bellamy, N; Kreeft, JH, 1988)	0.53
"The ocular bioavailability of radiolabeled flurbiprofen was determined after single or multiple topical dosing of rabbits."	( Multiple dosing increases the ocular bioavailability of topically administered flurbiprofen. Anderson, JA; Chen, CC, 1988)	0.77
" Side-effects were similar in nature to those of other drugs in this group and no correlation in their frequency or severity with the dosage of flurbiprofen was found."	( A long-term study of flurbiprofen in rheumatological disorders: II. Osteoarthrosis. Busson, M, 1986)	0.79
" Flurbiprofen was administered in a total daily dosage of 200 to 300 mg four times daily."	( Treatment of acute shoulder syndrome with flurbiprofen. Brinn, EL; Lamborn, KR; Lomen, PL; Mena, HR; Turner, LF, 1986)	1.45
" Flurbiprofen demonstrated linear systemic kinetics throughout the dosing range, with constant body clearance and unbound fraction in plasma."	( Relationship between the ocular and systemic disposition of flurbiprofen: the effect of altered protein dynamics at steady state. Liu, S; Tang-Liu, DD, 1987)	1.43
" Dose-response curves were studied at 4 h following administration of indomethacin on the 19th, 20th, and 21st days, and flurbiprofen on the 20th and 21st days."	( In vivo constriction of the ductus arteriosus by nonsteroidal antiinflammatory drugs in near-term and preterm fetal rats. Momma, K; Takao, A, 1987)	0.48
" Dose-response curves to noradrenaline and KCl administered as bolus doses were obtained."	( Effect of three loop diuretics and prostaglandins E2 & I2 on the isolated perfused rat mesenteric vasculature. Foy, JM; Nuhu, SZ, 1985)	0.27
" These results suggest that modulation of leukotaxis by NSAIDs may reflect a differential dose-response sensitivity of lipoxygenase and cycloxygenase pathways."	( In vivo modulation of leukotaxis by non-steroidal anti-inflammatory drugs. diZerega, GS; Nakamura, RM; Shimanuki, T, 1985)	0.27
" Many flurbiprofen-treated patients (46 percent) completing the trial followed a relatively low dosage regimen of 50 mg twice daily for more than half the study."	( Treatment of osteoarthritis of the knee. A comparison of flurbiprofen and aspirin. Brinn, EL; Lamborn, KR; Lomen, PL; Porter, GH; Turner, LF, 1986)	1
" From a practical point of view, 2 seems to be particularly useful for improving the pharmaceutical properties of flurbiprofen in various dosage forms."	( Improvement of dissolution and suppository release characteristics of flurbiprofen by inclusion complexation with heptakis(2,6-di-O-methyl)-beta-cyclodextrin. Hirayama, F; Imai, T; Irie, T; Maeda, T; Otagiri, M; Uekama, K, 1985)	0.71
"Miniaturised methods have been used to construct dose-response curves for the effects of inhibitory drugs on prostaglandin synthesis using individual rectal biopsies obtained from patients with ulcerative colitis."	( Inhibition of prostaglandin synthetase in human rectal mucosa. Hawkey, CJ; Lo Casto, M, 1983)	0.27
" Dose-response curves to noradrenaline administered as bolus doses or frequency-response curves from transmural arterial electrical stimulation were obtained."	( Effect of bumetanide, frusemide and prostaglandin E2 on the isolated perfused kidney of rat and rabbit. Foy, JM; Nuhu, SZ, 1984)	0.27
" Based on the inhibitory effect of the steroidal anti-inflammatory drugs, non-steroidal agents, such as indomethacin, were also expected to show some degree of inhibition; however, repeated tumor experiments demonstrate that indomethacin enhances TPA promotion in a dose-response manner."	( Indomethacin enhancement of TPA tumor promotion in mice. Fischer, SM; Gleason, GL; Mills, GD; Slaga, TJ, 1980)	0.26
" Sustained release dosage forms are available, which may be beneficial due to the short terminal phase elimination half-life of conventional immediate release flurbiprofen (3 to 6 hours)."	( Clinical pharmacokinetics of flurbiprofen and its enantiomers. Davies, NM, 1995)	0.78
" Oral dosing had exhibited no significant bone activity."	( Chiral pharmacokinetics of Rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. Bigornia, AE; Jee, WS; Murray, ED; Wechter, WJ, 1994)	0.57
" The potency ratio between the dose-response curves was 10 (6-20; 95% confidence intervals)."	( Antinociception produced by spinal delivery of the S and R enantiomers of flurbiprofen in the formalin test. Malmberg, AB; Yaksh, TL, 1994)	0.52
" The dose-response for ibuprofen and flurbiprofen was roughly equivalent to that of clofibric acid, whereas indomethacin was less active."	( Induction of peroxisomal beta-oxidation by nonsteroidal anti-inflammatory drugs. Eacho, PI; Foxworthy, PS; Perry, DN, 1993)	0.56
"015), and the dosing frequency of relief medication (P < ."	( Flurbiprofen in the prophylaxis of migraine. Kunkel, RS; Solomon, GD, )	1.57
"The effect of food on the plasma concentration-time profile of sustained release dosage forms of ibuprofen and flurbiprofen has been investigated in healthy Asian Indian volunteers, in two separate studies."	( The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. Kelkar, MG; Nayak, PJ; Pargal, A, 1996)	0.75
" A dose-response study with flurbiprofen (single doses of 5, 10, 20, and 40 mg/kg) and equimolar doses of nitroxybutyl-flurbiprofen was performed; assessing their effect on intestinal permeability (at 18-20 hours), with 51Cr EDTA, and the number of pointed (< 5 mm) and longitudinal (> 5 mm) small intestinal ulcers at 24 hours."	( Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Bjarnason, I; Jacob, M; Macpherson, A; Mahmud, T; Price, AB; Rafi, S; Scott, D; Sherwood, R; Sigthorsson, G; Somasundaram, S; Wrigglesworth, JM, 1997)	0.86
" Male Sprague-Dawley rats were dosed with two doses of metronidazole (50 mg/kg, 12 and 1 h pre-NSAID) or a single 100 mg/kg dose of tempo 1 h prior to NSAIDs."	( Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers. Davies, NM; Jamali, F, 1997)	0.3
"5 days of dosing were used to detect newly occurring hemorrhages and erosions."	( Clinical endoscopic evaluation of the gastroduodenal tolerance to (R)- ketoprofen, (R)- flurbiprofen, racemic ketoprofen, and paracetamol: a randomized, single-blind, placebo-controlled trial. Caubet, JF; Handley, DA; Jerussi, TP; McCray, JE, 1998)	0.52
" Dose-response for intestinal ulcer production was observed for rac- and (S)-flurbiprofen; animals given (R)-flurbiprofen exhibited no ulcers."	( Mechanism of enhancement of intestinal ulcerogenicity of S-aryl propionic acids by their R-enantiomers in the rat. Gibson, K; Kantoci, D; Leipold, D; Liu, Y; McCracken, JD; Mineyama, Y; Murray, ED; Quiggle, D; Wechter, WJ, 1998)	0.53
" Three dosage forms were selected for this study: capsules, suppositories, and creams."	( Effect of chemical structure on the release of certain propionic acid derivatives from their dosage forms. el-Bary, AA; el-Nabarawi, MA; Mohamed, MI, 1998)	0.3
" Groups of six rats received either vehicle or analgesic drug and antinociception was evaluated by evaluating the dose-response curves over time."	( Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998)	0.3
" It is concluded that the current microemulsion system might be applicable to formulate the parenteral dosage form of poorly water-soluble flurbiprofen without chemical modification."	( Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. Hwang, KJ; Kim, CK; Lee, MK; Park, KM, 1999)	0.78
"The present investigation was undertaken to explore the ulcer healing and antiangiogenic efficacy of two dosage schedules of topically administered amiloride in mechanically produced corneal ulcers in rabbits and to compare its effect with the conventional topical antiinflammatory angiostatic agent flurbiprofen."	( Topical amiloride accelerates healing and delays neovascularization in mechanically produced corneal ulcers in rabbits. Chugh, P; Gupta, B; Sood, AK, 1999)	0.48
" Groups of 6 rats received either vehicle or the enantiomer in turn and antinociception was determined by evaluating the dose-response curves over time."	( Analysis of antinociceptive effects of flurbiprofen enantiomers in a rat model of arthritic pain. Cabré, F; Díaz, MI; Domínguez, AM; García, ML; Hernández, GP; López-Muñoz, FJ; Mauleón, D; Ventura, R, 2000)	0.58
"5 mg; the sore throat pain model is a sensitive assay for demonstration of the dose-response relationship of an analgesic agent."	( Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model. Christian, J; Gibb, IA; Homan, HD; Schachtel, BP, 2002)	0.59
" Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid beta protein precursor (APP) transgenic mice, and plasma and brain levels of Abeta and the drug were evaluated."	( NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. Das, P; Eriksen, JL; Golde, TE; Jessing, KW; Koo, EH; McLendon, DC; Ozols, VV; Sagi, SA; Smith, TE; Weggen, S; Zavitz, KH, 2003)	0.88
" Since the disk assembly in the USP for patch dosage forms was unsuited for use in a release test due to penetration of the dissolution medium into the cataplasm from the screw part of the device and the cataplasm swelled, new holders were designed."	( Investigation of the release test method for the topical application of pharmaceutical preparations: release test of cataplasm including nonsteroidal anti-inflammatory drugs using artificial sweat. Kobayashi, D; Kogo, T; Morimoto, Y; Numajiri, S; Shimamura, T; Tairabune, T; Ueda, H, 2004)	0.32
" Selected binary systems were used for preparation of direct compression tablets with reduced drug dosage (50 mg)."	( Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes. Cirri, M; Corti, G; Maestrelli, F; Mura, P; Rangoni, C, 2005)	0.59
" Furthermore, to assess time profiles of KP concentration in the skin and plasma, guinea pigs received a repeated topical application of R-KP and S-KP at a dosage of 40 mg/kg over a period of 3 days."	( Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. Chikamatsu, N; Igarashi, T; Nagata, O; Nakazawa, T; Shimo, T; Yamamoto, M, 2006)	0.33
" In murine models of AD, (R)-flurbiprofen lowered brain levels of Abeta(1-42), and chronic dosing reduced brain amyloid pathology and prevented defects in learning and memory."	( Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. Geerts, H, 2007)	0.95
" This mucoadhesive formulation offers many advantages over buccal lozenges because it allows for reduction in daily administrations and daily drug dosage and is suitable for the treatment of irritation, pain, and discomfort associated with gingivitis, sore throats, laryngopharyngitis, cold, and periodontal surgery."	( Mucoadhesive bilayered tablets for buccal sustained release of flurbiprofen. Ambrogi, V; Blasi, P; Giovagnoli, S; Perioli, L; Ricci, M; Rossi, C, 2007)	0.58
" We have examined the inhibitory effect of free fatty acid (FFA), a binding inhibitor for site II of HSA, on the binding of flurbiprofen in-vitro and in-vivo by ultrafiltration, to establish an effective dosage of FP-ax."	( Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats. Arimori, K; Higuchi, S; Kawai, K; Ogata, K; Takamura, N; Tokunaga, J, 2008)	0.89
" The heart rate (HR), mean arterial pressure (MAP) and SpO2 were monitored during the operation, and the induction time, recovery time, propofol dosage and adverse effect were recorded."	( [Application of flurbiprofen preemptive analgesia combined with intravenous propofol anesthesia in induced abortion]. Lao, JX; Liu, WX; Tan, SX; Zhang, YF, 2008)	0.69
" Further experimental work towards identifying the most efficacious COX-2 inhibitors, as well as the mechanism of action and the optimal dosage regimen should be executed."	( Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. Banerjee, A; Nivsarkar, M; Padh, H, )	0.13
" In three other groups (n = 8 in each group), the selected dosage of 10 mg/kg was administrated intravenously at 6, 12 and 24 hours after I/R."	( Therapeutic time window of flurbiprofen axetil's neuroprotective effect in a rat model of transient focal cerebral ischemia. Dong, HL; Liu, JL; Lu, Y; Sang, HF; Wang, C; Xiong, LZ, 2008)	0.64
" The effect became less potent with time despite continuous dosing indicating adaptation for both topical and systemic effects."	( Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety. Campanella, C; Jamali, F, 2009)	0.35
" The repeated dosing rather than the magnitude of t(1/2) may influence the gut safety profile of NSAIDs."	( Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety. Campanella, C; Jamali, F, 2009)	0.35
" Consistent with the enhanced solubility, the plasma exposure (both AUC and Cmax) of flurbiprofen when dosed as the mixed system was significantly higher (as much as 2 to 3-fold) than that without surfactant or beta-CD, with surfactant alone, or with beta-CD alone."	( Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound. Balakrishnan, P; Choi, HG; Han, MJ; Joe, JH; Kim, JO; Li, DX; Oh, DH; Park, SM; Seo, Y; Yan, YD; Yong, CS, 2010)	0.87
" PGE(2) levels in mice dosed with R-2-phenylpropionic acid were elevated."	( Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents. Bjarnason, IT; Hotz-Behofsits, C; Simpson, RJ; Walley, M, 2010)	0.36
" A novel population pharmacokinetic model is developed to estimate the individual pharmacokinetic parameter for patients intravenous injecting FA in terms of patients' characteristics and dosing history, and to design a prior dosage regimen."	( [Population pharmacokinetic modeling of flurbiprofen]. Gong, SJ; Huang, PF; Lin, WW; Wang, CL, 2010)	0.63
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Blood samples were collected prior to dosing and at predefined intervals for 24 h after dose."	( A randomised, two-period, cross-over, open-label study to evaluate the pharmacokinetic profiles of single doses of two different flurbiprofen 8.75-mg lozenges in healthy volunteers. Annoni, O; Brunner, M; Burian, A; Lauro, V; Martin, W; Matzneller, P; Tacchi, R; Zeitlinger, M, 2012)	0.58
" However, its multiple dosing due to short elimination half life is a concern for such treatment."	( Formulation, characterization and in vitro-in vivo evaluation of flurbiprofen-loaded nanostructured lipid carriers for transdermal delivery. Chauhan, MK; Kawadkar, J; Kishore, R; Pathak, A, 2013)	0.63
"To compare tissue concentrations of flurbiprofen resulting from topical application and oral administration according to the regulatory approved dosing guidelines."	( Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration. Kai, S; Kawaguchi, Y; Kitamura, N; Kondo, E; Yasuda, K, 2013)	2.11
" This was done to evaluate potential degradation and thereby biological conversion of the cyclodextrins if dosed orally, as the intestinal tract contains α-amylase for digestive purposes."	( In vitro investigations of α-amylase mediated hydrolysis of cyclodextrins in the presence of ibuprofen, flurbiprofen, or benzo[a]pyrene. Holm, R; Jørgensen, EB; Larsen, KL; Lumholdt, LR, 2012)	0.59
" No significant differences between treatment groups were found in neuropsychological tests but a positive dose-response trend was found on executive function in APOE4 carriers."	( CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. Bottini, G; Calza, L; Casula, D; Cicirello, H; Fernandez, M; Fiorentini, F; Franceschi, M; Frigerio, E; Giardino, L; Imbimbo, BP; Norris, D; Nunez, M; Ross, J; Scarpini, E; Sharma, S; Sivilia, S; Winston, J, 2013)	0.39
" No dropsy and erythema were observed after continuous dosing 7 d of FP NLC-gel on the rabbit skin, and the xylene-induced ear drossy could be inhibited by FP NLC-gel at different dosages."	( Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and percutaneous absorption mechanism. Han, F; Li, S; Song, A; Su, Z, 2015)	0.69
" Our data for the given example, however, puts the benefit of individual drug dosing to question, if it is exclusively based on genotype."	( CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. Lutz, RW; Lutz, WK; Schönfelder, G; Vogl, S, 2015)	0.63
" The novel controlled delivery system with combination of pH-modulated solid dispersion and osmotic pump system is not only a promising strategy to improve the solubility and oral bioavailability of poorly soluble ionizable drugs but also an effective way to reduce dosing frequency and minimize the plasma fluctuation."	( A novel osmotic pump-based controlled delivery system consisting of pH-modulated solid dispersion for poorly soluble drug flurbiprofen: in vitro and in vivo evaluation. Li, S; Liu, D; Pan, W; Wang, X; Wang, Y; Yang, X; Zhang, L; Zhao, Q, 2015)	0.62
"Compared with the control group, the VAS score at 48 h after surgery, and the dosage of the supplemented Sauteralgyl were evidently lower, and the time of both exhaust and defecation after surgery was significantly earlier, and the degree of nausea after surgery was obviously milder in patients of the EA group (P<0."	( [Electroacupuncture Intervention Combined with Anesthetics for Analgesia and Post-surgical Gastrointestinal Recovery in Pneumectomy Patients]. Chen, TY; Ma, W; Wang, K; Wu, YY; Xu, JJ; Zhou, J, 2015)	0.42
"EA intervention combined with anesthetics is effective in reducing the dosage of the supplemented Sauteralgyl and the degree of postoperative nausea, and in improving postoperative gastrointestinal functional recovery in patients undergoing pneumectomy."	( [Electroacupuncture Intervention Combined with Anesthetics for Analgesia and Post-surgical Gastrointestinal Recovery in Pneumectomy Patients]. Chen, TY; Ma, W; Wang, K; Wu, YY; Xu, JJ; Zhou, J, 2015)	0.42
" The dose-response curve (DRCs) shows that the combination of rac-Flur (31."	( Antinociceptive Effect of Racemic Flurbiprofen and Caffeine Co-Administration in an Arthritic Gout-Type Pain in Rats. Espinosa-Juárez, JV; Jaramillo-Morales, OA; Liévano-Reyes, R; López-Muñoz, FJ; Pérez-Méndez, HI; Solís-Oba, A, 2016)	0.71
"To develop the first photoactive biomaterial coating capable of controlled drug dosing via inclusion of synthesised drug-3,5-dimethoxybenzoin (DMB) conjugates in a poly(2-methyoxyethyl acrylate) (pMEA) scaffold."	( Photochemically Controlled Drug Dosing from a Polymeric Scaffold. Donnelly, L; Gorman, SP; Hardy, JG; Irwin, NJ; Jones, DS; McCoy, CP, 2017)	0.46
" Biorelevant release tests have become a standard in the prediction of in vivo pharmacokinetics but also in quality control of novel dosage forms."	( A comparison of two biorelevant in vitro drug release methods for nanotherapeutics based on advanced physiologically-based pharmacokinetic modelling. Gao, F; Jung, F; Nothnagel, L; Thurn, M; Vogel, V; Wacker, MG, 2018)	0.48
"Tribo-electrification is a common occurrence within the pharmaceutical industry where solid dosage forms constitute majority of pharmaceutical formulations."	( The effect of mesoporous silica impregnation on tribo-electrification characteristics of flurbiprofen. Afzal, MS; Ghori, MU; Granollers, M; Šupuk, E; Zanin, F, 2018)	0.7
" Consequently, the development of an easy-to-swallow liquid oral dosage form supported by a combined PBPK-IVIVC model was approached."	( Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001. Ashtikar, M; Geisslinger, G; Jung, F; Nothnagel, L; Parnham, MJ; Rossmanith, T; Thurn, M; Wacker, MG, 2019)	0.51
" The pain intensity, consumed sufentanil dosage of the PCA, and the side effects was not different between groups."	( Effect of flurbiprofen axetil on postoperative delirium for elderly patients. Chen, H; Han, F; Hu, Y; Wang, L; Wang, X; Wang, Y; Wei, L; Zhao, W, 2019)	0.92
" The present study tested the hypothesis that multimodal analgesia with combined ropivacaine wound infiltration and intravenous flurbiprofen axetil after radical thyroidectomy provided better analgesia than a single dosage of tramadol."	( Multimodal analgesia with ropivacaine wound infiltration and intravenous flurbiprofen axetil provides enhanced analgesic effects after radical thyroidectomy: a randomized controlled trial. Li, X; Tan, H; Yang, J; Yu, L, 2019)	0.95
" The second phase was similar to the first, except each treatment was administered at a dosage of 1 drop/eye, twice daily for 5 days and CS was measured before treatment initiation and at 15 minutes and 24 and 48 hours after the last dose."	( Effects of topical instillation of 0.1% diclofenac sodium, 0.5% ketorolac tromethamine, and 0.03% flurbiprofen sodium on corneal sensitivity in ophthalmologically normal cats. Meekins, JM; Rankin, AJ; Roberts, JK; Roush, JK, 2021)	0.84
" Flurbiprofen is widely used as an oral formulation (tablet dosage form) to control pain in spondylitis; however, owing to its short half-life (3."	( Transdermal delivery of flurbiprofen from polyoxypropylene-polyoxyethylene block copolymer stabilized reduced graphene oxide to manage pain in spondylitis: In vitro and in vivo studies. Li, T; Yang, C, 2021)	1.84
" The dosage of sufentanil and the times of pressing analgesia pump in group D & F were significantly less than those in group F (p<0."	( Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. Chen, Y; Du, J; Tao, H; Zong, S, )	0.38

Role	Description
non-steroidal anti-inflammatory drug	An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
non-narcotic analgesic	A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
antipyretic	A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor	A compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
fluorobiphenyl	Any member of the class of biphenyls that is a mono or poly-substituted biphenyl having fluro group as one of the substituents.
monocarboxylic acid	An oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Flurbiprofen Action Pathway	29	67

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	37.6282	0.0072	15.7588	89.3584	AID1224835; AID588342
glp-1 receptor, partial	Homo sapiens (human)	Potency	35.4813	0.0184	6.8060	14.1254	AID624172
SMAD family member 2	Homo sapiens (human)	Potency	13.8006	0.1737	34.3047	61.8120	AID1346859
PPM1D protein	Homo sapiens (human)	Potency	37.0259	0.0052	9.4661	32.9993	AID1347411
SMAD family member 3	Homo sapiens (human)	Potency	13.8006	0.1737	34.3047	61.8120	AID1346859
AR protein	Homo sapiens (human)	Potency	39.1533	0.0002	21.2231	8,912.5098	AID743036; AID743053
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	8.6349	0.0133	26.9810	70.7614	AID1346978
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	6.3096	0.0013	18.0743	39.8107	AID926
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	30.6379	0.0006	57.9133	22,387.1992	AID1259377
EWS/FLI fusion protein	Homo sapiens (human)	Potency	19.9970	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259256
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	62.6019	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	27.5357	0.0008	17.5051	59.3239	AID1159527
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	54.9410	0.3758	27.4851	61.6524	AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	19.3312	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	11.5145	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743079
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	13.8014	0.0010	19.4141	70.9645	AID743094; AID743191
caspase-3	Homo sapiens (human)	Potency	8.6349	0.0133	26.9810	70.7614	AID1346978
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	7.7606	19.7391	45.9784	64.9432	AID1159509
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	53.5802	0.0003	23.4451	159.6830	AID743065; AID743067
histone deacetylase 9 isoform 3	Homo sapiens (human)	Potency	45.0033	0.0376	17.0823	61.1927	AID1259364; AID1259388
Interferon beta	Homo sapiens (human)	Potency	37.0259	0.0033	9.1582	39.8107	AID1347411
Cellular tumor antigen p53	Homo sapiens (human)	Potency	32.5805	0.0023	19.5956	74.0614	AID651631
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	15.8489	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Acid-sensing ion channel 3	Rattus norvegicus (Norway rat)	IC50 (µMol)	229.0870	9.5000	9.5000	9.5000	AID1476081
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	724.7000	0.1100	7.1903	10.0000	AID1449628
Fatty acid-binding protein, liver	Rattus norvegicus (Norway rat)	Ki	111.5900	0.0150	1.2487	6.9200	AID407366; AID407369
Amyloid-beta precursor protein	Homo sapiens (human)	IC50 (µMol)	305.0000	0.0005	3.8895	10.0000	AID255950
Prostaglandin G/H synthase 1	Ovis aries (sheep)	IC50 (µMol)	0.1683	0.0003	2.1774	10.0000	AID1282661; AID162021; AID162150; AID462317
Prostaglandin G/H synthase 1	Ovis aries (sheep)	Ki	1.0000	0.0016	2.1212	9.0000	AID162164
Fatty acid-binding protein, intestinal	Homo sapiens (human)	Ki	24.1333	0.3000	5.4814	9.4000	AID1801103; AID407368
Aldo-keto reductase family 1 member C4	Homo sapiens (human)	IC50 (µMol)	100.0000	2.3000	4.8633	8.2500	AID703399
Prostaglandin G/H synthase 1	Homo sapiens (human)	IC50 (µMol)	0.6754	0.0002	1.5574	10.0000	AID1330180; AID313126; AID625243
Prostaglandin G/H synthase 2	Homo sapiens (human)	IC50 (µMol)	0.5740	0.0001	0.9950	10.0000	AID1282662; AID1330181; AID162497; AID313125; AID625244
Aldo-keto reductase family 1 member C3	Homo sapiens (human)	IC50 (µMol)	1.5600	0.0500	2.2070	10.0000	AID703400
Aldo-keto reductase family 1 member C2	Homo sapiens (human)	IC50 (µMol)	32.5000	0.3700	4.0951	9.2800	AID703401
Acid-sensing ion channel 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	169.8240	2.0000	2.0000	2.0000	AID1476078
Aldo-keto reductase family 1 member C1	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0060	3.1265	7.9000	AID703402
Prostaglandin G/H synthase 2	Mus musculus (house mouse)	IC50 (µMol)	0.5000	0.0005	0.4008	6.2000	AID462318
Solute carrier family 22 member 6	Homo sapiens (human)	IC50 (µMol)	1.5000	0.2700	4.5306	9.9000	AID681160
Prostaglandin G/H synthase 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1700	0.0029	1.8232	10.0000	AID254854
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
UDP-glucuronosyltransferase 1A3	Homo sapiens (human)	Km	90.0000	7.3400	7.3400	7.3400	AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
cellular response to starvation	Albumin	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Albumin	Homo sapiens (human)
cellular response to calcium ion starvation	Albumin	Homo sapiens (human)
cellular oxidant detoxification	Albumin	Homo sapiens (human)
transport	Albumin	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
cognition	Amyloid-beta precursor protein	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglial cell activation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
suckling behavior	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation involved in immune response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of translation	Amyloid-beta precursor protein	Homo sapiens (human)
protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
intracellular copper ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
endocytosis	Amyloid-beta precursor protein	Homo sapiens (human)
response to oxidative stress	Amyloid-beta precursor protein	Homo sapiens (human)
cell adhesion	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of epidermal growth factor-activated receptor activity	Amyloid-beta precursor protein	Homo sapiens (human)
Notch signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
axonogenesis	Amyloid-beta precursor protein	Homo sapiens (human)
learning or memory	Amyloid-beta precursor protein	Homo sapiens (human)
learning	Amyloid-beta precursor protein	Homo sapiens (human)
mating behavior	Amyloid-beta precursor protein	Homo sapiens (human)
locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
axo-dendritic transport	Amyloid-beta precursor protein	Homo sapiens (human)
cholesterol metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of cell population proliferation	Amyloid-beta precursor protein	Homo sapiens (human)
adult locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
visual learning	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglia development	Amyloid-beta precursor protein	Homo sapiens (human)
axon midline choice point recognition	Amyloid-beta precursor protein	Homo sapiens (human)
neuron remodeling	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of Wnt signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular matrix organization	Amyloid-beta precursor protein	Homo sapiens (human)
forebrain development	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection development	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of chemokine production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-6 production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of multicellular organism growth	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of neuron differentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of glycolytic process	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of JNK cascade	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Amyloid-beta precursor protein	Homo sapiens (human)
collateral sprouting in absence of injury	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of inflammatory response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of synapse structure or activity	Amyloid-beta precursor protein	Homo sapiens (human)
synapse organization	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular process controlling balance	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic assembly at neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
neuron apoptotic process	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
neuron cellular homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Amyloid-beta precursor protein	Homo sapiens (human)
response to interleukin-1	Amyloid-beta precursor protein	Homo sapiens (human)
modulation of excitatory postsynaptic potential	Amyloid-beta precursor protein	Homo sapiens (human)
NMDA selective glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of spontaneous synaptic transmission	Amyloid-beta precursor protein	Homo sapiens (human)
cytosolic mRNA polyadenylation	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Amyloid-beta precursor protein	Homo sapiens (human)
cellular response to amyloid-beta	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of presynapse assembly	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection maintenance	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of T cell migration	Amyloid-beta precursor protein	Homo sapiens (human)
central nervous system development	Amyloid-beta precursor protein	Homo sapiens (human)
fatty acid metabolic process	Fatty acid-binding protein, intestinal	Homo sapiens (human)
long-chain fatty acid transport	Fatty acid-binding protein, intestinal	Homo sapiens (human)
intestinal lipid absorption	Fatty acid-binding protein, intestinal	Homo sapiens (human)
fatty acid transport	Fatty acid-binding protein, intestinal	Homo sapiens (human)
lipid metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
androgen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
retinoid metabolic process	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
bile acid biosynthetic process	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
steroid metabolic process	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
androgen metabolic process	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
bile acid and bile salt transport	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
daunorubicin metabolic process	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
doxorubicin metabolic process	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
cellular response to jasmonic acid stimulus	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
prostaglandin metabolic process	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
progesterone metabolic process	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
prostaglandin biosynthetic process	Prostaglandin G/H synthase 1	Homo sapiens (human)
response to oxidative stress	Prostaglandin G/H synthase 1	Homo sapiens (human)
regulation of blood pressure	Prostaglandin G/H synthase 1	Homo sapiens (human)
cyclooxygenase pathway	Prostaglandin G/H synthase 1	Homo sapiens (human)
regulation of cell population proliferation	Prostaglandin G/H synthase 1	Homo sapiens (human)
cellular oxidant detoxification	Prostaglandin G/H synthase 1	Homo sapiens (human)
prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to oxidative stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
embryo implantation	Prostaglandin G/H synthase 2	Homo sapiens (human)
learning	Prostaglandin G/H synthase 2	Homo sapiens (human)
memory	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of blood pressure	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell population proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to xenobiotic stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to nematode	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fructose	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to manganese ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cyclooxygenase pathway	Prostaglandin G/H synthase 2	Homo sapiens (human)
bone mineralization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fever generation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic plasticity	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin secretion	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to estradiol	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to lipopolysaccharide	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to vitamin D	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to heat	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to tumor necrosis factor	Prostaglandin G/H synthase 2	Homo sapiens (human)
maintenance of blood-brain barrier	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of protein import into nucleus	Prostaglandin G/H synthase 2	Homo sapiens (human)
hair cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of apoptotic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vasoconstriction	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
decidualization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of inflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to glucocorticoid	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of calcium ion transport	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fatty acid	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to mechanical stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to lead ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to ATP	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to hypoxia	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to non-ionic osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to fluid shear stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of transforming growth factor beta production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fibroblast growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of platelet-derived growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular oxidant detoxification	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of neuroinflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to homocysteine	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to angiotensin	Prostaglandin G/H synthase 2	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
bile acid secretion	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
vitamin D3 metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
retinoid metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
response to nutrient	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
steroid metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
positive regulation of cell population proliferation	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
male gonad development	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to starvation	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
farnesol catabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cyclooxygenase pathway	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
keratinocyte differentiation	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
progesterone metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
retinol metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
retinal metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
macromolecule metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
daunorubicin metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
doxorubicin metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
regulation of retinoic acid receptor signaling pathway	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
testosterone biosynthetic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
renal absorption	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to calcium ion	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to prostaglandin stimulus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to corticosteroid stimulus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to jasmonic acid stimulus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cellular response to prostaglandin D stimulus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
negative regulation of retinoic acid biosynthetic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
regulation of testosterone biosynthetic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
positive regulation of endothelial cell apoptotic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin metabolic process	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
digestion	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
steroid metabolic process	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
positive regulation of cell population proliferation	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
epithelial cell differentiation	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
progesterone metabolic process	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
daunorubicin metabolic process	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
doxorubicin metabolic process	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
cellular response to jasmonic acid stimulus	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
cellular response to prostaglandin D stimulus	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
retinoid metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
xenobiotic metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
digestion	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
bile acid metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
bile acid and bile salt transport	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
intestinal cholesterol absorption	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
epithelial cell differentiation	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
progesterone metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
retinal metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
cholesterol homeostasis	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
daunorubicin metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
doxorubicin metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
response to organophosphorus	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
cellular response to jasmonic acid stimulus	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
prostaglandin metabolic process	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
monoatomic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
response to organic cyclic compound	Solute carrier family 22 member 6	Homo sapiens (human)
inorganic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 6	Homo sapiens (human)
alpha-ketoglutarate transport	Solute carrier family 22 member 6	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 6	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier family 22 member 6	Homo sapiens (human)
transmembrane transport	Solute carrier family 22 member 6	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 6	Homo sapiens (human)
renal tubular secretion	Solute carrier family 22 member 6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
oxygen binding	Albumin	Homo sapiens (human)
DNA binding	Albumin	Homo sapiens (human)
fatty acid binding	Albumin	Homo sapiens (human)
copper ion binding	Albumin	Homo sapiens (human)
protein binding	Albumin	Homo sapiens (human)
toxic substance binding	Albumin	Homo sapiens (human)
antioxidant activity	Albumin	Homo sapiens (human)
pyridoxal phosphate binding	Albumin	Homo sapiens (human)
identical protein binding	Albumin	Homo sapiens (human)
protein-folding chaperone binding	Albumin	Homo sapiens (human)
exogenous protein binding	Albumin	Homo sapiens (human)
enterobactin binding	Albumin	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
long-chain fatty acid transmembrane transporter activity	Fatty acid-binding protein, intestinal	Homo sapiens (human)
fatty acid binding	Fatty acid-binding protein, intestinal	Homo sapiens (human)
protein binding	Fatty acid-binding protein, intestinal	Homo sapiens (human)
long-chain fatty acid binding	Fatty acid-binding protein, intestinal	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
retinal dehydrogenase activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
aldo-keto reductase (NADPH) activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
electron transfer activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
bile acid transmembrane transporter activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
androsterone dehydrogenase activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
testosterone dehydrogenase (NAD+) activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
chlordecone reductase activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
aldose reductase (NADPH) activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
ketosteroid monooxygenase activity	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
bile acid binding	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
peroxidase activity	Prostaglandin G/H synthase 1	Homo sapiens (human)
prostaglandin-endoperoxide synthase activity	Prostaglandin G/H synthase 1	Homo sapiens (human)
protein binding	Prostaglandin G/H synthase 1	Homo sapiens (human)
heme binding	Prostaglandin G/H synthase 1	Homo sapiens (human)
metal ion binding	Prostaglandin G/H synthase 1	Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	Prostaglandin G/H synthase 1	Homo sapiens (human)
peroxidase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin-endoperoxide synthase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
enzyme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
heme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein homodimerization activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
metal ion binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	Prostaglandin G/H synthase 2	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
retinal dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
aldose reductase (NADPH) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
aldo-keto reductase (NADPH) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
all-trans-retinol dehydrogenase (NAD+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
phenanthrene 9,10-monooxygenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin D2 11-ketoreductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
geranylgeranyl reductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
ketoreductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
prostaglandin-F synthase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
androsterone dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
testosterone dehydrogenase (NAD+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
ketosteroid monooxygenase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
Delta4-3-oxosteroid 5beta-reductase activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
bile acid binding	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
aldose reductase (NADPH) activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
phenanthrene 9,10-monooxygenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
carboxylic acid binding	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
bile acid binding	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
ketosteroid monooxygenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
indanol dehydrogenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
androsterone dehydrogenase activity	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
aldose reductase (NADPH) activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
aldo-keto reductase (NADPH) activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
protein binding	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
phenanthrene 9,10-monooxygenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
carboxylic acid binding	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
bile acid binding	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
3beta-hydroxy-5beta-steroid dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
5alpha-androstane-3beta,17beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
androsterone dehydrogenase (B-specific) activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
androstan-3-alpha,17-beta-diol dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
ketosteroid monooxygenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
indanol dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
androsterone dehydrogenase activity	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
solute:inorganic anion antiporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
protein binding	Solute carrier family 22 member 6	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
antiporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
chloride ion binding	Solute carrier family 22 member 6	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 6	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier family 22 member 6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
extracellular region	Albumin	Homo sapiens (human)
extracellular space	Albumin	Homo sapiens (human)
nucleus	Albumin	Homo sapiens (human)
endoplasmic reticulum	Albumin	Homo sapiens (human)
endoplasmic reticulum lumen	Albumin	Homo sapiens (human)
Golgi apparatus	Albumin	Homo sapiens (human)
platelet alpha granule lumen	Albumin	Homo sapiens (human)
extracellular exosome	Albumin	Homo sapiens (human)
blood microparticle	Albumin	Homo sapiens (human)
protein-containing complex	Albumin	Homo sapiens (human)
cytoplasm	Albumin	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Fatty acid-binding protein, intestinal	Homo sapiens (human)
microvillus	Fatty acid-binding protein, intestinal	Homo sapiens (human)
apical cortex	Fatty acid-binding protein, intestinal	Homo sapiens (human)
cytosol	Fatty acid-binding protein, intestinal	Homo sapiens (human)
nucleus	Fatty acid-binding protein, intestinal	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
cytoplasm	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
extracellular exosome	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C4	Homo sapiens (human)
photoreceptor outer segment	Prostaglandin G/H synthase 1	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 1	Homo sapiens (human)
endoplasmic reticulum membrane	Prostaglandin G/H synthase 1	Homo sapiens (human)
Golgi apparatus	Prostaglandin G/H synthase 1	Homo sapiens (human)
intracellular membrane-bounded organelle	Prostaglandin G/H synthase 1	Homo sapiens (human)
extracellular exosome	Prostaglandin G/H synthase 1	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 1	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 1	Homo sapiens (human)
nuclear inner membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
nuclear outer membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum lumen	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
caveola	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein-containing complex	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
nucleus	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cytoplasm	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
extracellular exosome	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C3	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C2	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
extracellular exosome	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
cytosol	Aldo-keto reductase family 1 member C1	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
caveola	Solute carrier family 22 member 6	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 6	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 6	Homo sapiens (human)
protein-containing complex	Solute carrier family 22 member 6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1667259	Antioxidant activity assessed as AAPH-induced radical scavenging activity by measuring trolox equivalents for oxygen radical absorbance capacity measured every minute for 90 mins by ORAC-FL assay	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID93272	Percent inhibition of collagen-induced platelet aggregation at a concentration of 100 uM	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	Replacement of aromatic or heteroaromatic groups in nonsteroidal antiinflammatory agents with the ferrocene group.
AID407369	Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID320595	Ulcerogenic effect in mouse at 123 umol/kg, po relative to flurbiprophen	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents.
AID1307689	Inhibition of COX in human whole blood assessed as increase in 13-HODE production at 2 uM pre-incubated for 20 mins before stimulation with LPS and A23187 for 120 mins by LC-MS/MS method	2016	Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9	Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID592741	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrate production at 10 uM treated 30 mins before LPS challenge measured after 24 hrs by Griess reagent method relative to control	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID703400	Inhibition of human recombinant N-terminal His6-tagged AKR1C3 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID93273	Percent inhibition of collagen-induced platelet aggregation at a concentration of 20 uM	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	Replacement of aromatic or heteroaromatic groups in nonsteroidal antiinflammatory agents with the ferrocene group.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID183692	Evaluated for the percentage inhibition by adjuvant arthritis test at a dose of 50 mg/kg administarted perorally	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	Replacement of aromatic or heteroaromatic groups in nonsteroidal antiinflammatory agents with the ferrocene group.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID634118	Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	Marine sponge Hymeniacidon sp. amphilectane metabolites potently inhibit rat brain microglia thromboxane B2 generation.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID592754	Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as reduction of amyloid beta (1 to 42) level at 100 uM after 24 hrs by ELISA	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID1273102	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID19262	Aqueous solubility	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Prediction of drug solubility from Monte Carlo simulations.
AID624632	Drug glucuronidation reaction catalyzed by human recombinant UGT1A3	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID310933	Permeability across PAMPA membrane after 7 hrs	2007	Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4	In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1667274	Effect on nitric oxide production in mouse BV2 cells at 0.5 to 10 uM measured after 30 mins by Griess reagent based ELISA	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID311367	Permeability coefficient in human skin	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID574424	Displacement of S-phenyl 3-(4-hydroxy-3,5-dimethylstyryl)benzothioate from human TTR assessed as fluorescence at 37 degC after 3 hrs	2011	Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4	A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1822499	Antifungal activity against Candida albicans SN152 harbouring erg3delta delta/erg11delta delta assessed as Cyp51-mediated fungal growth inhibition measured every 40 mins for 48 hrs by double dilution method	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Fluconazole-COX Inhibitor Hybrids: A Dual-Acting Class of Antifungal Azoles.
AID1273091	Inhibition of COX in human HuH7 cells after 48 hrs by fluorometric assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID162497	In vitro inhibitory activity against Prostaglandin G/H synthase 2 (COX-2) in human	1999	Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3	Structure-based design of COX-2 selectivity into flurbiprofen.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1273101	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID320592	Antiinflammatory activity against carrageenan-induced hind paw edema in rat at 41 umol/kg, po after 3 hrs relative to flurbiprophen	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents.
AID227718	Binding energy by using the equation deltaG obsd = -RT ln KD	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Functional group contributions to drug-receptor interactions.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1667272	Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production at 2.5 uM preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID386885	Antibacterial activity against Staphylococcus aureus ATCC 19433 by cup plate method	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1053371	Inhibition of ovine COX-1 using arachidonic acid as substrate assessed as oxygen consumption at 30 uM measured within 10 to 50 secs	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors.
AID1667262	Inhibition of recombinant human MAOA expressed in baculovirus infected in BTI cells using kynuramine as substrate after 30 mins by fluorescence based assay	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1221821	Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1	Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1667276	Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production at 2.5 uM preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by ELISA relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1476081	Inhibition of rat ASIC3 receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 6.4-gated currents by two electrode voltage clamp	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID253569	Absolute oral bioavailability after administration to rats at a dose of 7.6 mg/kg orally	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID387119	Analgesic activity in Swiss albino mouse assessed as effect on reaction time for tail withdrawal administered at 10 mg/kg, po after 4 hrs by tail immersion method	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID320596	Inhibition of lipid peroxidation in mouse gastric mucosa tissue assessed as malondialdehyde level per 100 mg tissue relative to flurbiprophen	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents.
AID407368	Displacement of 1-anilinonaphthalene-8-sulphonic acid from I-FABP	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID1374201	Cytotoxicity against LPS-induced mouse BV2 cells assessed as effect on cell viability at 2.5 to 10 uM pretreated for 30 mins followed by LPS-stimulation after 24 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1667260	Inhibition of recombinant human MAOA expressed in baculovirus infected in BTI cells at 10 uM using kynuramine as substrate after 30 mins by fluorescence based assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1054847	Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis at 40 uM after 30 mins by turbidimetric assay relative to control	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID255283	Concentration required to inhibit A beta 40 peptide; nd is not determined	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID682161	TP_TRANSPORTER: inhibition of E217betaG in the presence of Flurbiprofen at a concentration of 50uM in membrane vesicles from MRP4-expressing Sf9 cells	2003	Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
AID89236	In vitro inhibition of collagen-induced platelet aggregation in human platelet rich plasma	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and platelet aggregation inhibitory activity of 4,5-bis(aryl)-2-substituted-thiazoles.
AID256360	Percent inhibition against beta-amyloid-42 (Abeta42) secretion was evaluated in human neuroglioma cells (H4-APP695NL) at 100 uM	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID703402	Inhibition of human recombinant N-terminal His6-tagged AKR1C1 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
AID1211791	Fraction unbound in human hepatocytes	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1211797	Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID781326	pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID237685	Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID396392	Inhibition of lipid peroxidation in rat assessed as malondialdehyde level per 100 mg of tissue	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	1,3,4-Oxadiazole/thiadiazole and 1,2,4-triazole derivatives of biphenyl-4-yloxy acetic acid: synthesis and preliminary evaluation of biological properties.
AID612763	Ratio of AUC in plasma to AUC in cerebrospinal fluid in rat	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	NSAID-derived γ-secretase modulation requires an acidic moiety on the carbazole scaffold.
AID253784	Maximum time corresponding to maximum concentration after administration to rats at a dose of 7.6 mg/kg orally	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1273090	Inhibition of COX in human Mahlavu cells after 48 hrs by fluorometric assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID1053370	Inhibition of human recombinant COX-2 assessed as inhibition of 2-AG cyclooxygenation at 30 uM measured within 10 to 50 secs	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors.
AID396389	Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema administered orally at equimolar oral dose relative to 10 mg/kg flurbiprofen measured after 4 hrs of carrageenan challenge	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	1,3,4-Oxadiazole/thiadiazole and 1,2,4-triazole derivatives of biphenyl-4-yloxy acetic acid: synthesis and preliminary evaluation of biological properties.
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681779	TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Flurbiprofen: 1000 uM) in Xenopus laevis oocytes	1999	Molecular pharmacology, May, Volume: 55, Issue:5	Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540230	Dose normalised AUC in rat after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID404304	Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID745126	Inhibition of amyloid beta (1 to 40) formation in Wistar rat primary cortical neurons at 0.5 uM after 24 hrs by ELISA relative to control	2013	Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9	Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer's disease agents.
AID377718	Lipophilicity, log D at pH 7.4	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substances.
AID1374199	Cytotoxicity against mouse BV2 cells assessed as effect on cell viability up to 10 uM after 30 mins by MTT assay	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1667266	Disaggregation of self-induced amyloid beta (1 to 42) (unknown origin) preformed fibrils at 25 uM measured after 24 hrs by thioflavin-T fluorescence assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1060646	Antineuroinflammatory activity in rat brain neonatal microglia	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Dactyloditerpenol acetate, a new prenylbisabolane-type diterpene from Aplysia dactylomela with significant in vitro anti-neuroinflammatory activity.
AID396388	Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema administered orally at equimolar oral dose relative to 10 mg/kg flurbiprofen measured after 3 hrs of carrageenan challenge	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	1,3,4-Oxadiazole/thiadiazole and 1,2,4-triazole derivatives of biphenyl-4-yloxy acetic acid: synthesis and preliminary evaluation of biological properties.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1211798	Intrinsic clearance in human using well stirred liver model by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID624647	Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID624640	Drug glucuronidation reaction catalyzed by human recombinant UGT2B7	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID253823	Elimination phase half-life after administration to rats at a dose of 7.6 mg/kg orally	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1141095	Ulcerogenic activity in albino rat stress model assessed as ulcer index at 10 mg/kg, po after 7 hrs	2014	Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10	Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.
AID1374194	Inhibition of cupric ion-mediated amyloid beta (1 to 42) aggregation at 25 uM after 24 hrs by thioflavin T fluorescence assay relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID574422	Inhibition of wild type-TTR expressed in Escherichia coli assessed as amyloid fibril formation at pH 4.4 at 7. 2 uM after 72 hrs by acid-mediated aggregation assay relative to control	2011	Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4	A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386899	Inhibition of lipid peroxidation in rat assessed as malondialdehyde level per 100 mg of tissue at 30 mg/kg, po	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID1667265	Inhibition of Cu2+-induced HFIP-pretreated amyloid beta (1 to 42) (unknown origin) aggregation at 25 uM measured after 24 hrs by thioflavin-T fluorescence assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID592849	Antiamyloidogenic activity in mouse N2A cells assessed as reduction of amyloid beta (1 to 42)/(1 to 40) ratio at 100 uM treated 24 hrs before amyloid beta (1 to 42)/(1 to 40) challenge measured after 8 hrs by MALDI/TOF analysis	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID1625110	Inhibition of HFIP-pretreated human amyloid beta (1 to 42) self-induced aggregation at 25 uM measured after 24 hrs by thioflavin-T fluorescence assay relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID162021	In vitro inhibitory activity against Prostaglandin G/H synthase 1 in sheep	1999	Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3	Structure-based design of COX-2 selectivity into flurbiprofen.
AID1667264	Inhibition of HFIP-pretreated amyloid beta (1 to 42) (unknown origin) self-aggregation at 25 uM after 24 hrs by thioflavin-T fluorescence assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID515780	Intrinsic solubility of the compound in water	2010	Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19	QSAR-based solubility model for drug-like compounds.
AID1585853	Cytotoxicity against human BV2 cells assessed as decrease in cell viability up to 10 uM measured after 24 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1054848	Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis after 30 mins by turbidimetric assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID1374203	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production at 2.5 uM pretreated for 30 mins followed by LPS-stimulation measured after 24 hrs by Griess assay relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1175391	Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 250 uM after 30 mins by Fluo-4 AM fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24	Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.
AID1273107	Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID320593	Antiinflammatory activity against carrageenan-induced hind paw edema in rat at 41 umol/kg, po after 4 hrs relative to flurbiprophen	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents.
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID396390	Analgesic activity in Swiss albino mouse assessed as inhibition of tail withdrawal administered orally at equimolar oral dose relative to 10 mg/kg flurbiprofen after 4 hrs	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	1,3,4-Oxadiazole/thiadiazole and 1,2,4-triazole derivatives of biphenyl-4-yloxy acetic acid: synthesis and preliminary evaluation of biological properties.
AID377717	Dissociation constant, pKa of the compound	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Chamazulene carboxylic acid and matricin: a natural profen and its natural prodrug, identified through similarity to synthetic drug substances.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID386886	Antibacterial activity against sEscherichia coli ATCC 25922 by cup plate method	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID1330181	Inhibition of COX-2 (unknown origin)	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID1616921	Inhibition of catalytic activity of His6-tagged Lactobacillus johnsonii N6.2 cinnamoyl esterase LJ0536 expressed in Escherichia coli BL21 (DE3) assessed as reduction in hydrolysis of 4-nitrophenyl butyrate in 4-nitrophenol at 400 uM in presence of 2.5 to	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Exhaustive Repertoire of Druggable Cavities at Protein-Protein Interfaces of Known Three-Dimensional Structure.
AID1625131	Inhibition of LPS-induced TNFalpha production in mouse BV2 cells at 2.5 uM pretreated for 30 mins followed by LPS-stimulation and measured after 24 hrs by ELISA relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1667261	Inhibition of recombinant human MAOB expressed in baculovirus infected in BTI cells at 10 uM using kynuramine as substrate after 30 mins by fluorescence based assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID243230	Binding affinity towards human serum albumin	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1657546	Antiinflammatory activity against LPS-induced rat Primary neonatal microglia assessed as inhibition in TXB2 generation preincubated for 20 mins followed by PMA-stimulation and measured after 70 mins by immunoassay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	6-Deoxy- and 11-Hydroxytolypodiols: Meroterpenoids from the Cyanobacterium HT-58-2.
AID1625132	Inhibition of LPS-induced TNFalpha production in mouse BV2 cells at 10 uM pretreated for 30 mins followed by LPS-stimulation and measured after 24 hrs by ELISA relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID386895	Gastrointestinal toxicity in rat assessed as gastric mucosal damage severity index at 30 mg/kg, po	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1307688	Inhibition of COX in human whole blood assessed as increase in 15-HETE production at 2 uM pre-incubated for 20 mins before stimulation with LPS and A23187 for 120 mins by LC-MS/MS method	2016	Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9	Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution.
AID1476080	Inhibition of rat ASIC2a receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 4-gated currents at 1 mM by two electrode voltage clamp relative to control	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID253641	Area under curve after administration to rats at adose of 1.5 mg/kg intravenously	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1625112	Inhibition of Electrophorus electricus AChE at 50 uM using acetylthiocholine iodide as substrate measured after 15 mins by Ellman's method relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID253728	Maximal concentration in rats after 1.5 mg/kg intravenous dose	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID253844	Concentration ratio in cerebrospinal fluid and plasma	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1625113	Inhibition of rat serum BuChE at 25 uM using butyrylthiocholine iodide as substrate after 15 mins by Ellman's method relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID320594	Analgesic activity in mouse at 41 umol/kg, po by tail immersion method relative to flurbiprophen	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents.
AID1374207	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production at 10 uM pretreated for 30 mins followed by LPS-stimulation measured after 24 hrs by ELISA relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID692103	Inhibition of gamma secretase assessed as reduction in Abeta42 production	2011	Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3	γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.
AID1374204	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production at 10 uM pretreated for 30 mins followed by LPS-stimulation measured after 24 hrs by Griess assay relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1273100	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID386887	Antimicrobial activity against Candida albicans ATCC 2091 by cup plate method	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID93279	percent inhibition of serotonin release from platelets at a concentration of 20 uM	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	Replacement of aromatic or heteroaromatic groups in nonsteroidal antiinflammatory agents with the ferrocene group.
AID310931	Partition coefficient, log P of the compound	2007	Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4	In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID253587	Total body clearance after administration to rats at a dose of 1.5 mg/kg intravenously	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1282661	Inhibition of ovine COX1 assessed as production of PGF2-alpha preincubated with compound followed by the addition of 5 uM arachidonic acid as substrate by enzyme immunoassay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
AID1636440	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID592847	Antiamyloidogenic activity in mouse N2A cells assessed as degradation of amyloid beta (1 to 42) level at 100 uM treated 24 hrs before amyloid beta (1 to 42) challenge measured after 8 hrs by MALDI/TOF analysis	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID1282662	Inhibition of recombinant human COX2 assessed as production of PGF2-alpha preincubated with compound followed by the addition of 5 uM arachidonic acid as substrate by enzyme immunoassay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
AID1374195	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells at 10 uM using kynuramine as substrate after 30 mins by fluorescence assay relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1585860	Anti-inflammatory activity in human BV2 cells assessed as inhibition of LPS-stimulated TNFalpha release at 10 uM preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA relative to control	2018	Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1667269	Cytotoxicity against mouse BV2 cells assessed as reduction in cell viability at 0.5 to 10 uM measured after 30 mins by MTT assay	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID253720	Maximal concentration in rats after 7.6 mg/kg oral dose	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1175392	Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 50 uM after 30 mins by Fluo-4 AM fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 24, Issue:24	Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.
AID592744	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay relative to control	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID1211792	Hepatic clearance in human	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1282660	Inhibition of FAAH in Sprague-Dawley rat brain homogenates preincubated for 10 mins followed by addition of substrate measured after 30 mins by liquid scintillation counting	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
AID1476082	Inhibition of rat ASIC3 receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 6.4-gated currents at 3 mM by two electrode voltage clamp relative to control	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID781329	pKa (acid-base dissociation constant) as determined by other workers	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID253786	Maximum time corresponding to maximum concentration after administration to rats at a dose of 1.5 mg/kg intravenously	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID346025	Binding affinity to beta cyclodextrin	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID78137	In vitro inhibition of collagen-induced platelet aggregation in guinea pig platelet rich plasma	1981	Journal of medicinal chemistry, Dec, Volume: 24, Issue:12	Synthesis and platelet aggregation inhibitory activity of 4,5-bis(aryl)-2-substituted-thiazoles.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1625109	Antioxidant activity assessed as trolox equivalents of AAPH radical scavenging activity at 1 to 10 uM preincubated for 15 mins followed by AAPH addition measured every min for 90 mins by ORAC-FL assay	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1667277	Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production at 10 uM preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by ELISA relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID574423	Displacement of 4-fluorophenyl 3-(4-hydroxy-3,5-dimethylstyryl)benzoate from recombinant TTR assessed as fluorescence at 37 degC after 3 hrs	2011	Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4	A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
AID255950	Inhibitory concentration against beta-amyloid-42 (Abeta42) secretion was evaluated in human neuroglioma cells (H4-APP695NL)	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID313126	Inhibition of COX1	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Structural and functional basis of cyclooxygenase inhibition.
AID1667270	Cytotoxicity against LPS-induced mouse BV2 cells assessed as reduction in cell viability at 0.5 to 10 uM preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID592848	Antiamyloidogenic activity in mouse N2A cells assessed as degradation of amyloid beta (1 to 40) level at 100 uM treated 24 hrs before amyloid beta (1 to 40) challenge measured after 8 hrs by MALDI/TOF analysis	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID253826	Elimination phase half-life after administration to rats at a dose of 1.5 mg/kg intravenously	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1585856	Anti-inflammatory activity in human BV2 cells assessed as inhibition of LPS-stimulated NO release at 10 uM preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay relative to control	2018	Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1211795	Dissociation constant, pKa of the compound	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID386884	Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured 4 hrs after carrageenan challenge	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
AID681160	TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells	2000	The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1	Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1.
AID592746	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay relative to control	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID592743	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrate production at 100 uM treated 30 mins before LPS challenge measured after 24 hrs by Griess reagent method relative to control	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID703401	Inhibition of human recombinant N-terminal His6-tagged AKR1C2 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID677462	Dissociation constant, pKa of the compound	2012	European journal of medicinal chemistry, Jul, Volume: 53	Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID1625122	Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1585855	Anti-inflammatory activity in human BV2 cells assessed as inhibition of LPS-stimulated NO release at 2.5 uM preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay relative to control	2018	Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID540233	Dose normalised AUC in human after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1273105	Cytotoxicity against human SNU475 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID1667273	Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production at 10 uM preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay relative to control	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1585859	Anti-inflammatory activity in human BV2 cells assessed as inhibition of LPS-stimulated TNFalpha release at 2.5 uM preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA relative to control	2018	Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID162164	Binding affinity of compound towards prostaglandin G/H synthase 1 was evaluated	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1625128	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells at 2.5 uM pretreated for 30 mins followed by LPS-stimulation and measured after 24 hrs by Griess assay relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1374196	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells at 10 uM using kynuramine as substrate after 30 mins by fluorescence assay relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID540232	Dose normalised AUC in monkey after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1625111	Inhibition of Cu2+-induced human amyloid beta (1 to 42) aggregation at 25 uM after 24 hrs by thioflavin T-based fluorometric assay relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1616920	Inhibition of catalytic activity of His6-tagged Lactobacillus johnsonii N6.2 cinnamoyl esterase LJ0536 expressed in Escherichia coli BL21 (DE3) assessed as reduction in hydrolysis of 4-nitrophenyl butyrate in 4-nitrophenol pre-incubated for 2 hrs	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Exhaustive Repertoire of Druggable Cavities at Protein-Protein Interfaces of Known Three-Dimensional Structure.
AID256322	Compound was tested for interaction with baculovirus-insect cells expressing human cytochrome P450; No interactions at 100 uM	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID253638	Area under curve after administration to rats at a dose of 7.6 mg/kg orally	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1211794	Fraction unbound in blood (not specified)	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1374192	Antioxidant activity assessed as trolox equivalent of APPH-induced radical scavenging activity at 1 to 10 uM pretreated for 15 mins followed by APPH addition measured at 1 min interval for 90 mins by ORAC-FL assay	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1273106	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID467611	Dissociation constant, pKa of the compound	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID253744	Intestinal drug absorption was estimated in vitro using human colon adenocarcinoma (Caco-2) cell monolayers	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1374200	Cytotoxicity against mouse BV2 cells assessed as reduction in cell viability at 40 uM after 30 mins by MTT assay relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID396391	Gastrointestinal toxicity in rat assessed as gastric mucosal damage severity index administered at equimolar oral dose relative to 30 mg/kg flurbiprofen	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	1,3,4-Oxadiazole/thiadiazole and 1,2,4-triazole derivatives of biphenyl-4-yloxy acetic acid: synthesis and preliminary evaluation of biological properties.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625277	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID592745	Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as reduction of amyloid beta (1 to 42) level at 1 uM after 24 hrs by ELISA relative to control	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID235171	Selectivity ratio of COX-1 to that of COX-2	1999	Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3	Structure-based design of COX-2 selectivity into flurbiprofen.
AID253891	In vivo steady state metabolic clearance of the compound	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1667263	Inhibition of recombinant human MAOB expressed in baculovirus infected in BTI cells using kynuramine as substrate after 30 mins by fluorescence based assay	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1330180	Inhibition of COX-1 (unknown origin)	2017	Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1	Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
AID93278	percent inhibition of serotonin release from platelets at a concentration of 100 uM	1983	Journal of medicinal chemistry, Feb, Volume: 26, Issue:2	Replacement of aromatic or heteroaromatic groups in nonsteroidal antiinflammatory agents with the ferrocene group.
AID1273103	Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID1273104	Cytotoxicity against human FOCUS cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.
AID781330	pKa (acid-base dissociation constant) as determined by potentiometric titration	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID592742	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID1636356	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID703399	Inhibition of human recombinant N-terminal His6-tagged AKR1C4 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis	2012	Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17	3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1374206	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production at 2.5 uM pretreated for 30 mins followed by LPS-stimulation measured after 24 hrs by ELISA relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1374193	Inhibition of self-induced aggregation of amyloid beta (1 to 42) (unknown origin) at 25 uM after 24 hrs by thioflavin T fluorescence method relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID592755	Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as increase of amyloid beta (1 to 37) level at 100 uM after 24 hrs by ELISA	2011	Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7	Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.
AID462317	Inhibition of ovine COX1	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
AID313125	Inhibition of COX2	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Structural and functional basis of cyclooxygenase inhibition.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1476078	Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 6.7-gated currents by two electrode voltage clamp	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID1585852	Cytotoxicity against human BV2 cells assessed as decrease in cell viability up to 10 uM preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1616922	Non-competive inhibition of catalytic activity of His6-tagged Lactobacillus johnsonii N6.2 cinnamoyl esterase LJ0536 expressed in Escherichia coli BL21 (DE3) assessed as substrate Vmax by measuring hydrolysis of 4-nitrophenyl butyrate in 4-nitrophenol at	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Exhaustive Repertoire of Druggable Cavities at Protein-Protein Interfaces of Known Three-Dimensional Structure.
AID162166	Kinetic constant of compound towards inhibition of prostaglandin G/H synthase 1	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors.
AID19006	Calculated membrane partition coefficient (Kmemb)	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID407366	Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID462318	Inhibition of mouse COX2	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
AID1476079	Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes assessed as inhibition of pH 6.7-gated currents at 3 mM by two electrode voltage clamp relative to control	2017	Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19	Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID1625129	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells at 10 uM pretreated for 30 mins followed by LPS-stimulation and measured after 24 hrs by Griess assay relative to control	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID254854	Concentration required to inhibit cyclooxygenase-1 in rat blood	2005	Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18	Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540231	Dose normalised AUC in dog after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID162150	Reversible competitive inhibition of prostaglandin G/H synthase 1	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors.
AID239780	Percentage plasma protein binding towards human serum albumin	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504797	Fluorescence polarization-based biochemical high throughput confirmation assay for activators of the Protein Kinase A-R2B (PKA-R2B) complex	2006	Analytical chemistry, Dec-15, Volume: 78, Issue:24	Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504796	Counterscreen for activators of the Protein Kinase A-R2B (PKA-R2B) complex: fluorescence polarization-based biochemical high throughput screening assay to identify fluorescence polarization assay artifacts	2006	Analytical chemistry, Dec-15, Volume: 78, Issue:24	Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1801103	Fluorophore Displacement Assay from Article 10.1021/cb5005178: \\Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.\\	2014	ACS chemical biology, Nov-21, Volume: 9, Issue:11	Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1346898	Rat ASIC1 (Acid-sensing (proton-gated) ion channels (ASICs))	2001	The Journal of neuroscience : the official journal of the Society for Neuroscience, Oct-15, Volume: 21, Issue:20	Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors.
AID1345206	Human COX-2 (Cyclooxygenase)	1999	Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3	Structure-based design of COX-2 selectivity into flurbiprofen.
AID1345284	Human COX-1 (Cyclooxygenase)	1999	Proceedings of the National Academy of Sciences of the United States of America, Jun-22, Volume: 96, Issue:13	Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	497 (25.09)	18.7374
1990's	408 (20.60)	18.2507
2000's	441 (22.26)	29.6817
2010's	510 (25.74)	24.3611
2020's	125 (6.31)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	466 (22.49%)	5.53%
Reviews	71 (3.43%)	6.00%
Case Studies	64 (3.09%)	4.05%
Observational	1 (0.05%)	0.25%
Other	1,470 (70.95%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (65)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT02391688]	Phase 1	30 participants (Actual)	Interventional	2014-11-30	Completed
The Effects of Remimazolam Tosilate Sedation Compared With Midazolam Sedation in Dental Patients: A Double Blind, Prospective , Randomized Controlled Trial [NCT04602845]	Phase 4	81 participants (Actual)	Interventional	2021-04-01	Completed
Evaluation of the Effects of Different Analgesics on Pain and Health-related Quality of Life of Patients With Pericoronitis in the Short-term Period: A Randomized, Double-blind, Clinical Trial [NCT03745599]	Phase 4	60 participants (Actual)	Interventional	2017-11-01	Completed
Effect of Preemptive Analgesia With Flurbiprofen Axetil on Perioperative Sleep Quality and Postoperative Pain in Patients Undergoing Sevoflurane Inhalation. [NCT04611763]	Phase 1	100 participants (Anticipated)	Interventional	2021-09-01	Recruiting
Effect of Over-the-counter Non-steroidal Anti-inflammatory Treatments on Cough Reflex Sensitivity in Subjects With Upper Respiratory Tract Infection [NCT05955885]	Early Phase 1	120 participants (Anticipated)	Interventional	2023-07-01	Recruiting
A Phase 1 Open-label Study to Assess the Effect of BMS-986419 on the Single Dose Pharmacokinetics of Probe Substrates (Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, and Fexofenadine) in Healthy Participants [NCT05932277]	Phase 1	22 participants (Actual)	Interventional	2023-06-29	Completed
Effect of BMS-986020 on the Pharmacokinetics of Montelukast, Flurbiprofen, and Digoxin as Probe Substrates for CYP2C8, CYP2C9, and P-gp [NCT02227173]	Phase 1	20 participants (Actual)	Interventional	2014-09-30	Completed
Impact of Perioperative Dexamethasone and Flurbiprofen Axetil on Delirium After Surgery for Non-small Cell Lung Cancer: A 2x2 Factorial Randomized Controlled Trial [NCT03200600]	Phase 4	126 participants (Actual)	Interventional	2017-08-02	Terminated(stopped due to Protocol violation occurred frequently during the postoperative period.)
Cocktail Phenotypic Approach to Explore Antidepressant Pharmacokinetic Variability: a Pilot Study [NCT02438072]		100 participants (Anticipated)	Interventional	2014-12-31	Recruiting
Impact of Perioperative Dexamethasone and Flurbiprofen Axetil on Long-term Survival After Surgery for Non-small Cell Lung Cancer: A 2x2 Factorial Randomized Controlled Trial [NCT03172988]	Phase 4	126 participants (Actual)	Interventional	2017-08-02	Terminated(stopped due to Protocol violation occurred frequently during the postoperative period.)
Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants [NCT03131973]	Phase 1	26 participants (Actual)	Interventional	2017-05-13	Completed
Efficiency of Flurbiprofen 2.5% in Comparison to 98% Aloe Vera Gel as an Adjunctive Therapy to Scaling and Root Planning in the Initial Treatment of Stage III Chronic Periodontitis in Smoking Patients [NCT06041178]	Phase 4	60 participants (Actual)	Interventional	2022-09-30	Completed
Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects [NCT02206854]	Phase 1	16 participants (Actual)	Interventional	2014-06-30	Completed
Flurbiprofen Axetil and Nalbuphine for Postoperative Pain and Discomfort After Orbital Decompression [NCT03562611]		63 participants (Actual)	Interventional	2018-06-08	Completed
The Effects of Non-steroidal Anti-inflammatory Drugs on Circulating Markers of Bone Metabolism Following Plyometric Exercise in Humans [NCT05512013]	Phase 1	12 participants (Actual)	Interventional	2022-02-15	Completed
Comparison of Two Kinds of Postoperative Analgesia After Amputation:a Randomized Clinical Trial [NCT02114463]	Phase 4	36 participants (Anticipated)	Interventional	2014-03-31	Recruiting
Effectiveness, Safety and Economic Evaluation of Chinese Tuina (Chinese Massage and Flurbiprofen Cataplasms) in the Treatment of Chronic Nonspecific Low Back Pain [NCT04976790]		90 participants (Anticipated)	Interventional	2021-10-28	Recruiting
A Phase 1, Single-center, Open-label, Sequential Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants [NCT05852769]	Phase 1	18 participants (Actual)	Interventional	2023-05-31	Completed
[NCT02674737]		80 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Prospective Analgesic Compound Efficacy (PACE) Study [NCT02403687]		300 participants (Actual)	Observational [Patient Registry]	2015-06-30	Completed
The Safety and Efficacy of 5% Lidocaine Patch and Flurbiprofen Patch for Relieving Acute Low Back Pain [NCT03171987]	Phase 4	120 participants (Anticipated)	Interventional	2017-06-14	Recruiting
An Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Cytochrome P450 Probe Drugs in Healthy Adult Subjects [NCT00964106]	Phase 1	87 participants (Actual)	Interventional	2009-08-26	Completed
A Single-center, Open-label, Four-period, Fixed-sequence Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on the Pharmacokinetics of Flurbiprofen, Omeprazole, Midazolam, and Their Respective Metabolites in Healthy Subjects [NCT05254548]	Phase 1	22 participants (Actual)	Interventional	2022-02-18	Completed
A Single Center, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK376501 on Hepatic Cytochrome P450 Activity in Healthy Adult Subjects [NCT00615212]	Phase 1	23 participants (Actual)	Interventional	2008-01-02	Completed
[NCT02670954]		154 participants (Actual)	Interventional	2015-10-31	Completed
Effects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Substrates for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp in Healthy Subjects [NCT02762123]	Phase 1	28 participants (Actual)	Interventional	2016-05-31	Completed
Evaluation of the CYP2C9 Activity With Dried Blood Spots on Filter Paper Obtained With a Simple Finger Prick [NCT01026714]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2009-11-30	Completed
Analgesia Effects of Nalbuphine vs Sulfentanil in Patient-controlled Intravenous Analgesia After Cesarean Section [NCT02604797]		80 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
A Phase I Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 Pharmacokinetics and to Assess the Effect of GSK2248761 on CYP450 Probe Drugs in Healthy Adult Subjects [NCT00920088]	Phase 1	24 participants (Actual)	Interventional	2009-06-30	Completed
Tumor Hospital of Guangxi Medical University, China [NCT02569905]	Phase 4	166 participants (Actual)	Interventional	2014-04-30	Completed
The Effect of Sex Difference in Preemptive Analgesic Effects With Flurbiprofen Axetil on Postoperative Pain and Sleep Quality of Patients Under General Anesthesia [NCT04627779]		100 participants (Anticipated)	Interventional	2021-01-01	Not yet recruiting
Benefits of Enhanced Recovery After Surgery in Patients Undergoing Endoscopic Sinus Surgery [NCT04048070]		55 participants (Actual)	Interventional	2018-05-03	Completed
Comparative, Randomized, Two-period, Two-treatment, Two-sequence, Single Dose, Open-label, Crossover Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET (One Tablet) of (Sanovel İlaç San. ve Tic. A.Ş., İstanbul / Türkiye) Versu [NCT01910090]	Phase 1	36 participants (Actual)	Interventional	2012-12-31	Completed
The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis [NCT00425451]	Phase 2	80 participants (Actual)	Interventional	2008-08-31	Completed
The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis [NCT01040286]	Phase 2	0 participants	Interventional	2009-08-31	Completed
Effects of Genotype on CYP2C9 Drug Interactions [NCT01061112]		23 participants (Actual)	Observational	2009-12-31	Completed
[NCT01998217]	Phase 4	60 participants (Actual)	Interventional	2012-09-30	Completed
Phase IV Study of Flurbiprofen Axetil for Uterine Contraction Pain After Abortion [NCT00725218]	Phase 4	97 participants (Actual)	Interventional	2008-05-31	Completed
Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects [NCT04425902]	Phase 1	20 participants (Actual)	Interventional	2020-12-16	Completed
A Phase 1, Open-Label, Two-Part, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Voxelotor on the Pharmacokinetics of Selected CYP and Transporter Probe Substrates in Healthy Participants [NCT05981365]	Phase 1	18 participants (Actual)	Interventional	2023-04-17	Completed
Pain Treatment in Posterior Thoracolumbar Operation a Randomized Study to Assess the Effect of Local Analgesia After Operation [NCT01872494]	Phase 4	71 participants (Actual)	Interventional	2013-05-31	Completed
Bioequivalence Study of Flurbiprofen 8.75 mg Lozenge vs. the Reference Product Strepfen 8.75 mg Lozenge in Healthy Volunteers [NCT04670601]	Phase 1	24 participants (Actual)	Interventional	2018-06-19	Completed
A Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study to Determine the Efficacy, Onset, and Duration of Action of Flurbiprofen 8.75 mg Lozenge Compared to Its Vehicle Control Lozenge in Patients With Painful Pharyngitis [NCT01049334]	Phase 3	204 participants (Actual)	Interventional	2009-11-30	Completed
A Repeat-Dose, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Study to Determine the Safety and Efficacy of Flurbiprofen 8.75 mg Lozenge Compared to Its Vehicle Control Lozenge in Patients With Painful Pharyngitis [NCT01048866]	Phase 3	198 participants (Actual)	Interventional	2009-11-30	Completed
The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy [NCT06000137]		129 participants (Actual)	Interventional	2022-02-10	Completed
A Randomized, Blinded, Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Single and Repeat Dose Escalation of the Oral YAK3/DYRK3 Inhibitor GSK626616AC in Healthy Subjects [NCT00443170]	Phase 1	90 participants (Actual)	Interventional	2006-11-30	Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Flurbiprofen Tape for Treatment of Chronic Low Back Pain [NCT00759330]	Phase 2	127 participants (Actual)	Interventional	2007-10-31	Completed
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type [NCT00322036]	Phase 3	800 participants (Actual)	Interventional	2006-05-31	Terminated(stopped due to Myriad has discontinued the development of Flurizan.)
Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type [NCT00105547]	Phase 3	1,600 participants (Actual)	Interventional	2005-02-28	Completed
Evaluation of the Analgesic Effects of Locally Applied Flurbiprofen and Bupivacaine in the Oral Surgery Model [NCT00001724]	Phase 2	100 participants	Interventional	1997-11-30	Completed
Subglottic Instillation of Flurbiprofen to Prevent Laryngeal Inflammation Resulting From Endotracheal Intubation: Prospective Pilot Study, Randomized, Double Blind, Placebo Controlled. [NCT04708964]	Phase 2	70 participants (Anticipated)	Interventional	2021-01-31	Not yet recruiting
[NCT01731067]	Phase 1	10 participants (Anticipated)	Interventional	2012-11-30	Completed
Comparison of Efficacy and Safety of Different Analgesic Modes in Minimally Invasive Esophagectomy for Esophageal Cancer [NCT05504265]	Phase 2/Phase 3	102 participants (Anticipated)	Interventional	2022-08-10	Not yet recruiting
Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects [NCT02456844]	Phase 1	24 participants (Actual)	Interventional	2015-05-31	Completed
Effect of Dexmedetomidine Combined With Dezocine and Flubiprofen for Postoperative Intravenous Patient Controlled Analgesia After Colorectal Surgery [NCT03014713]	Phase 4	50 participants (Anticipated)	Interventional	2016-09-30	Recruiting
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Postoperative Hyperalgesia Induced by Remifentanil in Patients Undergoing Lower Abdomimal Surgery [NCT02043366]		180 participants (Actual)	Interventional	2014-02-28	Completed
A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Onset-of-Action Study Utilizing the Double-Stopwatch Method [NCT01986361]	Phase 3	122 participants (Actual)	Interventional	2013-09-30	Completed
Efficacy of Dezocine for the Prevention of Catheter-related Bladder Discomfort [NCT03147066]	Phase 4	96 participants (Actual)	Interventional	2017-09-01	Completed
The Use of Non-Steroidal Anti-Inflammatory Drugs as a Tool of Positive Change in Peri-Implants Mucositis Microbiome [NCT03090009]	Early Phase 1	100 participants (Anticipated)	Interventional	2017-04-30	Not yet recruiting
Oral Flurbiprofen Spray for Mucosal Graft Harvesting at the Palatal Area: A Randomized Placebo-controlled Study [NCT03165929]	Early Phase 1	48 participants (Actual)	Interventional	2016-05-31	Completed
A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects [NCT04643249]	Phase 1	14 participants (Actual)	Interventional	2020-11-10	Completed
A Phase I, Open-Label Study to Assess the Effects of PRC-4016 (Icosabutate) on the Pharmacokinetics of Midazolam, Omeprazole, Flurbiprofen and Simvastatin in Healthy Male/Female Subjects [NCT02367937]	Phase 1	16 participants (Actual)	Interventional	2014-08-31	Completed
The Effect of Doctor-nurse-patient Cooperative Analgesic Linkage Program on Movement Evoked Pain After Laparotomy for Patients With Hepatobiliary and Pancreatic Disease [NCT03823846]		80 participants (Anticipated)	Interventional	2017-11-01	Recruiting
The Application of Transversus Abdominis Plane Block Plus Rectus Sheath Block in Peritoneal Dialysis Catheter Placement and Analgesia Based on Transversus Abdominis Plane Block Combined With κ Receptor Agonist and NSAID(Non-steroidal Anti-inflammatory Dru [NCT02984865]		190 participants (Anticipated)	Interventional	2016-12-20	Recruiting
Flurbiprofen Axetil and Nalbuphine for Postoperative Pain and Discomfort After Oculoplastic Surgery [NCT03422887]		330 participants (Actual)	Interventional	2018-01-18	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00759330 (10) [back to overview]	Acetaminophen Used During the Tape Treatment Phase
NCT00759330 (10) [back to overview]	Acetaminophen Used During the Tape Treatment Phase
NCT00759330 (10) [back to overview]	Change From Baseline in Total Tender Point Examination Score
NCT00759330 (10) [back to overview]	Percent Change From Baseline in Total Functional Rating Index (FRI)
NCT00759330 (10) [back to overview]	Percentage of Patients Who Discontinued
NCT00759330 (10) [back to overview]	Average Daily Categorical Pain Scale Scores
NCT00759330 (10) [back to overview]	Cumulative Summed Pain Intensity Difference (SPID+)
NCT00759330 (10) [back to overview]	Pain Intensity Difference (PID+)
NCT00759330 (10) [back to overview]	Patient Assessment of Wearability of Therapy
NCT00759330 (10) [back to overview]	Patient Global Impression of Change (PGIC)
NCT01048866 (19) [back to overview]	Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)
NCT01048866 (19) [back to overview]	Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline
NCT01048866 (19) [back to overview]	Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose
NCT01048866 (19) [back to overview]	Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe
NCT01048866 (19) [back to overview]	Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline
NCT01048866 (19) [back to overview]	Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline
NCT01048866 (19) [back to overview]	Change From Baseline in Body Temperature at 2 Hours Post Initial Dose
NCT01048866 (19) [back to overview]	Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline
NCT01048866 (19) [back to overview]	Change From Baseline in Body Temperature at End of Study
NCT01048866 (19) [back to overview]	Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Difficulty Swallowing Scale (DSS2)
NCT01048866 (19) [back to overview]	Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Swollen Throat Scale (SwoTS2)
NCT01048866 (19) [back to overview]	Post 24 Hour, Multiple Dose Results: Weighted Sum of Pain Intensity Differences (SPID) Over 2 Hours for the Sore Throat Pain Intensity Scale (STPIS SPID2)
NCT01048866 (19) [back to overview]	Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)
NCT01048866 (19) [back to overview]	Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at End of Study (Day 7)
NCT01048866 (19) [back to overview]	Participant Satisfaction Score 24 Hours After Initial Dose
NCT01048866 (19) [back to overview]	Percentage of Participants Who Took Rescue Pain Medication
NCT01048866 (19) [back to overview]	Post 24 Hour, Multiple Dose Results: Sore Throat Relief As Reported by Participants 2 Hours After Dosing
NCT01048866 (19) [back to overview]	Sore Throat Relief As Reported by Participants 2 Hours After Initial Dose
NCT01048866 (19) [back to overview]	Time to First Rescue Pain Medication
NCT01049334 (16) [back to overview]	Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe
NCT01049334 (16) [back to overview]	Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8
NCT01049334 (16) [back to overview]	Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement
NCT01049334 (16) [back to overview]	Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL)
NCT01049334 (16) [back to overview]	Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)
NCT01049334 (16) [back to overview]	Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)
NCT01049334 (16) [back to overview]	Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline
NCT01049334 (16) [back to overview]	Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline
NCT01049334 (16) [back to overview]	Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline
NCT01049334 (16) [back to overview]	Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline
NCT01049334 (16) [back to overview]	Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose
NCT01049334 (16) [back to overview]	Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7)
NCT01049334 (16) [back to overview]	Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose
NCT01049334 (16) [back to overview]	Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose
NCT01049334 (16) [back to overview]	Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05
NCT01049334 (16) [back to overview]	Participant Satisfaction Scores 24 Hours After Initial Dose
NCT01986361 (9) [back to overview]	Change From Baseline at Individual Timepoints in Sore Throat Scale (STS)
NCT01986361 (9) [back to overview]	Kaplan-Meier Estimates for Time of First Indication of Sore Throat Relief as Measured By Any Reduction in the Sore Throat Scale (STS)
NCT01986361 (9) [back to overview]	Kaplan-Meier Estimates for Time of First Perceived Pain Reduction on the Sore Throat Scale (STS) Which is Followed by ≥ 20% Pain Reduction on the Sore Throat Pain Intensity Scale (STPIS)
NCT01986361 (9) [back to overview]	Kaplan-Meier Estimates for Time of First Perceived Pain Relief
NCT01986361 (9) [back to overview]	Kaplan-Meier Estimates for Time to First Perceived Pain Relief That Is Confirmed By Meaningful Pain Relief
NCT01986361 (9) [back to overview]	Kaplan-Meier Estimates for Time to Meaningful Pain Relief
NCT01986361 (9) [back to overview]	Percentage of Participants With Meaningful Pain Relief
NCT01986361 (9) [back to overview]	Percentage of Participants With Perceived Pain Relief
NCT01986361 (9) [back to overview]	Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Scale (STS) Over the 3 Hours Post-baseline (STS SPID3)
NCT02043366 (2) [back to overview]	Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm
NCT02043366 (2) [back to overview]	Normalized Area of Hyperalgesia Around the Incision
NCT04425902 (171) [back to overview]	Time to Cmax (Tmax) for Caffeine
NCT04425902 (171) [back to overview]	Tmax for 1-hydroxymidazolam
NCT04425902 (171) [back to overview]	Tmax for 36-hydroxymontelukast
NCT04425902 (171) [back to overview]	Tmax for 5-hydroxyomeprazole
NCT04425902 (171) [back to overview]	Tmax for Alpha-hydroxymetoprolol
NCT04425902 (171) [back to overview]	Tmax for Digoxin
NCT04425902 (171) [back to overview]	Tmax for Flurbiprofen
NCT04425902 (171) [back to overview]	Tmax for Metoprolol
NCT04425902 (171) [back to overview]	Tmax for Midazolam
NCT04425902 (171) [back to overview]	Tmax for Montelukast
NCT04425902 (171) [back to overview]	Tmax for Omeprazole
NCT04425902 (171) [back to overview]	Tmax for Pravastatin
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Erythrocytes
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Hematocrit
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Hemoglobin
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Oral Temperature
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Pulse Rate
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Respiratory Rate
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Erythrocytes
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Hematocrit
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Hemoglobin
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Oral Temperature
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Pulse Rate
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Respiratory Rate
NCT04425902 (171) [back to overview]	Treatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK3640254
NCT04425902 (171) [back to overview]	Treatment C: AUC(0-t) for GSK3640254
NCT04425902 (171) [back to overview]	Treatment C: Cmax for GSK3640254
NCT04425902 (171) [back to overview]	Treatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254
NCT04425902 (171) [back to overview]	Treatment C: t1/2 for GSK3640254
NCT04425902 (171) [back to overview]	Treatment C: Tmax for GSK3640254
NCT04425902 (171) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF)
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Albumin, Globulin, Protein
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Amylase, Lipase
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Erythrocytes
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Volume
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Hematocrit
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Hemoglobin
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Oral Temperature
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Pulse Rate
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Respiratory Rate
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT04425902 (171) [back to overview]	Treatment A: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Albumin, Globulin, Protein
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Amylase, Lipase
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
NCT04425902 (171) [back to overview]	Cmax for Alpha-hydroxymetoprolol
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Albumin, Globulin, Protein
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Amylase, Lipase
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Erythrocytes
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Volume
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Hematocrit
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Hemoglobin
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Oral Temperature
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Pulse Rate
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Respiratory Rate
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of SBP and DBP
NCT04425902 (171) [back to overview]	Treatment B: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Albumin, Globulin, Protein
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Amylase, Lipase
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in SBP and DBP
NCT04425902 (171) [back to overview]	Treatment B: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Albumin, Globulin, Protein
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Amylase, Lipase
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Erythrocytes
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Volume
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Hematocrit
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Hemoglobin
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Oral Temperature
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Pulse Rate
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Respiratory Rate
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of SBP and DBP
NCT04425902 (171) [back to overview]	Treatment C: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Albumin, Globulin, Protein
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Amylase, Lipase
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Erythrocytes
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Volume
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Hematocrit
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Hemoglobin
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Oral Temperature
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Pulse Rate
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Respiratory Rate
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in SBP and DBP
NCT04425902 (171) [back to overview]	Apparent Terminal Phase Half-life (t1/2) for Caffeine
NCT04425902 (171) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine
NCT04425902 (171) [back to overview]	AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine
NCT04425902 (171) [back to overview]	AUC(0-infinity) for 1-hydroxymidazolam
NCT04425902 (171) [back to overview]	AUC(0-infinity) for 36-hydroxymontelukast
NCT04425902 (171) [back to overview]	AUC(0-infinity) for 5-hydroxyomeprazole
NCT04425902 (171) [back to overview]	AUC(0-infinity) for Alpha-hydroxymetoprolol
NCT04425902 (171) [back to overview]	AUC(0-infinity) for Digoxin
NCT04425902 (171) [back to overview]	AUC(0-infinity) for Flurbiprofen
NCT04425902 (171) [back to overview]	AUC(0-infinity) for Metoprolol
NCT04425902 (171) [back to overview]	AUC(0-infinity) for Midazolam
NCT04425902 (171) [back to overview]	AUC(0-infinity) for Montelukast
NCT04425902 (171) [back to overview]	AUC(0-infinity) for Omeprazole
NCT04425902 (171) [back to overview]	AUC(0-infinity) for Pravastatin
NCT04425902 (171) [back to overview]	AUC(0-t) for 1-hydroxymidazolam
NCT04425902 (171) [back to overview]	AUC(0-t) for 36-hydroxymontelukast
NCT04425902 (171) [back to overview]	AUC(0-t) for 5-hydroxyomeprazole
NCT04425902 (171) [back to overview]	AUC(0-t) for Alpha-hydroxymetoprolol
NCT04425902 (171) [back to overview]	AUC(0-t) for Digoxin
NCT04425902 (171) [back to overview]	AUC(0-t) for Flurbiprofen
NCT04425902 (171) [back to overview]	AUC(0-t) for Metoprolol
NCT04425902 (171) [back to overview]	AUC(0-t) for Midazolam
NCT04425902 (171) [back to overview]	AUC(0-t) for Montelukast
NCT04425902 (171) [back to overview]	AUC(0-t) for Omeprazole
NCT04425902 (171) [back to overview]	AUC(0-t) for Pravastatin
NCT04425902 (171) [back to overview]	Cmax for 1-hydroxymidazolam
NCT04425902 (171) [back to overview]	Cmax for 36-hydroxymontelukast
NCT04425902 (171) [back to overview]	Cmax for 5-hydroxyomeprazole
NCT04425902 (171) [back to overview]	Treatment A: Change From Baseline in SBP and DBP
NCT04425902 (171) [back to overview]	Cmax for Digoxin
NCT04425902 (171) [back to overview]	Cmax for Flurbiprofen
NCT04425902 (171) [back to overview]	Cmax for Metoprolol
NCT04425902 (171) [back to overview]	Cmax for Midazolam
NCT04425902 (171) [back to overview]	Cmax for Montelukast
NCT04425902 (171) [back to overview]	Cmax for Omeprazole
NCT04425902 (171) [back to overview]	Cmax for Pravastatin
NCT04425902 (171) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Caffeine
NCT04425902 (171) [back to overview]	Ratio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam
NCT04425902 (171) [back to overview]	Ratio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast
NCT04425902 (171) [back to overview]	Ratio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole
NCT04425902 (171) [back to overview]	Ratio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol
NCT04425902 (171) [back to overview]	Ratio of Cmax of 1-hydroxymidazolam to Midazolam
NCT04425902 (171) [back to overview]	Ratio of Cmax of 36-hydroxymontelukast to Montelukast
NCT04425902 (171) [back to overview]	Ratio of Cmax of 5-hydroxyomeprazole to Omeprazole
NCT04425902 (171) [back to overview]	Ratio of Cmax of Alpha-hydroxymetoprolol to Metoprolol
NCT04425902 (171) [back to overview]	t1/2 for 1-hydroxymidazolam
NCT04425902 (171) [back to overview]	t1/2 for 36-hydroxymontelukast
NCT04425902 (171) [back to overview]	t1/2 for 5-hydroxyomeprazole
NCT04425902 (171) [back to overview]	t1/2 for Alpha-hydroxymetoprolol
NCT04425902 (171) [back to overview]	t1/2 for Digoxin
NCT04425902 (171) [back to overview]	t1/2 for Flurbiprofen
NCT04425902 (171) [back to overview]	t1/2 for Metoprolol
NCT04425902 (171) [back to overview]	t1/2 for Midazolam
NCT04425902 (171) [back to overview]	t1/2 for Montelukast
NCT04425902 (171) [back to overview]	t1/2 for Omeprazole
NCT04425902 (171) [back to overview]	t1/2 for Pravastatin
NCT04425902 (171) [back to overview]	Treatment C: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin

Acetaminophen Used During the Tape Treatment Phase

The percentage of patients who used rescue medication during the tape treatment phase. (NCT00759330)
Timeframe: Day 1 through Day 7 of the tape treatment phase

Intervention	percentage of patients (Number)
Placebo Tape, Daily for 12 Hours	50
Flurbiprofen Tape, Daily for 12 Hours	54.8
Placebo Tape, Daily for 24 Hours	36.4
Flurbiprofen Tape, Daily for 24 Hours	62.8

Intervention	mg (Least Squares Mean)
Placebo Tape, Daily for 12 Hours	2226.9
Flurbiprofen Tape, Daily for 12 Hours	1617.5
Placebo Tape, Daily for 24 Hours	1585.4
Flurbiprofen Tape, Daily for 24 Hours	2141.3

Intervention	units on a scale (Least Squares Mean)
Placebo Tape, Daily for 12 Hours	13.9
Flurbiprofen Tape, Daily for 12 Hours	11.7
Placebo Tape, Daily for 24 Hours	19.2
Flurbiprofen Tape, Daily for 24 Hours	9.2

Intervention	percent change from baseline (Least Squares Mean)
Placebo Tape, Daily for 12 Hours	20.6
Flurbiprofen Tape, Daily for 12 Hours	29.0
Placebo Tape, Daily for 24 Hours	28.2
Flurbiprofen Tape, Daily for 24 Hours	25.4

Intervention	units on a scale (Mean)
	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
Flurbiprofen Tape, Daily for 12 Hours	4.8	4.7	4.5	4.0	4.4	4.2	3.8
Flurbiprofen Tape, Daily for 24 Hours	5.7	4.9	4.8	5.0	4.8	4.8	4.4
Placebo Tape, Daily for 12 Hours	5.3	4.7	5.0	5.0	5.1	4.9	4.6
Placebo Tape, Daily for 24 Hours	5.3	4.5	4.3	4.5	4.2	4.2	4.1

Intervention	units on a scale (Least Squares Mean)
	SPID for Day 4	SPID for Day 7
Flurbiprofen Tape, Daily for 12 Hours	6.3	12.1
Flurbiprofen Tape, Daily for 24 Hours	5.2	10.2
Placebo Tape, Daily for 12 Hours	4.6	8.4
Placebo Tape, Daily for 24 Hours	6.7	13.0

Intervention	participants (Number)
	Ease of application, 1: Excellent	Ease of application, 2: Good	Ease of application, 3: Fair	Ease of application, 4: Poor	Stays in place, 1: Excellent	Stays in place, 2: Good	Stays in place, 3: Fair	Stays in place, 4: Poor	Comfortable to wear, 1: Excellent	Comfortable to wear, 2: Good	Comfortable to wear, 3: Fair	Comfortable to wear, 4: Poor
Flurbiprofen Tape, Daily for 12 Hours	1	9	11	20	16	11	11	3	18	14	9	0
Flurbiprofen Tape, Daily for 24 Hours	3	9	12	18	10	20	2	10	22	14	2	4
Placebo Tape, Daily for 12 Hours	1	5	5	8	8	3	5	3	8	8	0	3
Placebo Tape, Daily for 24 Hours	0	3	9	10	6	5	7	4	9	8	2	3

Intervention	participants (Number)
	1: Very much improved	2: Much improved	3: Improved	4: No change	5: Worse	6: Much worse	7: Very much worse
Flurbiprofen Tape, Daily for 12 Hours	7	10	12	10	2	0	0
Flurbiprofen Tape, Daily for 24 Hours	9	4	11	18	0	0	0
Placebo Tape, Daily for 12 Hours	3	1	4	10	1	0	0
Placebo Tape, Daily for 24 Hours	3	3	8	8	0	0	0

Intervention	percentage of participants (Number)
	Poor	Fair	Good	Very Good	Excellent
Flurbiprofen 8.75 mg Lozenge	25.0	27.0	26.0	14.0	8.0
Placebo Lozenge	25.3	29.5	24.2	12.6	8.4

Intervention	percentage of participants (Number)
	Extremely dissatisfied	Very dissatisfied	Dissatisfied	Somewhat satisfied	Satisfied	Very satisified	Extremely satisfied
Flurbiprofen 8.75 mg Lozenge	4.0	4.0	10.9	27.7	23.8	24.8	5.0
Placebo Lozenge	5.2	9.4	14.6	32.3	26.0	7.3	5.2

Intervention	percentage of participants (Number)
	Yes	No
Flurbiprofen 8.75 mg Lozenge	13.9	86.1
Placebo Lozenge	25.8	74.2

Intervention	percentage of doses (Number)
	No relief	Slight relief	Mild relief	Moderate relief	Considerable relief	Complete relief
Flurbiprofen 8.75 mg Lozenge	9.7	21.7	25.2	16.5	18.9	8.0
Placebo Lozenge	23.0	24.8	19.0	13.7	14.7	4.9

Intervention	percentage of participants (Number)
	2 - <4 hours	4 - <6 hours	6 - <24 hours	24 - <72 hours	72 - 168 hours	Did not rescue
Flurbiprofen 8.75 mg Lozenge	2.0	2.0	5.9	3.0	1.0	86.1
Placebo Lozenge	6.2	2.1	13.4	3.1	1.0	74.2

Intervention	participants (Number)
	No inflammation	Mild inflammation	Moderate inflammation	Severe inflammation
Flurbiprofen 8.75 mg Lozenge	0	48	42	11
Placebo Lozenge	1	42	50	7

Intervention	units on a scale (Mean)
	Minutes post dose: 2	Minutes post dose: 4	Minutes post dose: 6	Minutes post dose: 8	Minutes post dose: 10	Minutes post dose: 12	Minutes post dose: 14	Minutes post dose: 16	Minutes post dose: 18	Minutes post dose: 20	Minutes post dose: 22	Minutes post dose: 24	Minutes post dose: 26	Minutes post dose: 28	Minutes post dose: 30	Minutes post dose: 32	Minutes post dose: 34	Minutes post dose: 36	Minutes post dose: 38	Minutes post dose: 40
Flurbiprofen 8.75 mg Lozenge	-0.1	-0.3	-0.6	-0.9	-1.4	-1.9	-2.4	-3.0	-3.5	-4.1	-4.7	-5.2	-5.9	-6.5	-7.2	-7.9	-8.6	-9.3	-10.1	-10.8
Placebo Lozenge	-0.2	-0.4	-0.8	-1.2	-1.6	-2.1	-2.5	-2.9	-3.3	-3.7	-4.1	-4.5	-4.9	-5.3	-5.8	-6.2	-6.6	-7.1	-7.5	-7.9

Intervention	units on a scale (Mean)
	Minute 5	Minute 10	Minute 15	Minute 20	Minute 25	Minute 30	Minute 35	Minute 40	Minute 45	Minute 50	Minute 55	Minute 60	Minute 70	Minute 80	Minute 90	Minute 100	Minute 110	Minute 120	Minute 130	Minute 140	Minute 150	Minute 160	Minute 170	Minute 180
Flurbiprofen 8.75 mg Lozenge	-0.4	-0.7	-0.9	-1.0	-1.3	-1.6	-1.8	-2.0	-2.2	-2.3	-2.4	-2.5	-2.6	-2.7	-2.7	-2.7	-2.7	-2.7	-2.6	-2.6	-2.5	-2.4	-2.3	-2.3
Placebo Lozenge	-0.4	-0.6	-0.6	-0.6	-0.7	-1.0	-1.0	-1.1	-1.2	-1.3	-1.1	-1.1	-1.2	-1.1	-1.0	-1.0	-1.0	-1.0	-1.0	-0.9	-0.8	-0.9	-0.8	-0.8

Intervention	g (Mean)
Normal Saline	60.57
Flurbiprofen AxetilⅠ	78.29
Flurbiprofen AxetilⅡ	68.50
Butorphanol	79.7
Butorphanol-Flurbiprofen Axetil	81.64
Sufentanil	89.5

Intervention	cm^2 (Mean)
Normal Saline	60.46
Flurbiprofen AxetilⅠ	53.64
Flurbiprofen AxetilⅡ	56.57
Butorphanol	54.00
Butorphanol-Flurbiprofen Axetil	52.5
Sufentanil	49.89

Intervention	Hours (Median)
Treatment A: Probe Substrates	2.000
Treatment C: Probe Substrates + GSK3640254 200 mg	3.000

Intervention	Hours (Median)
Treatment A: Probe Substrates	1.000
Treatment C: Probe Substrates + GSK3640254 200 mg	1.000

Intervention	Hours (Median)
Treatment A: Probe Substrates	6.000
Treatment C: Probe Substrates + GSK3640254 200 mg	6.000

flurbiprofen

Description

Cross-References

Synonyms (257)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (2)

Pathways (1)

Protein Targets (43)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (370)

Molecular Functions (117)

Ceullar Components (79)

Bioassays (329)

Research

Studies (1,981)

Market Indicators

Research Demand Index: 76.72

Study Types

Clinical Trials (65)

Trial Overview

Trial Outcomes

Acetaminophen Used During the Tape Treatment Phase

Acetaminophen Used During the Tape Treatment Phase

Change From Baseline in Total Tender Point Examination Score

Percent Change From Baseline in Total Functional Rating Index (FRI)

Percentage of Patients Who Discontinued

Average Daily Categorical Pain Scale Scores

Cumulative Summed Pain Intensity Difference (SPID+)

Pain Intensity Difference (PID+)

Patient Assessment of Wearability of Therapy

Patient Global Impression of Change (PGIC)

Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)

Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline

Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose

Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe

Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline

Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline

Change From Baseline in Body Temperature at 2 Hours Post Initial Dose

Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline

Change From Baseline in Body Temperature at End of Study

Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Difficulty Swallowing Scale (DSS2)

Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Swollen Throat Scale (SwoTS2)

Post 24 Hour, Multiple Dose Results: Weighted Sum of Pain Intensity Differences (SPID) Over 2 Hours for the Sore Throat Pain Intensity Scale (STPIS SPID2)

Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)

Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at End of Study (Day 7)

Participant Satisfaction Score 24 Hours After Initial Dose

Percentage of Participants Who Took Rescue Pain Medication

Post 24 Hour, Multiple Dose Results: Sore Throat Relief As Reported by Participants 2 Hours After Dosing

Sore Throat Relief As Reported by Participants 2 Hours After Initial Dose

Time to First Rescue Pain Medication

Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe

Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8

Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement

Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL)

Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)

Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)

Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline

Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline

Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline

Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline

Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose

Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7)

Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose

Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose

Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05

Participant Satisfaction Scores 24 Hours After Initial Dose

Change From Baseline at Individual Timepoints in Sore Throat Scale (STS)

Kaplan-Meier Estimates for Time of First Indication of Sore Throat Relief as Measured By Any Reduction in the Sore Throat Scale (STS)

Intervention	Hours (Median)
Treatment A: Probe Substrates	3.033
Treatment C: Probe Substrates + GSK3640254 200 mg	4.000

Intervention	Hours (Median)
Treatment A: Probe Substrates	5.000
Treatment C: Probe Substrates + GSK3640254 200 mg	6.000

Intervention	Hours (Median)
Treatment A: Probe Substrates	1.500
Treatment C: Probe Substrates + GSK3640254 200 mg	3.000

Intervention	Participants (Count of Participants)
	AEs	SAEs
Treatment A: Probe Substrates	1	0
Treatment B: GSK3640254 200 mg	5	0
Treatment C: Probe Substrates + GSK3640254 200 mg	5	0

Intervention	Milliseconds (Mean)
	Baseline (Day 1, Pre-dose): PR Interval	Day 10: PR Interval	Baseline (Day 1, Pre-dose): QRS Duration	Day 10: QRS Duration	Baseline (Day 1, Pre-dose): QT Interval	Day 10: QT Interval	Baseline (Day 1, Pre-dose): QTcF Interval	Day 10: QTcF Interval
Treatment A: Probe Substrates	154.8	158.2	92.5	95.0	391.2	398.3	401.0	405.8

Intervention	Grams per liter (Mean)
	Baseline (Day -1): Albumin	Day 10: Albumin	Baseline (Day -1): Globulin	Day 10: Globulin	Baseline (Day -1): Protein	Day 10: Protein
Treatment A: Probe Substrates	42.9	42.2	27.4	25.9	70.3	68.1

Intervention	Units per liter (Mean)
	Baseline (Day -1): Lipase	Day 10: Lipase	Baseline (Day -1): Amylase	Day 10: Amylase
Treatment A: Probe Substrates	29.4	31.6	59.5	56.9

Intervention	International units per liter (Mean)
	Baseline (Day -1): Creatine kinase	Day 10: Creatine kinase	Baseline (Day -1): Lactate dehydrogenase	Day 10: Lactate dehydrogenase	Baseline (Day -1): ALT	Day 10: ALT	Baseline (Day -1): ALP	Day 10: ALP	Baseline (Day -1): AST	Day 10: AST	Baseline (Day -1): Gamma-glutamyl transferase	Day 10: Gamma-glutamyl transferase
Treatment A: Probe Substrates	103.7	66.9	131.3	114.8	15.6	20.1	62.7	60.8	14.6	15.6	19.1	18.9

Intervention	10^12 cells per liter (Mean)
	Baseline (Day -1)	Day 10
Treatment A: Probe Substrates	4.836	4.664

Intervention	Millimoles per liter (Mean)
	Baseline (Day -1): Glucose	Day 10: Glucose	Baseline (Day -1): Carbon Dioxide	Day 10: Carbon Dioxide	Baseline (Day -1): Cholesterol	Day 10: Cholesterol	Baseline (Day -1): Triglycerides	Day 10: Triglycerides	Baseline (Day -1): Anion Gap	Day 10: Anion Gap	Baseline (Day -1): Calcium	Day 10: Calcium	Baseline (Day -1): Chloride	Day 10: Chloride	Baseline (Day -1): Phosphate	Day 10: Phosphate	Baseline (Day -1): Potassium	Day 10: Potassium	Baseline (Day -1): Sodium	Day 10: Sodium	Baseline (Day -1): Urea	Day 10: Urea
Treatment A: Probe Substrates	5.0348	4.8211	104.1	25.4	4.4570	3.8118	1.2232	1.1814	7.9	13.8	2.3765	2.3141	25.8	103.7	1.1075	1.1754	4.48	4.43	137.7	138.4	4.8195	5.9458